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Dendritic cells (DCs) are key antigen-presenting cells in the immune system that can 
induce pathogen-specific T cell responses by presenting antigen (signal 1) to antigen-specific T 
cells in combination with co-stimulatory/inhibitory molecules (signal 2) and secretion of 
cytokines (signal 3). The ability of DCs to orchestrate CD8
+
 T cell responses, combined with the 
ability to generate high numbers of DCs in vitro allows for their use in DC-based vaccination 
protocols. The success of DC-based vaccination protocols and other forms of immunotherapy of 
cancer is believed to depend on the successful induction of both effector CD8
+
 T cell (CTLs), 
able to migrate into and kill tumors, and long-lived memory cells, able to generate a secondary 
response upon tumor recurrence. However, the signals that drive the differentiation of CD8
+
 T 
cells into each of these T cell subsets and the role of DCs in this respect remain unclear. Studies 
have suggested that the same DC can induce effector cells early after maturation while inducing 
memory cells after prolonged maturation when the DCs have become exhausted.  
Here, I analyzed the role of DCs matured under conditions mimicking acute/early 
inflammation (“inflammatory-DCs”) or mimicking chronic/late inflammation (“non-
inflammatory-DCs”) on the differentiation of CD8+ T cells. I observed that “inflammatory-DCs” 
produce high levels of IL-12p70 and induce the differentiation of naïve CD8
+
 T cell into 
cytolytic effector cells with peripheral homing ability. Furthermore, I demonstrate the role of IL-
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12p70 in this process.  In contrast, “non-inflammatory-DCs” (exhausted DCs) do not produce IL-
12p70 and induce the direct differentiation of naïve CD8
+
 T cells into central-memory cells. The 
superior ability of “inflammatory-DCs” to induce anti-tumor responses guided me to develop an 
alternative, low-cost method of generating “inflammatory-DCs” with strong CTL inducing 
ability. Lastly, I show that modulation of the tumor-chemokine environment by IFN , poly-I:C 
and indomethacin enhanced the attraction of tumor-specific CTLs while reducing regulatory T 
cell attraction. 
Together, the presented data broadens our understanding of the mechanisms of DC-
induced effector and memory cell differentiation and might lead to the improved DC-based 
cancer vaccines.   
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1.0  INTRODUCTION 
Dendritic cells (DCs) play a crucial role in the induction of adaptive T cell responses 
needed for the defense against infections and tumors. The ability of DCs to take up, process and 
present antigen (Ag) to Ag-specific T cells, combined with the ability of DCs to selectively 
secrete polarizing cytokines and chemokines, allows for the generation of robust T cell responses 
and is the basis for DC-based vaccines. For protection against intracellular pathogens and 
tumors, the induction of Ag-specific cytolytic CD8
+
 T cells (CTLs) capable of migrating to the 
sites of infections is essential, while the generation of long-lived Ag-specific memory CD8
+
 T 
cells is crucial for long-term protection.  
1.1.1 Dendritic cell subsets 
DCs are generated from either myeloid or lymphoid bone marrow progenitors. The bone-
marrow derived precursors migrate thought the blood and home to tissues where they reside in 
an immature state, scanning the environment for pathogens (1). There are distinct subsets of DCs 
which can be distinguished based on phenotype, function and localization (2), i.e. myeloid DCs 
and plasmacytoid DC (pDCs). However, within these subsets, other subsets can be distinguished 
based on the “pattern” of surface protein expression. For example, in the skin, the dermis hosts 
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two subsets, namely CD1a
+
 DCs and CD14
+
 DCs, while there is a distinct subset in the 
epidermis, the Langerhans cells (LC) (2).   
One aspect in which these DCs differ is their expression of pattern-recognition receptors 
(PRRs), which respond to evolutionary conserved molecular patterns on pathogens, known as 
pathogen-associated molecular patterns (PAMPs) (3-4). The triggering of these PRRs on non-
hematopoietic cells results in the secretion of inflammatory cytokines and chemokines, while the 
engagements of PRRs on the surface of DCs results in the activation and maturation of the DCs 
and their migration through the afferent lymph to draining lymph nodes (dLN), where they can 
interact with pathogen-specific T cells. Interestingly, the “same” PAMP (e.g. LPS) derived from 
different pathogens can activate DCs to secrete different cytokines (5).   
Another aspect in which the DC subsets differ is their ability to secrete polarizing 
cytokines and to induce distinct T cell responses (discussed below). For example, pDCs express 
Toll-like receptor (TLR) 7 and TLR9, which recognize viral antigens. pDCs are recognized as 
the major source of type I interferons (IFN ) (6). Interestingly, pDCs express the cytolytic 
molecules granzyme B and TRAIL and activation of pDCs by Imiquimod (a TLR7/8 ligand) or 
IFN  induces the expression of TRAIL on the pDC surface, which enables them to kill target 
cells (i.e. Jurkat cells, melanoma cell lines) (7-8). On the other hand, dermal CD14
+
 DCs express 
multiple TLRs (e.g. TLR2, TLR4, TLR5, TLR6, TLR8 and TLR10) and are able to produce a 
large set of cytokines, including IL-1 , IL-6, IL-8, IL-10 and IL-12 when stimulated through 
CD40 (9). 
The observation that CD8
+ 
DC, found in T cell areas of the spleen and lymph nodes of 
mice, are capable of cross-presenting exogenous antigen to the TCR of CD8
+ 
T cells (10) has 
resulted in their use for priming CD8
+
T cell responses to particulate antigens. Together with their 
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cross-presenting ability, CD8
+
DCs are also able to secrete large amounts of bioactive IL-12p70 
upon maturation (11), allowing them to induce cytotoxic effector CD8
+
T cells.   
The ability of CD8
+ 
DCs to cross-present exogenous antigens is of great interest since it 
allows the loading of DCs with whole protein or cell lysates. However, the lack of CD8  
expression by human dendritic cells has prevented the use of this subset for therapeutic purposes. 
Recent studies have therefore focused on finding a human homolog of mouse CD8
+
DCs. The 
newly described BDCA (Blood DC Antigen) surface proteins have allowed a better distinction of 
human DC subsets (12) and identified a BDCA3
+
 DC population as potential homolog of the 
mouse CD8
+
DC (13). This study showed that human BDCA3
+
 DC and mouse CD8
+ 
DCs had a 
very similar gene profile, setting them apart from other DC subsets. Further studies have 
identified other markers, XCR1 and CLEC9A (DNGR-1), that are conserved between mouse 
CD8
+ 
DCs and a subset of human BDCA3
+ 
DC (14-15). An important finding for the use of 
these DCs in clinical settings, is the ability to generate these cells in vitro from cord blood 
derived hematopoietic stem cells, although the yield is very low (15).  Like their mouse CD8
+
 
counterparts, human BDCA3
+
XCR1
+ 
DNGR-1
+
 DCs are able to cross-present antigen and 
produce high levels of IL-12p70 upon maturation with poly-I:C (15).  
1.1.2 DC maturation and polarization 
While it was originally thought that DCs in lymphoid organs exists in an immunogenic 
state, it was observed that targeting of antigens to DCs in vivo, using the DC expression of the 
surface protein CD205 (formerly DEC-205), results in the expansion of antigen-specific T cells, 
which subsequently disappear yielding a state of specific immune tolerance (16-17). These 
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studies showed that under steady-state conditions, in the absence of acute infection sand the 
associated inflammatory factors, DCs function in inducing peripheral tolerance (5). The 
tolerance-inducing ability of “steady-state DCs” can be of use in the treatment of autoimmune 
disease or in tissue transplantation by the induction of regulatory T (Treg) cells specific for auto-
antigens (18). DCs, however, can be matured by pro-inflammatory cytokines, such as TNF and 
type I interferons (IFNs), in the absence of PRR stimuli (19-20). DCs matured in this way exhibit 
elevated expression of co-stimulatory molecules (CD80, CD86 and CD40) and express CCR7, a 
chemokine receptor associated with lymphoid homing properties (20-22).  
The ability to mature DCs using cytokines has facilitated the development of DC-based 
vaccines for immunotherapy. However, studies have suggested that these types of DCs are 
unable to provide a (type-1) polarizing signal 3 to the responding T cells (23) and are thus unable 
to induce Th1/CTL responses. Ag-specific naïve T cells interacting with these DCs are able to 
undergo proliferation and activation, but are unable to produce IFN  and lack cytolytic ability. It 
has been suggested that DCs matured in the absence of PRR triggering play a fundamental role 
in the development and maintenance of Treg cells (24). In accordance with this notion is the 
observation from human in vitro studies demonstrating that monocyte-derived (mo)DCs matured 
in the presence of cytokines and prostaglandin E2 (without PRRs ligands) secrete higher levels of 
the Treg-attracting chemokine CCL22 when compared to moDCs matured with pro-inflammatory 
cytokines and a TLR ligand (25). DC activation in the absence of PRR signaling in vivo could 
occur in the lymph nodes by diffusion of pro-inflammatory cyt okines from the site of infection 
or in a bystander fashion at later stages of the immune response when most pathogens have been 
cleared.      
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In vitro studies have suggested that the inability of DCs to provide signal 3 during T cell 
priming results in the expansion of non-polarized cells (3, 26). However, other studies have 
shown that the combination of IFN and CD40 ligation can induce the generation of DCs with a 
high IL-12p70 secretion ability. The priming of DCs for the production of bioactive IL-12p70 
has been shown to require two signals (27). DCs matured by either TLR ligands alone or CD40L 
alone produce only marginal amounts of IL-12p70. In contrast, the production of IL-12p40, the 
inactive subunit of the IL-12 heterodimer which has an immune inhibitory function, could be 
induced by maturation with a single stimulus (4, 27).  
It was shown that maturation of DCs by TLR signals alone, in the absence of 
inflammatory signals (e.g. IFN ), induces the maturation of the DCs (4) and polarize them to 
preferentially secrete IL-23, which is associated with a Th17 T cell response (28). The 
combination of a pro-inflammatory cytokine (i.e. IFN ) with a TLR ligand (i.e. LPS or R848) 
allows DCs to secrete IL-12p70 during maturation (spontaneous secretion) and after secondary 
stimulation via CD40 (DCs)-CD40L (T cells) interactions. In contrast, DCs matured by 2 TLR 
ligands in the absence of inflammatory cytokines produce IL-12 during maturation, but fail to 
produce additional IL-12p70 upon subsequent CD40 triggering (29).  These results show the 
impact of different pathogen derived signals (direct through TLR ligands and indirect through 
cytokines) on the maturation of DCs and on controlling the induction of T cell responses.   
1.1.3 Signal 3 
As mentioned above, different DC subsets can elicit different T cell responses, depending 
on the cytokines they produce. DCs provide naïve (and memory) T cells in the lymph nodes 3 
different “signals” about the pathogen/tumor: i) information about the molecular identity of the 
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pathogen/tumor (i.e. antigen presented to the T cells in the form of pathogen/tumor-derived 
peptide bound to MHC molecule complexes; “signal 1”) ii) a signal about the pathogenicity of 
the pathogen/tumor, “instructing” the T cells how much to expand (i.e. by DC expression of co-
stimulatory and co-inhibitory molecules; “signal 2”)(3, 30), and iii) information about what type 
of immune response (e.g. Th1, Th2, Th17, Treg) is required (i.e. by the secretion of polarizing 
cytokines; “signal 3”).  
The T cell polarizing cytokines secreted by DCs during the DC:T cell interaction depend 
on the type of pathogen the DCs encounters (e.g. extracellular versus intracellular), the 
inflammatory milieu during which the DC is activated (e.g. acute inflammation versus 
late/chronic inflammation), the duration between DC activation and T cell encounter and 
possibly the antigen-dose (3-5, 26, 29, 31-35).   
 
1.1.3.1 IL-12p70: a “signal 3” cytokine critical for type-1 immune responses  
Type-1 immune responses (i.e. Th1 CD4
+ 
T cells and cytolytic CD8
+
 T cells) are required 
for the clearance of intracellular infections and are believed to be optimal for the elimination of 
tumors (36). The effective induction of type-1 immune responses depends, in large part, on the 
production of IL-12p70 by DCs. 
IL-12p70 is a heterodimeric cytokine that consist of the IL-12p35 and p40 subunits and is 
secreted by phagocytic cells in response to certain pathogens(37). Furthermore, the secretion of 
IL-12 by monocyte-derived DCs can be induced by their maturation in the presence of 
interferons and TLR-ligands (5, 27-28, 38). IL-12p70 binds to the IL-12R (consisting of 2 
subunits: IL-12R 1 and IL-12R 2) on responding cells, resulting in the phosphorylation, 
dimerization and translocation of Signal Transducers and Activators of Transcription (STAT) 1, 
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3, 4 and 5 resulting in gene transcription. The majority of the effects of IL-12 signaling are 
mediated through STAT4 (39). IL-12p70 has been shown to induce IFN  producing ability and 
cytolytic capacity in NK cells and CD8
+
T cells (40-43). More recently, it has been shown that 
IL-12 regulates the expression of the transcription factor T-bet (44), which can directly regulate 
IFN  production and granzyme B expression. Furthermore, IL-12 signaling represses Th2 T cell 
differentiation by inhibiting the expression of the Th2-associated transcription factor GATA-3 
(45), suggesting that IL-12 function both to stimulate Th1 differentiation and simultaneously 
inhibiting Th2 development.    
1.1.4 Antigen presentation by MHC class I molecules: Cross-presentation  
 The induction of CD8
+
 T cell responses is dependent on the presentation of peptide 
antigens on MHC class I molecules. MHC class I molecules usually present peptides derived 
from the DC itself, by proteasomal degradation of endogenous antigens. Since most cell types 
express MHC class I molecules, the presentation of endogenous antigens allows CD8
+
 T cells to 
recognize cell producing foreign (e.g. in the case of viral infection) or aberrant (e.g. in the case 
of transformation) peptides. One caveat of this system is that CD8
+
 T cells need to be primed by 
MHC class I: peptide complexes presented by DCs, suggesting that the DCs itself would need to 
be infected or have developed a mechanism to present exogenous antigens on C class I 
molecules. The ability of DCs to take-up exogenous antigens, process them and load them on 
MHC class I molecules for presentation to CD8
+
 T cells is termed” cross-presentation” (46).  
The classical pathway for the presentation of peptides on MHC class I molecules occurs 
via the endogenous degradation of cytosolic proteins. Endogenous proteins are degraded by 
proteasomes (47) and the resulting peptides are transported into the endoplasmatic reticulum 
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(ER) via TAP1/TAP2 molecules (Transporters associated with Antigen Presentation). Within the 
ER, newly formed MHC class I molecules are retained and bound to chaperone proteins, such as 
calnexin, calreticulin and tapasin, which help in the correct folding of the MHC molecules and 
localizing of the molecules to TAP1/TAP2 complexes. The MHC class I molecules are retained 
in the ER until peptide is bound. Following peptide binding, MHC class I molecules are 
transported through the Golgi apparatus to the cell surface (47-48) where they are presented to 
CD8
+
 T cells. 
The ability of DCs to cross-present exogenous antigens is of great interest in the case of 
DC-based cancer therapies, since this allows DCs to be loaded ex vivo with tumor lysates or 
tumor-derived proteins(49). While it was originally observed that soluble protein antigens did 
not induce CD8
+
 T cell immunity, particulate proteins antigens were able to elicit a CD8
+
 T cell 
response, suggesting that whole proteins could be cross-presented (50-51). The method of cross-
presentation requires three processes i) processing of antigen, ii) loading of peptides onto MHC 
class I molecules and iii) transport of the MHC class I molecules to the cell surface (52). There 
are two major tracks by which these processes can occur. During the endocytic pathway, the 
processing and loading of the antigens occurs in endosomal compartments with MHC molecules 
recycled from the cell surface (53). In the second pathway, cytolytic pathway, the antigens are 
translocated from the endosomes to the cytosol where they are processed and further follow the 
endogenous pathway (53).   
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1.1.5 Dendritic cells in immunotherapy: DCs in cancer   
The ability of DCs to act as inducers of immune responses, via Th1, Th2, Th17, and CTL 
induction, as well as regulators via the induction of Treg, has led to their use in immunotherapy 
against diseases such as cancer and autoimmunity as well as for the prevention of graft transplant 
rejection. One key aspect for the use of DCs in immunotherapies is the ability to produce large 
numbers of DCs ex vivo under clinically applicable conditions that can be injected into patients 
as therapeutic vaccine (54-55). The feasibility to generate DCs from blood-isolated monocytes 
using granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-4 has allowed for the 
study and use of DCs in clinical settings, since vast amounts of monocytes can be isolated from 
peripheral blood (19) while only few DCs are in circulation, although the injection of Flt3-ligand 
can increase the number of DC progenitors in circulation (56). Furthermore, tumors produce vast 
amounts of immune suppressive factors (e.g. IL-10, TGF , PGE2), which affects the immune-
stimulatory functions of endogenous DCs matured in the presence of these tumor-associated 
factors (e.g. reduced expression of co-stimulatory molecules, reduced secretion of factors 
required for T cell survival and CTL differentiation) (57-58). Ex vivo generated DC, in contrast, 
are not subjected to these immune-inhibitory factors and, when matured ex vivo are, partially, 
resistant to these factors (5, 59), suggesting that ex vivo-generated DCs are more suitable to be 
used as cancer vaccines.     
In 2010, the Food and Drug Administration (FDA) approved Sipuleucel-T (Provenge), 
the first cellular therapy for the treatment of cancer. This DC-containing vaccine improved the 
overall survival of patients with hormone refractory prostate cancer by 4 months (60). However, 
Provenge does not induce tumor regression or prolong time to disease progression, possibly due 
to the immature state of the cells used. The results of this study show the feasibility of using DC-
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containing, cellular vaccines to treat cancer, but also suggests the need to improve preparative 
methods for DC maturation ex vivo.     
The ability of DC-based vaccines to be safely used in cancer trials and induce immune 
responses has been shown in clinical trials against melanoma, lymphoma and renal cell 
carcinoma (61-63). However, the clinical response rate is usually low (<15%), suggesting the 
need for optimization of DC maturation protocols (64). 
Successful immunotherapy for the treatment of cancer and intracellular pathogens is 
believed to require the induction of Th1 CD4
+
 T cell and effector CTL CD8
+
 T cell responses. 
The generation of DCs that have a high IL-12p70 secretion following maturation and after CD40 
ligation is pivotal to the induction of such effector T cell responses. The ability of IL-12p70 to 
stimulate Th1 and CTL differentiation has been known for some time (65-66). Recent data has 
highlighted the role of DC-secreted IL-12p70 in the induction of type-1 anti-tumor responses in 
vitro (67-69) and as a predictor of the therapeutic potency of DCs in vivo (70).The ex vivo 
maturation of DCs using interferons and TLR-ligands have been demonstrated to prime DCs for 
high IL-12p70 production following CD40-stimulation (71-73). These so-called DC1s have been 
shown to have superior anti-tumor T cell inducing capacity (68-69) when compared to DCs that 
do not produce IL-12p70. Besides their high IL-12p70 producing capacity, DC1s have other 
advantages that should ensure the effective induction of anti-tumor immune responses. Like DCs 
mature in the presence of PGE2, DC1s have a high expression of the lymphoid chemokine 
receptor CCR7, which allows them to migrate in response to CCL19 and CCL21, two lymph 
node homing chemokines, suggesting these cells would be able to migrate to lymph nodes after 
injection (20, 74-75). Furthermore, unlike DCs matured in the presence of PGE2, DC1s produce 
high levels of the chemokines CXCL10/IP-10 and CCL5/RANTES, which can attract CXCR3- 
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and CCR5-expressing Th1/CTL cells, while they do not produce CCL22, a chemokine which has 
been associated with the attraction of Treg cells (25). This chemokine producing profile of DC1s, 
combined with their resistance to immune inhibitory factors produced by tumors, suggests that 
these DCs could attract Th1/CTL cells to tumor sites when injected into the tumor, which could 
result in enhanced anti-tumor effects(76). 
     
1.1.6 Dendritic cells in immunotherapy: DCs in autoimmunity/transplantation 
In the case of autoimmune diseases or to prevent rejection of transplanted tissues or 
organs, the induction of Treg cells is preferred (77). Studies of transplant tolerance have provided 
insight into the role of DCs in the prevention of allograft rejection. Murine liver transplants 
models have shown that there is an increased frequency of pDCs in sustained liver grafts 
compared to the spleen and that this increased frequency correlates with an increase in Treg cells 
(78-79). Infusion of mice with precursor (pre-) pDCs before heart transplantation resulted in 
prolonged cardiac allograft survival (80). Furthermore, human pDCs can induce Treg cell in vitro 
(81-82). Currently there are protocols described for the generation of tolerogenic DCs from 
monocyte-derived DC by the addition of immune inhibitory factors (e.g. Vitamin D3, 
glucocorticoid, IL-10) to DC cultures (30-31). These tolerogenic DCs express reduced levels of 
co-stimulatory molecules and exhibit reduced production of inflammatory cytokines when 
compared to non-tolerogenic DCs and these DCs can inhibit (DC-induced) T cell expansion and 
cytokine production (30). Adoptive transfer of tolerogenic DCs continues to represent a 
promising experimental treatment for autoimmune diseases.        
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1.2 EFFECTOR CD8+ T CELLS 
The effective treatment of cancers with DC-based vaccines relies on the induction of 
large numbers of cytolytic effector cells able to recognize tumor antigens. Following the 
elimination of tumors by the type-1 polarized DCs-induced CD8
+
 T cells, a population of 
memory cells should be formed which can provide long-term protection against disease 
recurrence.   
1.2.1 Effector CD8+ T cell differentiation 
Naive CD8
+ 
T cells in the lymphoid organs scan resident DCs for the cognate antigen. 
Using time-lapse microscopy, it has been shown that the interaction of naïve T cells with 
irrelevant Ag-bearing DCs are stochastic and short lived (i.e. in the order of minutes). However, 
upon recognition of its cognate Ag, Ag-specific T cells form stable clusters with DCs, which can 
lasts for up to 24 hours (41). Using plate-bound antigen and co-stimulatory molecules (e.g. anti-
CD28) or adherent cells transfected to express antigen and B7-1 (CD80), it was shown that short-
term (2-24 hours) interaction between T cells and Ag/co-stimulation induces an “auto-pilot” 
response in which the cells proliferate and undergo differentiation (83-85). However, other 
studies have suggested that prolonged interactions are required for optimal delivery of signal 3 
delivery to T cells and for the induction of cytolytic capacity in CD8
+
 T cells (86).      
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1.2.2 DCs, signal 3 and the induction of effector CD8+ T cells 
Studies using artificial antigen presenting cells consisting of microspheres bearing pMHC 
complexes and co-stimulatory molecules (e.g. B7 ligands) and CD8
+
 T cells from TCR 
transgenic mice, have suggested that the clonal expansion of naïve CD8
+
 T cells requires the 
presence of IL-12p70 during priming (87).  Hernandez et al., showed that injection of agonistic 
anti-CD40 antibodies resulted in the increased migration of DCs expressing high levels of co-
stimulatory molecules to the lymphoid organs and that these DCs were able to induce CD8
+
 T 
cell proliferation, but that the proliferating T cells did not acquire effector functions (88). In 
these studies, the addition of IL-12p70 to antigenic and co-stimulatory signals resulted in the 
acquisition of effector functions by the responding Ag-specific CD8
+
 T cells. Interestingly, the 
priming of naïve CD8
+
 T cells by high Ag-dose and co-stimulatory molecules in the absence of 
signal 3 (e.g. IL-12p70) induced tolerant or anergic CD8
+
 T cells which were unable to 
subsequently develop cytolytic function upon re-challenge (89-90).  
As mentioned before, the ability of DCs to provide signal 3 is dependent on their 
activation status and the duration of activation. Langenkamp et al., have shown that moDCs 
produce the pro-inflammatory cytokine IL-12p70 after receiving maturation stimuli, which lasts 
for about 24 hrs. Priming of naïve CD4
+
 T cells within this first period of DC maturation, when 
there is abundant IL-12p70 production, results in the generation of Th1-polarized T cells. 
However, these same DCs lose the ability to  secrete IL-12p70 later after maturation (>24hrs) 
and preferentially induce Th2 and non-polarized T cell differentiation (26). These long-term 
matured DCs are classically considered exhausted.  
The presence of IL-12p70 or IFN  during the priming period results in the activation of 
STAT 4 and the transcription of effector genes such as T-bet, IFN , granzyme B and perforin 
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(44, 91-92). Mouse studies have shown that the expression of the transcription factor T-bet is 
regulated by IL-12p70 (44). CD8
+
 T cells from IL-12p35
-/-
 mice exhibited reduced T-bet 
expression during the peak of the immune response after pathogenic infection. In contrast, a 
closely-related transcription factor, eomesodermin (eomes), which is increasingly expressed 
during the differentiation from effector to memory T cells (91), is elevated during the peak of the 
immune response in the IL-12p35
-/-
 mice.     
While IL-12p70 is recognized as the key cytokine for the induction of Th1 responses (66, 
93), other cytokines have been shown to be able to induce Th1 differentiation in the absence of 
IL-12p70. A study using DCs over-expressing the transcription factor T-bet (required for type-1 
polarization in T cells), showed the induction of Th1 T cell responses, which was largely IL-
12p70- independent (94). Furthermore, priming of naïve CD8
+
 T cells with anti-TCR antibodies 
in the presence of IL-27, an IL-12 family member, resulted in the increased expression of the 
cytolytic proteins granzyme B and perforin (95). More recently, it was shown that type-1 
interferons (IFN / ) could also provide signal 3 required for clonal expansion and effector and 
memory T cell differentiation (92, 96).  
Klechevsky et al., have shown that in vitro-generated and epidermis-derived Langerhans 
cells (LCs) are potent inducers of cytolytic CTLs (9). In contrast to CD14
+
 dermal DCs, LCs 
produce large amounts of IL-15 which can be secreted or “trans” presented to T cells in 
combination with IL-15R . Exogenous addition of IL-15 to co-cultures of CD14
+
 dermal 
DCs and T cells induces strong T cell priming, suggesting that IL-15 can substitute for IL-12p70 
as a Th1/CTL inducing signal 3 cytokine.      
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1.2.3 Chemokine-mediated effector CD8+ T cell migration 
Gradients of the chemokines CCL19 and/or CCL21, ligands for lymphoid-homing 
chemokine-receptor CCR7, allow naïve and central-memory CD8
+
 T cell to migrate into the 
lymph nodes and interact with Ag-presenting DCs (98-99). During the activation and 
differentiation of naïve CD8
+
 T cells into effector cells, the T cells down-regulate the expression 
of CCR7, allowing them to migrate out of the lymphoid organs and into the periphery. 
Furthermore, activated antigen-specific CD8
+
 T cells up-regulate surface expression of 
peripheral-homing chemokine receptors such as CCR5 and CXCR3, that allow them to respond 
to chemotactic gradients of inflammation associated/peripheral chemokines (RANTES/CCL5 
and Interferon-inducible protein-10 (IP-10)/CXCL10), respectively to traffic to infected tissues. 
In the inflamed tissue, effector CD8
+
 T cells migration is halted by encounter of antigens (100). 
While these “effector” chemokine receptors are required for peripheral homing, it has been 
suggested that their expression in the lymph nodes are also necessary for interaction of the T 
cells with the DCs and the optimal priming of Th1 responses (101).    
  Secretion of CXCL10 by cells in the central-nervous system (CNS) of mice infected with 
Toxoplasma gondii, resulted in the enhanced migration of CD8
+
 T cells to the infected tissue and 
accelerated the migration speed of CD8
+
 T cells in the brain. The involvement of chemokine-
chemokine receptors was shown by treatment of the infected animals with blocking anti-CXCL-
10 antibodies or treatment with the general 7-trans membrane G-protein coupled receptors, 
pertussis toxin (PTX), both of which reduced the infiltration of Ag-specific CD8
+
 T cells into the 
infected tissue and slowed the migration of cells in the brain (102).    
 Differentially matured DCs secrete different chemokines, allowing them to attract 
specific T cells and to elicit “pathogen-specific” responses (35). Type-1 polarized DCs are able 
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to produce CXCL10, allowing them to attract, and induce, Th1 and effector CXCR3
+
 CD8
+
 T 
cells. This ability of DCs has been shown to help in the DC-based vaccine treatment of 
malignant gliomas (76). The sub-cutaneous injection of type-1 polarized DCs, loaded with 
glioma-associated antigen (GAA)-derived epitopes, induced Ag-specific CTLs able to prolong 
survival of glioma-bearing mice, while intra-tumoral injection of the DCs resulted in the further 
enhancement of anti-glioma T cell responses, an effect that was absence in the case of injection 
of DCs derived from CXCL10 knockout mice (76).      
The ability of T cells to migrate to and enter into tumors has been shown to correlate with 
disease progression and overall patient survival for various types of cancer(23, 77). The analysis 
of the type of immune cells infiltrating the tumors, as well as the number of cells and their 
localization has been shown to be a good predictor of patient survival in colorectal cancer (103). 
T cell infiltration in tumor islets was positively correlated with progression-free and overall 
survival in patients with ovarian carcinomas (104). Analysis of resected colorectal tumor 
specimens for the presence of early metastatic infiltration showed that those specimens without 
infiltration had increased infiltration of CD8
+
 T cells and increased mRNA expression of type-1 
immune response associated genes. The presence of T cell infiltrate and the absence of 
metastatic infiltration correlated with increased disease-free and overall survival. Interestingly, 
metastatic free tumors contained increased numbers of (effector-) memory CD8
+
 T cells (105).  
The importance of CXCR3 expression and proper migration by activated CD8
+
 T cells 
was further highlighted by the finding that melanoma patients with many CXCR3
+
 CD8
+
 T cells 
in their tumor tissue have a better prognosis than patients with low numbers of CXCR3-
expressing T cells (36). The ability of effector T cells to migrate into tumor tissue is pivotal as it 
has been shown that the ratio of Treg:CTL in the tumor can be used as a diagnostic index. The 
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lower the Treg:CTL ratio (low Treg vs. high CTL) the better the disease prognosis (46).  Therefore, 
it appears that the success of cancer immunotherapies may be related to the capacity to induce 
high numbers of CXCR3
+
 tumor infiltrating lymphocytes (TILs)/CTLs that efficiently migrate 
into tumor tissues. This endpoint requires the expression of (tumor-) tissue specific chemokine 
receptors by the TILs/CTLs and a tumor chemokine milieu that favors the attraction of CTLs 
over Treg cells. 
Furthermore, the migratory abilities of T cells not only determine disease outcome, but 
can also affect the T cell differentiation. CD8
+
 T cells activated in lymph nodes undergo 
expansion and migrate to the periphery under the influence of chemotactic gradients sensed by 
CXCR3 and CCR5, as previously mentioned. However, the programming of activated CD8
+
 T 
cells into terminally-differentiated effector cells might occur at the site of infection under the 
influence of the pro-inflammatory environment. Mouse studies have shown that expression of 
CXCR3 and CCR5 by activated T cells plays a role in the subsequent induction of effector and 
memory CD8
+
 T cells. In an influenza model, Kohlmeier et al., showed that CCR5
-/- 
CXCR3
-/-
 
CD8
+
 T cells migrate to different parts of infected lungs when compared to WT (CCR5
+/+
 
CXCR3
+/+
) CD8
+
 T cells. The WT CD8
+
 T cells preferentially localize to tissues with high 
antigen density and inflammation where they may be induced to undergo further differentiation 
into effector CD8
+
 T cells. In contrast, the CXCR3
-/-
 CCR5
-/-
 CD8
+
 T cells tends to localize to 
tissues with less inflammation and lower Ag-density leading to a state of attenuated activation 
and enhanced memory cell development (106).  
Although the expression of CCR5 (and CXCR3) is principally associated with peripheral 
tissue homing ability, the interaction of CD4
+
 T cells with Ag-presenting dendritic cells induces 
the secretion of CCL3 and CCL4, two ligands for CCR5, and this helps in attracting naïve Ag-
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specific CD8
+
 T cells into DC-CD4
+
 T cell clusters, allowing for the improved induction of CTL 
responses and subsequent memory T cell development (107). Furthermore, interaction of specific 
CD8
+
 T cells with Ag-presenting DCs lead to the attraction and stable interaction of CD8
+
T cells 
with DCs in an Ag-independent manner. This recruitment is dependent on the expression of 
CCR5 on the “non-Ag-specific” CD8+ T cells (108). Since DCs that have taken up infected or 
transformed cells can present a range of antigenic epitopes, this CD8-CD8 help could provide a 
mechanism by which specific CD8
+
 T cells could attract other (CCR5
+
) CD8
+
 that are reactive 
against other antigens that the DCs might be cross-presenting allowing for the development of 
poly-specific CTL responses. While naïve CD8
+
 T cells do not express CCR5, the surface 
expression could be induced by inflammation (107).  
 Guarda et al., showed that CXCR3-expressing CD8
+
 T cells are also capable of 
migrating into “activated” lymph nodes where they can eliminate Ag-presenting DCs. This 
unexpected feature of CXCR3
+
 CD8
+
 T cells may limit the excessive induction of activated 
CD8
+
 T cells and control the number of effector CD8
+
 T cell in the periphery as a means to 
prevent unwanted auto-reactivity/autoimmunity (109).  
    DCs not only regulate T cell migration via secretion of chemokines, but they also 
regulate, as least in part, T cell expression of chemokine receptors (and other molecules involved 
in migration, such as integrins and lectins). T cells primed by DCs derived from Peyer’s patches 
or the mesenteric lymph node, induce the expression of chemokines and integrins associated with 
gut-homing (CCR9). In contrast, DCs derived from the skin induce skin-homing properties in T 
cells (39). In line with these studies are the observations that the priming of T cells by DCs that 
have been stimulated with metabolites of either vitamin A (retinoic acid; found mostly in the 
intestines) or vitamin D (1,25(OH)2D3; found in the epidermis of the skin) induce the surface 
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expression of the chemokines CCR9 (involved in migration to the gut) or CCR10 (involved in 
migration to the skin), respectively(37). While it is still unclear what mechanism underlies the 
induction of tissue-specific T cell homing by DCs, the ability of these APCs to instill tissue-
specific homing abilities in responding T cells might be considered as “signal 4” (110). This 
could help in generating DCs that “direct” T cells to specific tissues by regulating there 
chemokine receptor expression.     
1.3 MEMORY CD8+ T CELL DEVELOPMENT 
One of the key features of the adaptive immune response is the formation of memory 
cells. Following an infection, an effector response is elicited which results in the clearance of the 
infected cells and pathogens. When the pathogen is cleared, a contraction phase occurs during 
which the majority (>90%) of the Ag-specific CTL undergo apoptosis, leaving a small 
population of Ag-specific memory cells. These memory cells are long-lived cells that can 
provide life-long protection against subsequent infections with the same or cross-reactive 
pathogens in mice (111). The ability of the immune system to “remember” pathogens and mount 
rapid and robust responses to subsequent infection is the foundation for prophylactic vaccination 
strategies. Because of their essential role in vaccine development, many studies have examined 
the mechanism by which memory cells are generated and maintained as well as the basis for the 
enhanced capacity of TG cells to respond to subsequent infection.  
Initial studies in mouse have suggested that the size of the memory T cell pool is 
dependent on the primary clonal burst size attained by Ag-specific CTLs following infection. 
The massive clonal expansion during the primary infection results in a substantial increase 
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(~1000-fold) in the precursor frequency of Ag-specific memory T cells when compared to naïve 
T cells (112). The higher precursor frequency allows for the accelerated generation of large 
numbers of Ag-specific CTLs following subsequent re-infection.   
 
1.3.1 Effector-memory and central-memory T cells       
 Memory and naïve T cells also exhibit phenotypic and functional differences that allow 
for the more robust and accelerated response of memory T cells following re-challenge. Memory 
T cells are most commonly divided into two populations based on the expression of the CCR7 
and L-selectin (CD62L), central-memory T cells (TCM) and effector T cells (TEM) (113). These 
two populations have distinct homing and cytolytic capacities. Central-memory cells are CCR7
+
 
and CD62L
+
 and preferentially localize in lymphoid tissues. They lack direct cytolytic capability 
but exhibit proliferative ability. TCM cells are thought to be responsible for the rapid second wave 
of CTLs development after re-infection. TEM cells, in contrast, are CCR7
-
 CD62L
-
 and reside in 
peripheral tissues, where they express perforin and produce IFN  in response to cognate-Ag 
stimulation. The direct cytolytic function and localization of TEM cells allows them to respond 
acutely to re-challenge, explaining the more rapid clearance of secondary infections by memory 
T cells.  
Analysis of resected colorectal tumors revealed that tumors that had elevated numbers of 
infiltrated TEM cells had no histological sign of early metastatic invasion, while those tumors 
with signs of early metastatic invasion had reduced TEM infiltration (105). The absence of early 
metastatic invasion was shown to correlate with increased disease-free and overall survival 
(105). These results suggest that the level of TEM infiltration may have prognostic value.  The 
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functionality of TEM cells has also been studied in HIV/SIV infection models in non-human 
primates.  The presence of HIV/SIV-Ag-specific TEM cells at mucosal sites of viral entry was 
shown to provide protection against infection (49).  Recently, it was shown that after clearance 
of a vaccinia virus infection in the skin, TEM cells infiltrated these cutaneous sites and reside 
there for extended periods, providing long-term protection against reinfection of the skin, while 
TCM cells instead,can be found in circulation (114). In accordance with this mouse study, Clark et 
al. showed that patients with leukaemic cutaneous T cell lymphoma (L-CTLC), a malignancy of 
TCM cells, retained skin TEM cells after T cell depletion therapy with alemtuzumab, without 
exhibiting an increased risk of infections (115).    
Combined, these studies suggest that the presence of memory T cell populations with 
distinct localization abilities, self-renewal capacities and cytolytic properties have distinct 
functions in providing long-term immune protection to the host against pathogens/tumors. 
1.3.2 Memory CD8+ T cell differentiation 
While memory T cell development is widely studied, the pathway by which naïve CD8
+
 
T cells differentiate into memory cells remains controversial. The notion that the clonal burst 
size of the primary Ag-specific CTL population affects the size of the subsequent memory pool 
suggests that memory cells are directly derived from CTLs that survive the initial contraction 
phase. Studies using transgenic mice in which the Ag-specific CTLs could be labeled at early 
time-points, suggest that these T cells were maintained in the memory pool (32). The 
mechanism(s) by which certain CTLs survive the contraction phase and become memory T cells 
remains an area of active research.  
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The observation that during the peak of an immune response there are CD8
+
 T cells that 
have retained expression of IL-7R  (a cytokine receptor involved in survival of naïve and 
memory T cells) suggests the existence of a memory precursor population (116). The expression 
of IL-7R  by itself, however, is not enough for the generation of memory cells, since forced 
expression of the receptor by terminally differentiated effector cells did not alter contraction 
(117). Memory precursor T cells are IL-7R
+
  T-bet
low
 and, in mice, these cells are KLRG1
low
 
(Killer-cell lectin-like receptor subfamily G, member 1). The presence of a memory-precursor 
population suggests that effector and memory differentiation can occur independently. This 
notion is supported by the finding that naïve T cells undergo a primary asymmetric cell division 
during priming, in which the daughter cell closest (proximal) to the Ag-presenting APC acquires 
most of the effector molecules and eventually becomes a CTL while the more distant daughter 
cell are pre-disposed to become central-memory T cells (118). These two distinct daughter cells 
also have distinct T-bet expression, with the proximal cells having the highest T-bet expression 
and the more distant T cells typically have a T-bet
low
 expression profile (119). Interestingly, T-
bet expression negatively regulates the expression of IL-7R , providing support for the concept 
that IL-7R
-
 CTLs are derived from the DC-proximal T cells (120).  Using a transgenic mouse 
model in which T cells lose GFP expression upon differentiation into CTLs, it was shown that 
long-lived memory T cells may be generated without the requirement of evolving through an 
effector phase (32).  
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1.3.3 Inflammation and memory T cell differentiation 
 Studies using IFN -deficient mice showed a diminished contraction of CD8
+
 T 
cells after infection with attenuated L. monocytogenes or LCMV (42) . In line with this finding is 
the observation that pre-treatment of mice with ampicillin before infection with L. 
monocytogenes results in memory formation without contraction, while the simultaneous 
induction of an inflammatory response by injection of a TLR9 agonist (CpG-containg DNA), 
results in contraction of the responding CD8
+
 T cells (43). Furthermore, CD8
+
 T cells lacking the 
IL-12 receptor showed reduced proliferation as well as reduced contraction following infection 
(121). Accelerated memory formation is also observed in cells lacking T-bet, which is regulated 
by IL-12 (122). 
Badovinac et al., showed that the vaccination of mice with peptide-loaded DCs in the 
absence of overt inflammation resulted in the differentiation of the CD8
+
 T cells into memory 
cells by day 5. These T cells were able to undergo secondary expansion upon Ag-restimulation 
and provided protection to subsequent infections. The addition of pro-inflammatory stimuli 
together with the peptide-loaded DCs resulted in the generation of CTLs (123).  
These results highlight the role of inflammatory signals in the formation of memory T 
cells. It is, however, unclear how inflammatory signals affect the ability of DCs to induce 
effector versus memory differentiation. 
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1.3.4 The role of mTOR in effector versus memory CD8+ T cell differentiation  
 Recently, the importance of inflammation on the regulation of CTL and memory 
formation was further underscored by the finding that rapamycin induced the formation of 
memory T cells. Rapamycin is a well-established immunosuppressive drug commonly used in 
organ transplantation settings to suppress immune reactions against transplanted tissues (124-
127). Rapamycin inhibits the activation of the mammalian target of rapamycin (mTOR) complex 
I. IL-12 signaling during priming enhances and prolongs the activity of mTOR kinase resulting 
in the expression of T-bet and CTL differentiation, in an mTOR-dependent manner (128). 
Furthermore, the treatment of mice with rapamycin during the initial week of LCMV infection, 
results in normal expansion of primed T cells, but the contraction phase of the pathogen-specific 
T cell response is attenuated. Reduced contraction is associated with an increased population of 
CD8
+
 T cells with a memory-precursor phenotype (129).  mTOR kinase activity is also crucial 
for the development of memory cells under conditions of homeostatic proliferation (130). 
Furthermore, mTOR kinase activity regulates the migratory capacity of effector and memory T 
cells by modulating the expression of the transcription factor Kruppel-like factor 2 (KLF2), 
which  regulates the expression of trafficking proteins such as CCR7 and CD62L. (131). High 
mTOR kinase activity in T cells results in reduced expression of KLF2 leading to down-
regulation of the surface expression of CCR7 and CD62L, allowing these CTLs to leave 
lymphoid organs.    
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1.4 FEED-BACK INTERACTION BETWEEN T CELLS AND DENDRITIC CELLS 
As described above, DCs interact with T cells dictates T cell fate but it also affects the 
maturation and polarization of the DCs in a reciprocal manner.  
The binding of a CD28-Ig fusion protein to B7-1 and/orB7-2 (CD80 and CD86, 
respectively) on the DC surface results in the up-regulated expression of IL-6 and IFN  by the 
DCs, which allows these APCs to elicit strong immune responses both in vitro and in vivo (132). 
In contrast, interaction of B7-1 or B7-2 with CTLA-4, an inhibitory receptor which competes 
with CD28 for binding of B7 molecules and inhibits T cell activation, results in the induction of 
indeolamine 2,3- dioxygenase (IDO) by the DCs (133). DC produced IDO inhibits T cell 
proliferation, induces the apoptosis of lymphocytes and drives immune tolerance. Since CD28 is 
expressed by naïve T cells, while CTLA-4, which binds B7 with a higher affinity than CD28, is 
only expressed after activation and enhanced by CD28 signaling (134), it appears that T cells can 
first help DCs elicit a type-1 immune response (via CD28 signaling), followed by inducing 
inhibitory factors (via CTLA-4 signaling) at later time points during the immune response as a 
negative feed-back loop.   
CD4 Th cell interaction with antigen presenting DCs has been suggested to be required 
for the induction (“licensing”) of the DCs to induce CTL responses. The licensing of DCs by 
CD4 Th cells is suggested to be dependent on the expression of CD154 (CD40L) on the CD4
+
 T 
cells. Interaction of CD154 with its receptor, CD40, on the DC surface primes the DC for high 
IL-12p70 production (135-136). This interaction appears to be dependent on the cognate 
recognition of antigens on the same DC by CD4
+
T cells and CD8
+
T cells. DCs isolated from 
mice lacking MHC class II molecule expression are unable to induce full CD8
+
 CTLs and have 
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impaired CD8
+
  memory cell formation in response to herpes simplex virus-1 (HSV-1) infection 
(137).   
Naïve CD8
+
T cells, which do not express CD40L, produce IFN  rapidly after interaction 
with DCs. In cooperation with CD40L-expressing CD4
+
T cells, naïve CD8
+
T cells are able to 
induce IL-12p70 production by DCs and help in their maturation (138). In contrast to the helper 
function of naïve CD8
+
 T cells, CTLs have been shown to kill Ag-carrying DCs, a process which 
appears to prevent excessive T cell expansion and to limit tissue damage (139-140). Ag-loaded 
iDCs can be rescued from CTL-mediated killing by memory CD8
+
 T cells, suggesting a helper 
function for memory T cells. While interaction of iDCs with CTLs results in the simultaneous 
release of TNF  and granzyme B by CTLs, interaction of memory cells with iDC results in the 
rapid release of TNF , followed several hours later by granzyme B release (141). The rapid 
release of TNF  supports the up-regulation of the inhibitor of granzyme B, protease inhibitor PI-
9 (analog of murine SPI-6), by the DCs, protecting them from the subsequent released of 
granzyme B by the CTLs (141).  The ability of memory T cells to protect DCs from CTL-
mediated killing can be used for the enhancement of DC-based vaccines. In a mouse model, it 
was shown that the incorporation of “heterologous” (tumor-irrelevant) recall Ags on tumor-
peptide loaded DCs, helped in the induction of IL-12-dependent immune responses in tumor-
bearing mice, which have tumor-specific CTLs in their circulation that would kill tumor-peptide 
loaded DCs (142). These data suggest that the simultaneous targeting of tumor-irrelevant 
memory T cells and tumor-specific T cells may have the potential to protect DCs from CTL 
mediated elimination before being able to elicit strong CTL, thereby enhancing the efficacy of 
DC-based anti-tumor vaccines.    
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1.5 SCOPE OF THIS THESIS 
The scope of this thesis is to define the role of the maturation and polarization of DCs in the 
development of effector and memory CD8
+
 T cells and to evaluate the ability of lymphocytes to 
induce polarized DC1s as vaccination tools in cancer. Furthermore, in an attempt to develop 
improved treatment of advanced cancer, I explored the feasibility of modulating the tumor 
chemokine microenvironment to enhance the entry of DC1-induced effector CD8
+
 T cells into 
tumor tissues.     
In Chapter 2 I use a human in vitro model to analyze the effects of the differentiation 
status and IL-12 production ability of monocyte-derived DCs on the differentiation of naïve 
CD8
+
 T cells. I demonstrate that DCs matured in the presence of mediators of acute 
inflammation (interferons and TLR ligands), favor the induction of cytolytic CD8
+
 T cells with 
high expression of CXCR3 (receptor of CXCL9/MIG, CXCL10/IP10 and CXCL11/ITAC) and 
CCR5 (receptor for CCL5/RANTES) and peripheral homing abilities. In contrast, DCs matured 
under conditions mimicking chronic inflammation (matured in the presence of PGE2) or matured 
for prolonged period of time (so-called exhausted DCs) induce the proliferation and activation of 
CD8
+
 T cells, but do not imprint cytolytic abilities on them. The distinct ability of 
“inflammatory” type-1 polarized DCs (DC1s) to induce CTL functions is, in part, regulated by 
their elevated ability to secrete IL-12p70. Type-1 polarized DCs also induce 
CXCR3
+
CCR5
+
GrB
+
 effector CD8
+
T cells from melanoma derived CD8
+
T cells, showing the 
superior ability of these DCs to induce type-1 anti-tumor responses.  
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The anti-tumor CTL inducing capacity of type-1 polarized DC suggests that these DCs 
would be favorable as vaccine in therapeutic cancer vaccines. The high expression of CXCR3 
and CCR5 might allow the anti-tumor CTLs to migrate to tumor sites.  Since CTLs induced by 
type-1 polarized DCs can revert to memory cells upon prolonged culture and can acquire 
cytolytic capacity upon restimulation with Ag-loaded type-1 polarize DCs, vaccination with this 
type of DCs would produce an “immediate” anti-tumor CTL response that could eliminate 
tumors, followed by the development memory cells that can provide protection against tumor 
recurrence.       
The distinct CD8
+
 T cell priming abilities by differentially matured DCs observed in 
chapter 2, the activation of CD8
+
 T cells with cytolytic effector functions versus activation of 
CD8
+
 T cells without cytolytic effector functions, prompted me in Chapter 3 to examine the 
CD8
+ 
T cell differentiation pathway induced by the priming with low IL-12p70 producing 
“exhausted” DCs. I show that, in contrast to inflammatory DC1s, non-inflammatory, exhausted 
DCs lack expression of the transcription factor T-bet, which in T cells is associated with type-1 
polarization, and lack IL-12p70 secretion. CD8
+
T cells primed by these T-bet
-
/IL-12
-
 DCs show 
a reduced mTOR kinase activity when compared to (T-bet
+
/IL-12
+
) DC1-primed CD8
+
 T cells 
and directly differentiate into central-memory cells which are able to undergo secondary 
expansion sooner than DC1-primed CD8
+
 T cells and acquired cytolytic effector functions upon 
restimulation with DC1s. The data from chapter 3 suggest that exhausted DCs, which lack IL-12 
production during T cell priming, might have a specialized function in immune responses by 
inducing the direct differentiation of naïve CD8
+
 T cells into central-memory cells. This 
specialized central-memory inducing function of “non-inflammatory” exhausted DCs reconciles 
the observation that at later time points of an immune response there is a preferential induction of  
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memory T cells. The preferred induction of memory cells by these DCs would allow their use in 
prophylactic vaccine settings, in which the induction of large numbers of long-lived memory T 
cells is desired. Currently the induction of large numbers of central-memory cells is achieved by 
the priming of T cells in the presence of adjuvant, which elicits a strong inflammatory response, 
to ensure the induction of a large effector pool followed by memory cell formation. The memory 
cells are then “boosted” by vaccination to increase the number of specific memory cells. The 
interval between the priming and booster doses can take weeks or months. The accelerated 
generation of central-memory cells by non-inflammatory DCs might allow for the shortening of 
the interval between the prime-boosting. This would be favorable in situations where a rapid 
induction of large numbers of protective memory T cells is required (e.g. bioterrorism threats and 
epidemics).           
The combined data from chapters 2 and 3 indicate that the inflammatory environment in 
which DCs are matured and the duration of maturation determine the preferential induction of 
cytolytic effector versus central-memory CD8
+
 T cells. This differential T cell priming ability of 
DCs would allow for the optimization of the DC maturation methods for immunotherapy, 
depending on the T cell response (effector versus memory) that is desired.     
Since the results of chapters 2 and 3 show a distinct ability of type-1 polarized DCs to 
induce cytolytic effector CD8
+
 T cells, which is desirable in cancer immunotherapy, in Chapter 
4 I examine the feasibility of using lymphocytes to generate IL-12p70 secreting type-1 polarized 
DCs in order to limit the need for expensive recombinant clinical-grade cytokines. The ability of 
activated lymphocytes to secrete DC-polarizing cytokines allows for the maturation and type-1 
polarization of autologous DCs, which produce elevated levels of CTL-promoting IL-12 and 
CTL-attracting CXCL10/IP10. Furthermore, I show that this DC maturation and polarization 
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protocol works equally well with PBMCs from healthy donors and melanoma patients, providing 
support for the use of this method in cancer immunotherapy settings. The supernatant-matured 
DCs are able to migrate in response to CCL21, suggesting that after injection these DCs would 
be able to migrate to lymph nodes. When loaded with tumor-associated peptides, supernatant-
matured DCs are superior when compared to non-inflammatory DCs in inducing anti-tumor 
CD8
+
 T cell responses from naïve CD8
+
 T cells.  These data show the feasibility of producing 
low-cost type-1 polarized DCs using autologous lymphocytes. While the use of cytokine-
matured DCs in clinical settings might remain the preferred choice in countries where clinical 
studies have abundant funding, in many countries this might not be the case and the use of 
lymphocyte- or supernatant-matured DCs could provide an alternative method for type-1 
polarized DC generation.  
In chapters 2 and 3 and 4, I show that type-1 polarized DCs produce high levels of IL-
12p70 and are required for the induction of CXCR3
+
 CCR5
+
 cytolytic anti-tumor CD8
+
 T cells 
that have peripheral homing ability. However, tumors have developed multiple mechanisms to 
prevent elimination by T cells and most tumors do not produce chemokines (such as CXCL10 
and CCL5) that attract tumor-specific CTLs. Since type-1 DC-primed CD8
+
 T cells express 
CXCR3 and CCR5, in Chapter 5 I examine the ability of manipulating the tumor-chemokine 
environment to enhance the production of CTL-attracting chemokines. I show that the 
combination of IFN , COX-inhibitors (indomethacin), and poly-I:C, selectively enhances the 
production of CTL-attracting chemokines (CCL5 and CXCL10/IP10) while reducing the 
production of CCL22, a Treg-attracting chemokine, by tumor tissues in  an NF- B-dependent 
manner. The enhanced production of CXCL10/IP10 and CCL5 by the “triple combination-” 
treated tumor cells results in the attraction of CXCR3
+
 CCR5
+
 cytolytic effector CD8
+
 T cells, 
 31 
while inhibiting the attraction of unfavorable regulatory T cells (Treg). These data suggest that the 
unfavorable chemokine environment of tumors can be altered by the combined use of IFN , 
indomethacin and poly-I:C. This treatment could be used as a cancer therapy by itself in which 
case it would allow for the attraction of spontaneously arising anti-tumor T cells. Alternatively, it 
could be used in combination with tumor (peptide)-loaded cytokine- (chapter 2 and 3) or 
lymphocyte-supernatant-(chapter 4) matured DC1s, which would induce large numbers of 
cytolytic CXCR3
+
CCR5
+ 
tumor-specific CTLs that then can migrate to triple-combination 
treated tumors.    
 In Chapter 6 I combine the findings of the work presented in this thesis with the 
findings from other groups to provide an overview of the role of DCs activated in different 
conditions in the induction of different subsets of CD8
+
 T cells and their use in immunotherapy, 
alone or in combination with tumor-conditioning therapies. 
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2.1 ABSTRACT 
The ability of cancer vaccines to induce tumor-specific CD8
+
 T cells in the circulation of cancer 
patients has been shown to poorly correlate with their clinical effectiveness. Here, we report that 
although antigens presented by different types of mature dendritic cells (DCs) are similarly 
effective in inducing CD8
+
 T cell expansion, the acquisition of CTL function and peripheral-type 
chemokine receptors, CCR5 and CXCR3, requires antigen presentation by a select type of DCs. 
Both “standard” DCs (matured in the presence of PGE2) and type-1-polarized DCs (matured in 
the presence of interferons and TLR-ligands which prevent DC “exhaustion”) are similarly 
effective in inducing CD8
+
 T cell expansion and acquisition of CD45RO
+
IL-7R
+
IL-15R
+
 
phenotype. However, Granzyme B expression, acquisition of CTL activity and peripheral tissue-
type chemokine responsiveness are features exclusively exhibited by CD8
+
 T cells activated by 
type-1-polarized DCs. This advantage of type 1-polarized DCs was observed in polyclonally-
activated naïve and memory CD8
+
 T cells and in blood-isolated melanoma-specific CTL 
precursors. Our data help to explain the dissociation between the ability of cancer vaccines to 
induce high numbers of tumor-specific CD8
+
 T cells in the blood of cancer patients and their 
ability to promote clinical responses, providing for new strategies of cancer immunotherapy.  
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2.2 INTRODUCTION 
Recent trials of cancer vaccines demonstrated that the induction of high numbers of circulating 
tumor-specific CD8
+
 T cells is not necessarily accompanied by acquisition of an effector 
function (143-144), resulting in the limited ability of the current vaccines to induce tumor 
regression (145-148). This raises the question of whether the currently used vaccination 
strategies are optimal with regard to their ability to induce effector-type cytotoxic CD8
+
 T cells 
(CTLs) with tumor-relevant homing potential.  
In the case of CD4
+
 T cells, extensive studies in human and mouse models have 
demonstrated that dendritic cells (DCs) maturing in different environments or pre-activated for 
different periods of time can instruct  naïve CD4
+
  T cells to selectively acquire Th1 or Th2 
effector functions (3, 93, 149-150), leading to the concept of “signal 3” which selectively 
regulates the acquisition of T cell effector functions (3). While the role of the functional status of 
DCs in the development of effector CD8
+
 T cells is less clear, in several in vivo mouse models of 
infections it was demonstrated that inflammatory cytokines, such as IL-12, IFN  and IFN , not 
only regulate the proliferation of CD8
+
 T cells, but also their acquisition of CTL functions (121, 
151-152). 
In order to directly test if the induction of CTL functions and tumor-relevant chemokine 
responsiveness are differentially regulated by different DC types, we compared the phenotype 
and functions of human CD8
+
 T cells primed by different types of mature, highly-stimulatory 
DCs, such as type-1-polarized DCs matured in the presence of IFNs and TLR ligands (including 
the clinically-used TNF /IL-1 /Poly-I:C/IFN /IFN -matured DC1s; ClinicalTrials.gov: 
NCT00390338, NCT00099593, NCT00766753, NCT00558051 and NCT00970203) (71) and 
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non-polarized DCs matured in the presence of PGE2 (including the clinically-applied TNF /IL-
1 /IL-6/PGE2-matured “standard” (s)DCs) (20) that were previously shown to induce different 
numbers of tumor-specific T cells, as determined by IFN  ELISPOT (71).  
Our data indicate that while both type-1-polarized and non-polarized, DCs induce similar 
CD8+ T cell expansion, the induction of functional CTLs with peripheral homing capacity 
requires “non-exhausted” type-1-polarized DCs. In contrast, non-polarized DCs selectively 
induce CD8+ T cell expansion, without the accompanying development of CTL functions or 
peripheral homing potential. 
 
2.3 MATERIAL AND METHODS 
Cell lines, media and reagents. Serum-free AIM-V medium (Invitrogen, Carlsbad, CA) 
was used to generate DCs and IMDM (Invitrogen) with 5% human serum (Atlanta Biologicals, 
Norcross, GA) was used for in vitro sensitization (IVS) experiments. The following factors were 
used to generate mature DCs: rhuGM-CSF and IL-4 (gifts from Schering Plough, Kenilworth, 
NJ), IFN  (Intron A), rhuTNF , rhuIFN , rhuIL-1  (all from Strathmann Biotech, Germany), 
rhuIL-6 (Genzyme, Cambridge, MA), lipopolysaccharide (Sigma, St. Louis, MO), PGE2 (Sigma) 
and poly-I: C (Sigma). IL-2 (Chiron Corp, Emeryville, CA) and rhuIL-7 (Strathmann Biotech) 
were used to support the CD8
+
 T cell expansion.  
 
Generation and maturation of dendritic cells.  
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Peripheral blood mononuclear cells (PBMCs) were obtained from the blood of healthy 
donors or melanoma patients using lymphocyte separation medium (Cellgro Mediatech, 
Herndon, VA). Monocytes were isolated on density gradients, with Percoll (Sigma), followed by 
plastic adherence. Monocytes were cultured for 6 days in 24-well plates (Falcon) at 5x10
5 
cells 
per well in rhuGM-CSF and IL-4 (both 1000U/ml). At day 6, maturation was induced by 
exposing the DCs to the following combinations of maturation stimuli: LPS (250 ng/ml) and 
IFN  (1000 U/ml), LPS and PGE2 (10
-6 
M), TNF  (100ng/ml) and IFN , TNF and PGE2 for 48 
hours (apart from Fig 1B, when 24-96 hours maturation was used, as indicated). In addition, as 
representatives of clinically-applicable polarized and non-polarized DC currently used as cancer 
vaccines, we used non-polarized standard (s)DCs matured for 48 hours in the presence of TNF  
(100 ng/ml), IL-1  (25 ng/ml), PGE2 (10
-6 
M), and IL-6 (1000U/ml) (20), and alpha-type-1-
polarized DCs ( DC1) matured using the cytokine cocktail composed of TNF  (100 ng/ml), IL-
1  (25 ng/ml), IFN (1000 U/ml), Poly-I:C (20 g/ml); and IFN  (3000 U/ml) (71). 
 
Isolation of peripheral blood CD8
+ 
T cell populations.  
Peripheral blood mononuclear cells (PBMCs) were obtained from the blood of healthy 
donors or melanoma patients using lymphocyte separation medium (Cellgro Mediatech, 
Herndon, VA). Naïve CD8
+
CD45RA
+
CD45RO
- 
T cells were isolated from the lymphocyte 
fraction by negative selection with CD8 enrichment cocktail with the addition of biotinylated 
anti-CD45RO antibody, (StemCell Technologies Inc, Vancouver, Canada) as a uniform 
population of CD8
+
CCR7
+
CD45RA
+
CD45RO
-
cells (138, 153). CD8
+
CCR7
+
CD45RA
-
(CD45RO
+
) memory T cell population was flow-sorted using MoFlo high-speed cell sorter 
(Dako Cytomation), after labeling with appropriate antibodies. 
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Flow cytometry.  
Two- and three-color cell surface and intracellular immunostaining analysis was 
performed using Beckman Coulter Epics XL flow-cytometer, after staining with the antibodies 
against human Granzyme B (BD and CellSciences), CCR7 (R&D Systems), CCR5 (BD 
Pharmingen), or the corresponding isotypes IgG2a and IgG1. HLA-A2/MART127-35 tetramer 
staining (Beckman Coulter, Immunomics) was performed according to the manufacturer’s 
instructions.  
 
In vitro sensitization (polyclonal).  
Naïve CD8
+
CD45RA
+
CCR7
high
 T cells (5x10
5
 cells/well) were activated with SEB-
pulsed monocyte-derived DCs (5x10
4
 cells/well), as described (138, 153). Autologous or 
allogeneic DCs were used with similar results. On day 5-6, expanded CD8
+
 T cells were counted 
and analyzed for the expression of chemokine receptors and chemokine responsiveness, and for 
CTL phenotype and function (see Supplemental Fig. 1 for the kinetics of acquisition of CTL 
functions in the differentially-primed CD8
+
 T cells). Alternatively, the cultures were fed with 
low dose IL-2 and IL-7 (10 ng/ml) every two days and analyzed for cell surface and intracellular 
markers on day 16-20. When indicated, neutralizing IL-12 antibody (R&D Systems; Clone 
24910) was added at the beginning of the in vitro sensitization culture. In preliminary 
experiments, we compared the outcome of naïve CD8
+
 T cell priming by polarized and non-
polarized DCs in the additional presence of CD40L-expressing J558 cells. Since the presence of 
CD40L did not abolish the differences in the phenotype and function of the resulting T cells, all 
subsequent experiments were performed in the absence of CD40L.   
In vitro sensitization (melanoma-specific).  
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Bulk CD8
+
 T cells (5x10
5
 cells/well) were activated with the HLA-A2-restricted peptide 
MART127-35 pulsed autologous DCs (5x10
4
 cells/well). 3,000 rad-irradiated CD40L-J558 cells (5 
x 104) were added as surrogates of CD40L-expressing CD4+ Th cells, as described (71). On day 
4 rhuIL-2
 
(50 units/mL) and IL-7 (10 ng/mL) were added. CD8
+ 
T-cell cultures were expanded 
by an additional stimulation (day
 
14) with irradiated peptide-pulsed autologous PBMCs. At day
 
24, the differentially induced CD8
+
 T-cell lines were stained for CCR5, Granzyme B and 
MART1. CTL activity
 
was determined by 
51
Cr-release assays against HLA-A2
+
 melanoma (Fem 
X), with HLA-A2
neg
 397 melanoma cells serving as negative specificity control. 
 
Chemotaxis assay.  
Chemotaxis assays were performed in 96 well transwell plates with a 3 m pore size 
polycarbonate filter (Corning Inc, Corning, NY).  The lower chamber was filled with 200 l of 
rhuCCL19 (100-1000 ng/ml) or rhuCCL5 (100-1000ng/ml) in RPMI-1640+0.5% FBS 
(Chemotaxis media), 50 l (5x10
4
 cells) of differentially activated CD8
+
 T cells were added in 
the upper chamber and migration chambers were incubated for 3 h at 37
o
C.  After 3 h, the cells 
from lower wells were harvested, and counted. The number of cells that migrated in media alone 
was subtracted to normalize for background migration. 
 
CTL assay.  
Cytolytic activity against HLA-A2
+
 melanoma cells (Fem X) was determined by standard 
4 h
 51
Cr-release assays, with HLA-A2
neg
 397 melanoma cell line serving as negative
 
control of 
specificity. The results were calculated and recorded
 
as percent target killing at individual E:T 
ratios or percentage of cytolysis was  converted to lytic units (LU10/10
7
) as described (154). 
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Statistical analysis.  
The data was analyzed using student’s t test (with paired tests being used for comparisons 
including DC1- versus sDCs-induced responses from multiple donors). p values of less than 
0.05 were considered significant. 
 
 
 
 
2.4 RESULTS 
2.4.1 Independent regulation of CD8+ T cell expansion and acquisition of CTL functions 
by polarized and non-polarized DCs  
In order to delineate the requirements for the effective expansion of CD8
+
 T cells and 
their acquisition of effector functions, we compared the outcome of CD8
+
 T cell priming by DCs 
induced to mature by mediators of acute inflammation (combination of interferons and TLR 
ligands) or by mediators of chronic inflammation (presence of PGE2 (155-157)). While the DC 
maturation in the presence of PGE2 is associated with an irreversible process of DC “exhaustion” 
manifested by reduced ability to produce IL-12, the key mediator of inflammatory-type 
responses (39), and reduced ability to induce Th1 responses of CD4
+
 Th cells (5, 150, 158), type-
1-polarized DCs (DC1s) induced in the conditions of early inflammation avoid the maturation-
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associated DC “exhaustion”, retaining their ability to produce IL-12 and to induce Th1 responses 
of CD4
+
 Th cells (3, 5, 71, 158).  
As shown in Fig. 1A (left), both polarized and non-polarized DCs induced similar rates of 
expansion of naïve CD8
+
 T cells. However, only naïve CD8
+ 
T cells primed by the polarized 
DC1s in our previously-established model of priming of naïve CD8
+
 T cells (138, 153) 
demonstrated an effective induction of Granzyme B (GrB; right), a marker of effector T cell 
differentiation (159). In sharp contrast, the low IL-12-producing non-polarized DCs (5, 71, 158) 
did not prime naive CD8
+
 T cells to express GrB (Fig. 1A, right), despite inducing a similar or 
higher T cell expansion (Fig. 1A, left).  
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Figure 1.  Differential regulation of CD8+ T cell expansion versus the induction of CTL granules by DCs 
matured in different inflammatory conditions. 
Immature DCs were activated with different combination of cytokines (see Materials and Methods), resulting in 
different levels of IL-12p70 production (TNF /IFN : 3610±160 pg/ml; LPS/IFN : 3960±30 pg/ml; DC1: 
1900±120 pg/ml; TNF /PGE2: 330±80 pg/ml; LPS/PGE2 and sDC: both below 20 pg/ml).  For priming of naïve 
CD8+ T cells, DCs were harvested after 48 hours (additionally, 24- and 96 hour-matured DCs were tested in Fig 
1B), washed, pulsed with antigen (SEB) and co-incubated with naïve CD45RA+CD8+ T cells (triplicates). On day 
5, CD8+ T cells were counted to assess cell expansion (A, left) and stained for intracellular Granzyme B (GrB) (A; 
right)  The fold increase in MFI (mean fluorescent intensity) of GrB was calculated as the ratio of GrB MFI to 
isotype-control MFI (mean ± SE of three independent cultures). (A) Selective induction of GrB-expressing CD8+ T 
cells by polarized DCs. (B) Polarized DCs show persistent (although reduced) ability to induce Granzyme B-
expressing CD8+ T cells even after 96 hrs of DC maturation. 
 42 
Importantly for their use as therapeutic agents in vivo, type-1-polarized DCs retained a 
significant (although reduced) ability to induce GrB expression in expanding CD8
+
 T cells, even 
at later times (96hrs) after the induction of their maturation (Fig. 1B). These latter observations 
indicate that the maturation of DCs in the conditions mimicking early inflammation allows them 
to at least partially avoid or delay the acquisition of an “exhausted” status (150, 158), previously 
shown to be associated with abrogated ability to induce functional Th1 responses in the 
population of CD4
+
 T cells (150). 
Using the clinically-relevant TNF /IL-1 /Poly-I:C/IFN /IFN -matured DC1s (71) and 
TNF /IL-1 /IL-6/PGE2-matured “standard” (s)DCs (20) as representatives of type-1-polarized 
versus non-polarized DCs, we observed that the induction of GrB correlated with the superior 
cytolytic function of CD8
+
 T cells primed by the polarized DCs (Fig. 2A). In contrast, priming of 
CD8
+
 T cells by the PGE2-matured sDCs led to low levels of GrB and poor ability to kill 
antigen-pulsed target cells (Fig. 2A-C), despite effective proliferation of T cells in these cultures 
and induction of CD45RO (Fig. 1, 2B). In accordance with the central role of IL-12 in the 
development of CTL activity in CD8
+
 T cells, neutralization of that factor abrogated GrB 
induction by type-1 polarized DCs (Fig. 2D).  
Since certain conditions of effector T cell induction can be associated with their 
irreversible differentiation into short-lived, terminally-differentiated effector cells (160), we 
tested the ability of the DC1-induced effector cells to respond to secondary activation and 
undergo secondary CTL differentiation. As shown in Fig. 3, after completing the effector phase 
of activation (more than 2 weeks after priming), the DC1-primed CD8
+
 T cells down-regulated 
the levels of GrB expression and their cytolytic activity. Consistent with the ability of polarized 
DC1s to induce long-lived CD8
+
 T cells (71), such resting DC1-primed CD8
+
 T cells  
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Figure 2. Induction of cytolytic and non-cytolytic pathway of CD8+ T cell differentiation by polarized DC1s 
and standard DCs.   
Naïve CD8
+
 T cells primed with either polarized or non-polarized DCs, using DC1 (matured for 48 hours in TNF , 
IL-1 , IFN , Poly-I:C and IFN  and  sDCs (matured for 48 hours in TNF , IL-1 , IL-6 and PGE2 (20)), as the 
respective representatives. (A) Cytolytic function of day 5 primed CD8
+ 
T cells was assessed by standard 
51
Cr-
release assay using SEB pulsed JY cells as targets(153). Inset, data calculated as lytic units. (B-C) Intracellular 
expression of GrB and surface expression of CD45RO were determined by flow cytometry on day 5 (B) Data from a 
representative donor. Gray lines indicate isotype controls.  (C) Summary of data from 3 different donors. Fold 
increase in MFI of GrB and CD45RO was calculated as in Figure 1. Data is shown as mean and SEM of three 
independent experiments that all showed advantage of polarized DC1s in the induction of GrB (p < 0.02). (D) 
Neutralization of IL-12 abrogates the induction of GrB-positive CD8
+
 T cells by polarized DC1s. Representative 
data from 3 experiments that all yielded similar results 
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expressed high levels of IL-15R  and IL-7R  (CD127) (Fig 3A, see Supplemental Fig. 2 for the 
levels of both receptors in naïve CD8
+
 T cells), the memory cell-associated receptors for the 
homeostatic cytokines mediating long-term survival of CD8
+
 T cells (161-162), and were fully 
capable of rapidly re-acquiring high levels of CTL activity upon restimulation with polarized 
DC1s (Fig. 3B). 
 
Figure 3. CD8+ T cells primed by polarized DC1s revert to memory status and can be reactivated to undergo 
secondary CTL differentiation. 
 (A) Induction of memory CD8
+
 T cells at later stages of activation with DC1. Naïve CD8
+
 T cells were primed 
with DC1. After 3 weeks, the cells were analyzed for the expression of GrB, CD45RO, IL-7R , and IL-15R .
 
 (B) 
Effective induction of secondary CTL function in DC1-primed resting CD8
+
 T cells. Three weeks after priming 
with DC1s, resting CD8
+
 T cells were (re)stimulated for 24 hours with DC1s and re-assessed for CTL function. 
SEB pulsed JY cells were used as target population for Chromium release assay (153). Similar data was obtained in 
3 independent experiments, with the observed range of killing between 0% and 8.9% (at the maximal 30:1 ratio) for 
the resting CD8
+
 T cells and between 34.8% and 72% for the re-stimulated CD8
+
 T cells. 
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2.4.2 Polarized DC1s induce a switch in chemokine receptor expression and peripheral 
tissue-associated chemokine responsiveness in expanding CD8
+
 T cells: key role of IL-12.      
Since polarized DC1s and standard DCs both promoted the expansion of naive T cells 
but had a differential impact on the induction of their CTL function, we tested their influence on 
the CD8
+
 T cell expression of CCR7 and CCR5, the respective lymphoid versus peripheral 
effector-type chemokine receptors, and the migratory responsiveness to their respective ligands, 
lymph-node-associated CCL19/MIP3  (163-165) and CCL5/RANTES, a ubiquitous peripheral 
tissue-produced chemokine (163-164) known to be over-expressed in cancer tissues (164, 166).   
As shown in Fig. 4A and B, DC1s effectively induced the expression of CCR5, the 
chemokine receptor typical for effector (and effector-memory) CD8
+
 T cells (113, 167-168), 
with a concomitant loss of CCR7 on 50-70% of CD8
+
 T cells.  In contrast, CD8
+
 T cells 
stimulated by sDCs retained high levels of CCR7 expression, and did not acquire CCR5.  
In accordance with their differential expression of CCR7 and CCR5, the differentially-
activated CD8
+
 T cells showed reciprocal patterns of migratory responsiveness to the  LN-
associated versus peripheral tissue-associated chemokines (CCL19 and CCL5, respectively (163-
164, 166, 168)) with DC1-primed CTLs preferentially migrating towards the peripheral tissue 
chemokine CCL5 (RANTES), while the sDC-primed T cells preferentially responded to the 
lymphoid chemokine CCL19 (Fig. 4C). 
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Figure 4. Polarized DC1s induce a switch in chemokine receptor expression and chemokine responsiveness.  
Naïve CD8
+
 T cells were primed by DC1 or sDC. Differentially primed CD8
+
 T cells were harvested on day 5 and 
analyzed for the expression of chemokine receptors. (A) Data from a representative donor: Levels of expression of 
CCR7 and CCR5 (black lines), compared to isotope controls (gray lines). (B) Cumulative data from 3 donors. Fold 
increase in MFI of CCR7 and CCR5 were calculated as in Figure 1. Data is shown as mean + SEM of three 
independent experiments that all showed advantage of polarized DC1s in promoting the loss of CCR7 expression 
(p < 0.0005) and induction of CCR5 (p < 0.005). (C) Differentially primed CD8
+
 T cells were analyzed for their 
responsiveness to chemokine receptor ligands CCL19 and CCL5 by chemotaxis assay (mean ± SEM of three 
independent experiments) In the 3 donors tested, at the maximal concentrations of the two chemokines, the 
migration of DC1s to CCL19 was 3.4-fold to 5.2-fold lower than the migration of sDCs to CCL19, while the 
migration of DC1s in response to CCL5 was 3.6 to11.8- fold higher that the migration of sDCs. (D) IL-12 blocking 
antibody was added during the priming of naïve CD8
+
 T cells by polarized DC1s. CCR7 and CCR5 expression 
(black lines) was assessed by flow cytometry on day 5.  Gray line indicates isotype control in all histograms. Similar 
data was observed in two additional experiments. 
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Since in the CD4
+
 T cell system, the levels of DC-produced IL-12 were shown to be the 
key to the differential ability of DCs to induce a Th1 or Th2 pattern of differentiation in naïve 
CD4
+
 T cells (3, 93, 150) and recombinant IL-12 was shown to directly affect the expression of 
Th1 and Th2-associated chemokine receptors (169-170), we tested the role of IL-12 in the DC-
induced switch in chemokine receptor expression of CD8
+
 T cells. As shown in Fig. 4D, the 
neutralization of IL-12 during T cell priming abrogated the above differences, preventing the 
down-regulation of CCR7 and elevation of CCR5 on CD8
+
 T cells activated by the polarized 
DCs. These data indicate that IL-12, originally identified as a factor supporting killer activities of 
CD8
+
 T cells and NK cells (reviewed in (39)), is also a key DC-produced factor responsible for 
the switch from central to peripheral chemokine receptor pattern in the differentiating naïve 
CD8
+
 T cells. 
 
2.4.3 Polarized and non-polarized DCs differentially regulate CTL activity and 
chemokine receptor expression on tumor antigen-specific CD8
+
 T cells. 
Prompted by the results of the experiments with polyclonally-activated naïve CD8
+
 T 
cells (Fig 2A)   and similar data obtained using memory cells (Supplemental Fig. 3), we have 
compared the outcome of in vitro sensitization (IVS) of HLA-A2-restricted melanoma-specific 
CD8
+
 T cells using MART-127-35-loaded autologous DC1 or sDCs , currently applied as cancer 
vaccines.  
In contrast to the short-term experiments performed in the polyclonal system, the 
generation of high numbers of MART-1-specific T cells required prolonged cultures of the 
differentially-sensitized CD8
+
 T cells. While in these long-term cultures we could not detect the 
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differences in CCR7 expression between the differentially-sensitized CD8
+
 T cells (CCR7 was 
low on both populations, data not shown), exclusively the MART-1-specific (tetramer-positive) 
CD8
+
 T cells sensitized with polarized DC1s showed high GrB expression and high CTL 
activity against MART-1-expressing HLA-A2
+
 melanoma cells (but not against HLA-A2
-
 
melanoma cells; Fig. 5A-C). While in contrast to their inability to induce CTL activity in naïve 
CD8
+
 T cell population (see Figs 1-2), non-polarized DCs showed significant ability to induce 
CTL function in tumor-specific T cells from melanoma patients, though type-1 polarized DCs 
were clearly more efficient (Fig. 5C), with the level of advantage comparable to that observed in 
the polyclonal model of (re)activation of “bulk” (memory and naïve) CD8+ T cells 
(Supplemental Fig. 4).  In accordance with the data obtained in the polyclonal models (Fig 4), 
MART-1-specific CD8
+ 
T cells sensitized by polarized DC1s also showed elevated levels of 
CCR5 (Fig. 5D). 
In addition to CCR5, which shows high effectiveness in attracting mouse effector cells to 
melanoma lesions (171) and was recently implicated in the responsiveness of melanoma patients 
to immunotherapy (172), another CTL-associated chemokine receptor, CXCR3, has been 
recently implicated in melanoma regression (36) and prolonged survival of patients with 
advanced disease (23). Therefore, we compared the expression of CXCR3 on MART-1-specific 
CD8
+
 T cells pre-sensitized with polarized DC1s and standard DCs. As shown in Fig. 5D, 
polarized DC1 induced strongly elevated levels of CXCR3 in MART-1-specific CD8
+
 T cells 
from melanoma patients. 
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Figure 5. Polarized DC1s and non-polarized sDCs induce differential expression of GrB and melanoma-
relevant chemokine receptors on MART-1-specific CD8
+
 T cells.  
DC1 and sDCs from HLA-A2
+ 
melanoma patients were pulsed with the HLA-A2-restricted MART-1 peptide and 
used to stimulate autologous CD8
+
 T cells in an in vitro sensitization system (see M&M). (A) Intracellular 
expression of GrB in MART-1-tetramer
+
 CD8
+
 T cells. Similar data was obtained in case of two donors. (B-C) High 
CTL activity of DC1-sensitized CD8
+
 T cells against melanoma cells. Cytotoxic activity of the differentially 
primed CD8
+
 T cells was measured against MART-1-expressing HLA-A2
+
 melanoma cell line (Fem-X). The inset: 
HLA-A2
- 
melanoma cell line (melanoma 397) was used as a negative control of antigenic specificity. (B) 
Representative data from one patient. (C) Combined data from 4 different patients expressed as lytic units (p < 
0.005). (D) Surface expression of CCR5 and CXCR3 were measured in MART-1-tetramer
+
 CD8
+
 T cells. Left: 
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Representative data from a single melanoma patient. Right: Cumulative data from 3 melanoma patients expressed as 
the mean + SEM. DC1-sensitized  CD8
+
 T cells show enhanced expression levels of both CCR5 and CXCR3 
(p<0.05 in both cases). 
 
2.5 DISCUSSION 
Our data demonstrate that the ability of DCs to activate T cells and to efficiently induce their 
expansion does not predict their ability to induce CTL activity and the ability to respond to 
peripheral-type chemokines. In contrast, we observed that while the expansion of CD8
+
 T cells 
can be driven efficiently by the DCs matured in a wide spectrum of inflammatory conditions, the 
induction of the CD8
+
 T cell effector functions in naïve CD8
+
 T cells and a switch in their 
chemokine responsiveness was a sole property of the “non-exhausted” IL-12-producing DCs 
matured in the conditions that mimic acute inflammation (presence of interferons and TLR 
ligands). This “inflammatory” pathway of activation of CD8+ T cells, associated with the IL-12-
dependent induction of GrB
high
 CTLs, eventually results in a resting population of memory-type 
(CD8
+
CD45RO
+
GrB
low
) cells. In accordance with the previously-reported long-lived character of 
cells activated by the high IL-12-producing type-1-polarized DCs (71) and with the ability of 
recombinant IL-12 to promote CTL survival (173-174), the CD8
+
 T cells undergoing such 
“inflammatory” pathway of differentiation expressed high levels of IL-7 and IL-15 receptors 
(Fig. 3), known to be essential for the homeostatic proliferation and long term survival of CD8
+
 
T cells in vivo (161-162), and could effectively re-acquire CTL function following restimulation 
with polarized DCs. 
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The effectiveness of polarized DC1s in inducing functional CCR5 (and CXCR3)-
expressing CTLs suggest that these cells can be useful tools to direct the vaccination-induced T 
cells to tumors in therapeutic conditions. Since melanomas are known to over-express 
CCL5/RANTES (175-176), on which they rely as an autocrine growth factor (176-177), CCL5-
responsive DC1-induced T cells are likely to show improved therapeutic activity, not only due 
to their higher per-cell killer activity, but also due to their ability to preferentially home to tumor 
tissues. In support of the opposite roles of tumor-expressed CCR5 versus T cell expressed CCR5 
in melanoma progression (respectively, tumor-promoting vs. tumoricidal), it was recently shown 
that while overall populations of melanoma patients lacking functional CCR5 (CCR5Delta32
+
 
individuals) and CCR5-competent melanoma patients have similar course of disease, functional 
CCR5 is needed for positive response to immunotherapy (172). Similarly, in accordance with 
high expression of CXCR3 ligands: CXCL9/MIG and CXCL10/IP10, in melanoma tissues (178) 
and the presence of CXCR3 on tumor-infiltrating lymphocytes in regressing melanoma lesions 
(36), high levels of CXCR3 on circulating CD8
+
 T cells has been recently implicated in effective 
control of advanced melanoma (23). 
In contrast to such “pro-inflammatory/effector” pathway of differentiation driven by 
polarized DCs, naive CD8
+
 T cells activated by standard non-polarized DCs did not acquire CTL 
functions and remained responsive to LN-associated chemokines, even though they vigorously 
expanded. While our preliminary data indicate that such cells can be effectively reactivated by 
polarized DC1s (data not shown) to undergo secondary CTL differentiation, the identity and 
functional role of such “non-effector” CD8+ T cells induced by standard “exhausted” DCs 
remains a subject of our follow up studies. Interestingly, while non-polarized DCs were unable to 
induce the de novo effector function in naïve CD8
+
 T cells, they showed a significant (although 
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lesser than polarized DCs) ability to induce CTL function in (expectedly previously-primed) 
tumor-specific T cells from melanoma patients, type (Fig. 5A-C), and in the polyclonal model of 
(re)activation of “bulk”  (memory and naïve) CD8+ T cells (Supplemental Fig. 4). 
The current demonstration that the ability of DCs to induce proliferation and expansion 
of tumor-specific CD8
+
 T cells is independent from their ability to induce their tumor-relevant 
homing properties and tumoricidal effector functions, helps to interpret the limited effectiveness 
of cancer vaccines observed in recent clinical trials (145-148) and aid in designing corrective 
measures to enhance the efficacy of cancer immunotherapies. Several recently tested cancer 
vaccines involving antigenic peptides or tumor antigen-expressing viral vectors were shown to 
promote massive increase of blood-circulating tumor-specific CD8
+
 T cells but not clinical 
responses (143-144, 146-148). Interestingly, at least one study indicated that such split 
effectiveness of cancer vaccines can be corrected by a follow up treatment of the vaccinated 
patients with IFN  (143). While our current data (Fig. 2D) demonstrate the key role of IL-12 in 
the induction of functional CTLs by type-1-polarized DCs, it remains to be tested if other factors 
may supplement or replace the function of IL-12 in differentially-matured DCs. 
Our current data suggest that the limitations of current cancer vaccines, including ”standard” 
DC-based vaccines (179), may result from their selective deficit in inducing the effector 
functions in tumor-specific T cells, and may be corrected by the modification of the current 
therapeutic vaccines, or their combination with pro-inflammatory factors, capable of inducing 
tumoricidal function and tumor-homing ability in tumor-specific T cells. 
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2.6 IMPLICATIONS 
The goal of therapeutic (cancer) immunotherapies is the induction of large numbers of Ag-
specific CD8
+
 T cells followed by the development of long-lived memory T cells. The data 
presented in chapter 2 suggests that for the use in cancer vaccination strategies, type-1 polarized, 
inflammatory DC1s are superior in inducing the differentiation of naïve CD8
+
T cell cytolytic 
effector cells when compared with DCs matured under late/chronic inflammatory conditions. 
Since type-1 polarized DCs are also able to induce the expression of peripheral homing 
chemokine receptors CXCR3 and CCR5 on primed CD8
+
 T cells, these DCs could generate anti-
tumor immune responses. However, CD8
+
 T cells primed by DCs matured in the presence of 
PGE2 proliferated and were activated (as observed by CD45RO expression), but failed to acquire 
cytolytic ability and peripheral homing ability. In the next chapter, I examine the cell fate of 
naïve CD8
+
 T cells primed by these “PGE2-matured” DCs.      
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3.1 ABSTRACT 
 
The development of memory CD8
+
 T cells is particularly effective at late stages of immune 
responses but the mechanism of this temporal effect remains unclear. Here, we show that human 
T-bet
-
/IL-12
-
 dendritic cells (DCs) at late stages of activation or activated in the presence of the 
late-inflammatory mediator PGE2,  traditionally considered as “exhausted”, induce direct 
transition of naïve CD8
+
 T cells into central-memory cells (TCM; T-bet
low
/GrB
low
/CCR7
high
/IL-
7R
high
 with low mTOR activity). In contrast, T-bet
+
/IL-12
+ 
DCs induced by short-term exposure 
to IFNs and TLR-Ls, promote IL-12-dependent development of cytolytic effector CD8
+
 T cells 
(TEFF; T-bet
high
/GrB
high
/CCR7
low
/IL-7R
low
/mTOR
high
), followed by  the subsequent development 
of both central-memory (TCM) and effector-memory (TEM) cells. TCM cells induced by 
“exhausted” DCs share the phenotype and genetic profile with blood-isolated TCM cells and can 
undergo accelerated secondary expansion and effector (TEFF) differentiation when re-stimulated 
by the T-bet
+
/IL-12
+  “effector” DCs. Our data indicate that T-bet-/IL-12- “exhausted” DCs 
represent specialized “memory-DCs” promoting the direct differentiation of naïve CD8+ T cells 
into TCM cells.  
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3.2 INTRODUCTION 
Dendritic cells (DCs) are the key regulators of immune responses (1, 180-181). The 
environmental cues that DCs receive during their pathogen-triggered maturation and the duration 
of maturation, affect the immunostimulatory abilities of the DCs and the type of immune 
response (Th1, Th2, Th17 or Treg) that is elicited (3, 182-185). While short-time-activated DCs, 
particularly maturing in the presence of Toll-like Receptor Ligands (TLR-Ls) and interferons 
typical of early stages of inflammation (4, 186), produce high levels of the inflammatory 
cytokine IL-12p70 upon contact with T cells, allowing them to induce type-1 CD4
+
 T helper 
(Th1) responses, as well as to activate the effector functions of CTLs and NK cells (5, 23, 187-
189). In contrast, DCs at later stages of maturation or DCs maturing in conditions of chronic 
inflammation (typically associated with lack of interferons and predominance of PGE2 and other 
IL-12-suppressing factors (190-193)), rapidly lose the ability to secrete IL-12 (26, 187)  and 
become “exhausted”, losing the capacity to induce Th1 and CTL responses (26, 189, 194). 
Prompted by the high effectiveness of such nominally “exhausted” DCs in inducing the 
primary expansion of naïve CD4
+
 (26) and CD8
+
 T cells (189), and the documented negative 
impact of inflammation and inflammatory cytokines on the formation of CD8
+
 T cell memory in 
mouse in vivo models (43, 122-123, 195-197), we tested the impact of such “late-inflammation-
induced” (LI)DCs on the development of memory CD8
+
 T cells from human naïve precursors.  
Our data indicate that LIDCs, are in fact specialized in the direct induction of central-memory 
CD8
+
 T cells (TCM), in sharp contrast to T-bet
+
/IL-12
+
 “early-inflammation-induced” (EI)DCs 
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that induce a sequential development of mTOR
high
/T-bet
high
/GrB
high
 effector CD8
+
 T cells (TEFF), 
followed by the development of central-memory (TCM) and effector-memory (TEM) CD8
+
 T cells. 
 
3.3 MATERIALS AND METHODS  
Cell lines, media and reagents. Serum-free AIM-V medium (Invitrogen, Carlsbad, CA) 
and IMDM (Invitrogen) with 10% FBS were used to generate DCs. IMDM with 5% human 
serum (Gemini Bio-products, West Sacramento, CA) was used for in vitro sensitization (IVS) 
experiments. The following factors were used to generate mature DCs: rhuGM-CSF and IL-4 
(gifts from Schering Plough, Kenilworth, NJ), IFN  (Intron A), rhuTNF , rhuIFN , rhuIL-1  
(all from Strathmann Biotech, Germany), rhuIL-6 (Genzyme, Cambridge, MA), 
lipopolysaccharide (LPS), prostaglandin E2 (PGE2) and poly-I:C (Sigma, St. Louis, MO). IL-2 
and rhuIL-7 (Strathmann Biotech) were used to support the CD8
+
 T cell expansion.  
 
Generation and maturation of DCs. Peripheral blood mononuclear cells (PBMCs) were 
obtained from buffy coats (obtained from the blood bank) using lymphocyte separation medium 
(Cellgro Mediatech, Herndon, VA). Monocytes were isolated using density gradients made with 
Percoll (Sigma), followed by plastic adherence or by using CD14+ isolation kit (Miltenyi Biotec, 
Auburn, CA, USA) according to manufacturer’s instruction. Both protocols yielded similar results. 
Monocytes were cultured for 6 days in 24-well plates at 5-6x10
5 
cells per well in rhuGM-CSF 
and IL-4 (both 1000U/ml). At day 6, maturation was induced by exposing the DCs to the 
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following combinations of maturation stimuli: LPS (250 ng/ml) and IFN  (1000 U/ml); TNF  
(100 ng/ml), IL-1  (25 ng/ml), IFN (1000 U/ml), Poly-I:C (20 g/ml); and IFN  (3000 U/ml);  
LPS and PGE2 (10
-6 
M); TNF  (100 ng/ml), IL-1  (25 ng/ml), PGE2 (10
-6 
M), and IL-6 
(1000U/ml) (20).  
 
Isolation of naïve CD8
+ 
T cells. Peripheral blood mononuclear cells (PBMCs) were 
obtained from buffy coats (obtained from blood bank) using lymphocyte separation medium 
(Cellgro Mediatech, Herndon, VA). Peripheral lymphocytes were obtained following density 
gradients with percoll. Naïve CD8
+
CD45RA
+
CD45RO
- 
T cells were isolated from the 
lymphocyte fraction by negative selection with CD8 enrichment cocktail with the addition of 
biotinylated anti-CD45RO antibody, (StemCell Technologies Inc, Vancouver, Canada) as a 
uniform population of CD8
+
CCR7
+
CD45RA
+
CD45RO
-
cells. CD8
+
CCR7
-
CD45RA
-
CD45RO
+/-
 
effector and CD8
+
 CCR7
+
CD45RA
-
CD45RO
+
 central-memory T cells were flow-sorted using 
MoFlo high-speed cell sorter (Dako Cytomation), after labeling with appropriate antibodies. 
 
Flow cytometry 
Fluorescein isothiocyanate (FITC)-labeled anti-human CD80, CD40, granzyme B, CD45RO,  
Phyocoerythrin (PE)-labeled anti-human CD83, PE-Cy5-labeled anti-human CD8, CD25, CD62L and 
Allophycocyanin (APC)-labeled anti-human CD86 were all purchased from BD Biosciences (San Jose, 
CA). FITC-labeled and APC-labeled anti-human CCR7 was obtained from R&D systems. PE-labeled 
anti-human CD127 (IL-7R ) and purified anti-human/mouse T-bet were obtained from eBioscience. 
Alexa-Fluor 488-labeled rabbit-anti-human phosphorylated S6 (SER235/236) was purchased from Cell 
Signaling (Danvers, MA).  
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For surface staining, cells were transferred to a V-bottom 96-well plate and washed with FACS 
buffer (PBS/0.5%BSA/0.1% Azide). Cells were incubated with Abs for 45 minutes in the dark at RT. 
Following labeling, cells were washed twice and fixed with 2% para-formaldehyde and stored at 4 C until 
analysis.  
For intracellular staining, cells were transferred to 5ml FACS tubes and washed with PBS. Cells 
were fixed for 20min at 37C with 2% PFA, washed with PBS and subsequently permeabilized using 
100% ice cold methanol for 30min at -20C. Following permeabilization, cells were washed twice with 
FACS buffer and incubated with appropriate Abs for 30 min at RT in the dark. Following cell labeling, 
cells were washed with FACS buffer and either fixed (granzyme B and pS6 staining) or incubated for 30 
min with FITC-labeled anti-mouse IgG-Fab2 (T-bet staining), followed by washing with FACS buffer and 
fixation with 2% PFA. Fixed cells were analyzed using an Acurri C6 flow cytometer. Flow cytometry 
data was analyzed using FCS Express V3 software. 
 
In vitro sensitization and restimulation. Naïve CD8
+
CD45RA
+
CCR7
+
 T cells were 
activated with Staphyllococcus enterotoxin B (SEB)-pulsed monocyte-derived DCs in a 10:1 
ratio. Where indicated, naïve CD8
+
 T cells were labeled with carboxyfluorescein diacetate 
succinimidyl ester (CFSE; Invitrogen, Carlsbad, CA) according to manufacturer’s directions 
prior to co-culture with DCs.  On day 6-7, expanded CD8
+
 T cells were analyzed for phenotype 
and function. Alternatively, the cultures were fed with IL-2 (10 U/ml) and IL-7 (10 ng/ml) every 
two days and analyzed for cell surface and intracellular markers on day 18-21. When indicated, 
neutralizing IL-12 antibody (R&D Systems; Clone 24910) was added at the beginning of the in 
vitro sensitization culture.  
In some experiments, day 7 or day 21 differentially primed CD8
+
 T cells were collected, 
washed, counted and restimulated with SEB-loaded DCs for an additional 36 hours (for 
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granzyme B expression and CTL assay) or 4-5 days (for cell expansion). All cell counts were 
performed using a heamocytometer and trypan blue exclusion.  
  
CTL assay. Cytolytic activity against SEB-loaded JY-1 cells was determined by standard 
4 hour
 51
Cr-release assays. Following incubation 65 l of supernatant was transferred to 
lunaplates (PerkinElmer, Boston, MA) The percentage specific lysis was calculated using the 
following equation: [(experimental release - spontaneous release) / (maximum-release – 
spontaneous release)]*100, where spontaneous release is measure from supernatant of untreated 
target cells and maximum release is obtained from target cells treated with 1% Triton solution. 
Data are represented as mean +/- SEM for 4 independent experiments.    
 
Taqman analysis of mRNA expression. 
CD8
+
 T cell cultures and blood-isolated effector and central-memory cells were lysed 
using RLT buffer (RNeasy kit, Qiagen, Valencia, CA) and Total RNA was extracted using the 
RNeasy kit. 1 g of RNA extracted by above was used for cDNA synthesis and 25-50ng of 
subsequent cDNA was used to perform mRNA expression analysis by Taqman analysis on Step 
One Plus system (Applied Biosystems). All primer sets were purchased from Applied 
Biosystems.  
 
Statistical analysis. The data was analyzed using student’s t test (with paired tests being 
used for comparisons including “inflammatory” DC- versus ”exhausted”-DC-induced responses 
from multiple donors). p values of less than 0.05 were considered significant. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Late-inflammation-induced IL-12-/T-bet- DCs induce primary expansion of naïve 
CD8
+
 T cells but do not induce TEFF differentiation  
To analyze the role of “exhausted” DCs in the priming of naïve CD8+ T cells we induced 
the maturation of human monocyte-derived DCs by the exposure to TLR ligands and interferons 
typical of mimicking early/acute inflammation (4, 186) resulting in high-IL-12-producing DCs 
(5, 71, 189) or in the presence of prostaglandin E2 (PGE2), prevalent in chronic/late stage 
inflammation (190-193), for either 24 hours (early stage of maturation) or 96 hours (late stage of 
maturation). DCs activated by short-term exposure to the mediators of early inflammation were 
able of producing high amounts of IL-12 (Fig. 6A, top). As expected (187, 189, 198), the IL-12 
secretion by long-term matured inflammatory DCs was strongly diminished (Fig. 6A, bottom). In 
contrast, DCs activated in the presence of PGE2, demonstrated accelerated exhaustion, being 
unable to secrete IL-12, independently on the time-point of their activation (Fig. 6B). These 
differences in IL-12 producing capacity occurred despite the fact that the short- and long-term 
activated DCs all showed similar expression of maturation-associated co-stimulatory molecules 
(CD40, CD80, CD83 and CD86) as well as CCR7 (Fig. 6C-D). However, exclusively the DCs 
short-term activated in the early-inflammatory conditions expressed the transcription factor T-
bet, a typical marker of type-1 effector T cells (199) which expression by DCs facilitates the 
induction of Th1 responses (94, 200). Strikingly, T-bet expression was absent in long-term 
matured DCs, independently on the conditions of their maturation (Fig 6E-F), indicating a 
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general role of T-bet as a marker absent in “exhausted” DCs, independently on the path of their 
induction.  
 
 
Figure 6. LIDCs induce CD8
+
 proliferation and activation but do not support effector cell differentiation.   
Monocyte derived immature DCs were matured in different inflammatory conditions that either promote IL-12 
production (LPS + IFN  or IFN  + IFN  + TNF  + IL-1  and poly-I:C) or late/chronic-inflammatory conditions 
(LPS + PGE2 or TNF  + IL-1  + IL-6 and PGE2) for 24 or 96 hours. (A-B) Following 24 hour and 96 hour 
maturation, DCs were collected and cultured for 24 hours with CD40L expressing J558 cells. 24 hour supernatant of 
co-cultures was collected and analyzed for IL-12p70 production by ELISA. Bars represent mean +/- SEM of 
triplicate wells of one experiment. Data are representative of 3 independent experiments that yielded similar results. 
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<<; below detection limit.  (C-D) DC maturation status was determined by flow cytometry after 24 hours and 96 
hours of maturation. (E-F) 24 hour and 96 hour matured DCs were analyzed for T-bet expression by intracellular 
flow cytometry. (G) 24 hour matured DCs were loaded with SEB and co-cultured with CFSE-labeled naïve CD8
+ 
T 
cells for 5 days. T cell proliferation was determined by flow cytometry. (H) Naïve CD8
+
 T cells were primed by 
SEB-loaded EIDCs or LIDCs. Activation of day 6 primed CD8
+
 T cells was determined by flow cytometry. (I) Naïve 
CD8
+
 T cells were primed by SEB-loaded EIDCs or LIDCs in the presence of absence of anti-IL-12 blocking Ab. Day 
6 CD8
+
 T cells were analyzed for intracellular expression of granzyme B.  
 
 
Using DCs short-term-matured in the presence of poly-I:C, IFN  and IFN  as the model 
of IL-12
high
/T-bet
high
 early-inflammation-induced(EI)DCs, and short-term PGE2-matured DCs as 
the model of IL-12
low
/T-bet
low
 late-inflammation-induced (LI)DCs (which allowed for the parallel 
evaluation of their T cell-activating functions), we compared their ability to prime naive CD8
+
 T 
cells in our established polyclonal in vitro sensitization model (189). Both types of DCs 
promoted a similar expansion of naïve CD8
+
 T cells (Fig. 6G), and induced similar expression of 
CD45RO and CD25 on the differentially-primed CD8
+
 T cells (Fig. 6H).  
However, in contrast to the CD8
+
 T cells primed by EIDCs, that expressed high levels of 
the cytolytic effector protein granzyme B, the LIDC-primed CD8
+
 T cells did not acquire 
granzyme B expression (Fig 6I left). As expected, the differentiation of naïve CD8
+
 T cells into 
cytolytic effector T cells (TEFF) was IL-12-dependent, since blocking of IL-12 during the EIDC-
driven T cell priming prevented the induction of granzyme B (Fig. 6I right).  
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3.4.2 CD8+ T cells primed by LIDCs rapidly acquire central-memory phenotype and 
accelerated capacity to undergo secondary expansion 
Since mouse studies have shown that IL-12-driven activation of mTOR kinase favors the 
development of T-bet
+
 TEFF, and that mTOR inhibition facilitates effective memory formation 
(128-129), we compared the phosphorylation of ribosomal protein S6 (pS6), an established 
marker of mTOR activity (128-129), in the CD8
+
 T cells primed by the EIDCs- versus LIDCs. As 
shown in figure 7A, the EIDC-primed T cells showed high levels of phosphorylated S6. In 
contrast, CD8
+
 T cells primed by LIDCs showed only marginal S6 phosphorylation (Fig. 7A). In 
contrast to CD8
+
 T cells primed by EIDCs, LIDC-primed CD8
+
 T cells had limited expression of 
T-bet (Fig. 7B), the downstream factor of IL-12 signaling (44, 199, 201) and mTOR activity 
(128). The addition of endogenous IL-12 during the priming with LIDCs enhanced T-bet 
expression and S6 phosphorylation (data not shown).   
Since reduced mTOR activity has been shown to favor memory development (128-129), 
we analyzed the differentially primed CD8
+
 T cells for the expression of memory markers. As 
shown in figure 7C, CD8
+
 T cells primed by the LIDCs retained high expression of CCR7 and IL-
7R  (CD127), markers of central-memory cells, in a clear contrast to the EIDC-primed CD8
+
 T 
cells, which down-regulated both these markers at the same point of their activation. Such T-
bet
low
/mTOR
low
/CCR7
high
/IL-7R
high
 CD8
+
 T cells and T-bet
high
/mTOR
high
/CCR7
low
/IL-7R
low
 
CD8
+
 T cells induced in vitro by, respectively, the LIDCs- versus “EIDCs showed similar patterns 
of expression of the memory- and effector T cell-associated genes as in vivo-arising blood- 
isolated central-memory (TCM) and effector (TEFF) cells obtained by flow sorting (Fig. 7D-E), 
further supporting the notion that the LIDC-primed CD8
+
 T cells are TCM cells.        
 65 
 
 66 
Figure 7. CD8
+
 T cells primed by LIDCs have reduced mTOR activity and undergo accelerated central-
memory cell differentiation with secondary expansion capacity.  
Naïve CD8
+
 T cells were primed for 3 (A-B) or 6 days (C-F) with SEB-loaded EIDCS or LIDCs. Day 3 differentially 
primed CD8
+
 T cells were analyzed for the intracellular expression of (A) phosphorylated ribosomal protein S6 
(pS6) and (B) T-bet by flow cytometry. (C) Day 6 differentially primed CD8
+
 T cells were analyzed for surface 
expression of CCR7 and IL-7R  (CD127) by flow cytometry. (D-E) Quantitative RT-PCR was used to analyze the 
expression of effector cell associated genes (D) or central-memory associated (E) by blood-isolated effector cells 
(TEFF; dark grey bars), blood-isolated central-memory cells (TCM; light grey bars), day 6 EIDC-primed CD8
+
 T cells 
(EIDC-CD8; black bars) and LIDC-primed CD8
+
 T cells (LIDC-CD8; white bars). Data are shown as ratios of the 
expression level of each gene in each T cell subset to the expression of the same gene in TEFF cells or EIDC-CD8
+
 T 
cells and are the mean of 3 (blood-isolated) or 4 in vitro cultures +/- SEM. (F) Day 6 differentially primed CD8
+
 T 
cells were restimulated for an additional 4 days (+/- 24 hours in 4 individual experiments) with SEB-loaded LIDCs. 
The numbers of viable cells in restimulated cultures were determined using trypan blue exclusion. Data are 
represented as mean +/- SEM of 4 independent experiments.  
 
 
A key functional feature of memory CD8
+
 T cells is their ability to undergo effective 
secondary expansion upon challenge (202). As expected, while the EIDC-CD8
+
 T cells did not 
expand when restimulated at day 6 after priming, the T-bet
low
/mTOR
low
/CCR7
high
/IL-7R
high
 
CD8
+
 T cells primed by LIDCs efficiently expanded when restimulated at the same time point in 
parallel cultures (Fig. 7F).   
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3.4.3 TCM CD8
+
 T cells induced by LIDCs undergo secondary effector differentiation 
following their restimulation by EIDCs 
To directly compare the memory function of CD8
+
 T cells primed by the LIDCs versus 
EIDCs, we cultured the CD8
+
 T cells for 3 weeks in the presence of low dose IL-2 and IL-7, to 
allow the EIDC-primed CD8
+
 T cells to also differentiate into memory cells. Both populations of 
long-term cultured CD8
+
 T cells expressed only low levels of granzyme B, independently of the 
conditions of their priming (Fig. 8A). However, while the CD8
+
 T cells primed by EIDCs 
contained both CD62L
-
 CCR7
-
 effector-memory (TEM) and CD62
+
 CCR7
+
 TCM cells (Fig. 8A, 
bottom), the CD8
+
 T cells primed by LIDCs consisted of only CCR7
+
 CD62L
+
 TCM cells (Fig. 
8A, top). In contrast to the strict differences in their ability to undergo secondary expansion at 
day 6, both populations of long-term cultured CD8
+
 T cells were undergoing effective secondary 
expansion when restimulated at day 21 (Fig. 8B), although long-term cultured EIDC-CD8
+
 T 
cells expanded less than the CD8
+
 T cells induced by LIDC- cells, consistent with the lower 
proliferative capacity of the TEM cells (203-204).  
In contrast to naïve CD8
+
 T cells, both populations of the differentially-primed CD8
+
 T 
cells rapidly up-regulated the expression of granzyme B and acquired cytolytic function 
following restimulation with EIDCs (Fig. 8C-D).  
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Figure 8. TCM CD8
+
 T cells induced by LIDCs undergo secondary effector differentiation following re-
stimulation by EIDCs.  
EIDC- and LIDC-primed CD8
+
 T cells were cultured for 21 days. (A) Phenotype of long-term cultured differentially-
primed CD8
+
 T cells was analyzed by flow cytometry. (B) The secondary expansion (day 4) of resting CD8
+
 T cells 
after restimulation with SEB-loaded DCs was determined by cell count and trypan blue exclusion. (C) The 
acquisition of granzyme B expression by EIDC-restimulated CD8
+
 T cells was determined by flow cytometry. (D) 
The cytolytic capacity of differentially-primed resting CD8
+
 T cells restimulated with EIDCs was determined by 
standard 4 hour 
51
Chromium release assay using SEB-loaded JY-1 cells as targets. Insert: cytolytic capacity of day 7 
differentially primed CD8
+ 
T cells. Data are represented as mean +/- SEM for 4 independent experiments. Insert: 
cytolytic capacity of differentially-primed CD8
+
 T cells on day 6 after priming.    
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The current data demonstrate the unique role of DCs matured for extended periods of 
time or in the conditions of late/chronic inflammation, as specialized inducers of the direct 
differentiation of naïve CD8
+
 T cells into TCM cells, which are capable of accelerated secondary 
expansion and rapid TEFF differentiation following secondary activation by EIDCs.  These data 
help to explain the preferential development of memory CD8
+
 T cells at later stages of immune 
responses at the time when acute inflammation has ceased (195-196). In contrast to the acute 
inflammation dominated by the pathogen-derived- and exogenous distress signals, including 
TLR-ligands and interferons (186), the inflammatory process at the conclusion of immune 
responses is dominated by chronic inflammatory mediators that suppress IL-12 production and 
IL-12 responsiveness (190-193), including PGE2 used in the current study.  
The current data also helps to reconcile the apparent discrepancy between the relative 
patterns of the development of memory and effector CD8
+
 T cells supported by  different in vivo 
mouse models, which favor either a sequential (204-205) or parallel (to effector cells) mode (32) 
of memory T cell development (202). Our data suggest that in the conditions of active 
inflammation, where most of the antigen-carrying DCs are activated by interferons, TLR-ligands 
and other pro-inflammatory factors able of enhancing IL-12 production, the overall pattern of 
immunity will follow the sequential pattern when the originally predominant population of 
effector CD8
+
 T cells (TEFF) will gradually give rise to TCM and TEM subsets (see Fig 8). 
However, in case of pathogens inducing a lesser degree of inflammation (or weaker adjuvants in 
the case of vaccination), the pattern of local inflammation may allow both types of DCs (EIDCs 
and LIDCs) to co-exist and to induce both effector and memory T cells simultaneously. In 
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addition to their effects via DCs, inflammatory cytokines generated during an infection can also 
affect T cell differentiation also in a direct or an indirect way (121). 
The currently demonstrated new role of PGE2 in promoting the development of TCM-
driving “memory” DCs also help to understand the paradoxical impact of PGE2 on different 
aspects of the immune-stimulatory activity of DCs. While, similar to many other chronic 
inflammatory mediators, including IL-10, TGF  or steroids, PGE2 suppresses the IL-12p70 
production by DCs (93, 194). In contrast to these additional factors which also suppress DC 
maturation and their ability to activate T cells (3, 194), PGE2 uniquely promotes DC maturation 
(3, 20, 194), directing such IL-12-deficient mature DCs to the lymph nodes (206-207). In 
combination with this unique combination of features of PGE2, our current data suggest a unique 
role of PGE2 as the factor promoting the switch in DC activity from the induction of effector 
cells towards the preferential induction of memory CD8
+
 T cells at later stages of immune 
responses.  
The possibility of using this memory-promoting activity of the PGE2-matured (or DCs 
“exhausted” by prolonged exposure to other maturation-inducing factors) may allow to shorten 
the duration of the vaccination schemas needed to achieve optimal protection against infective 
agents, by allowing shorter prime-boost cycles. While our data shows that the cells primed by the 
EIDCs and LIDCs both are able of effective secondary expansion at day 21 (see Fig. 8B), the 
memory cells primed by LIDCs could be effectively restimulated already at day 6 after priming, 
at the time when restimulation of the EIDC-primed TEFF was clearly ineffective and resulted in 
contraction of the activated CD8
+
 T cell pool (see Fig. 7F). However, potential advantages of 
such approach need to be considered in the context of the ability of PGE2 and PGE2-matured 
DCs to promote the preferential recruitment and activation of Tregs and MDSCs, while 
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suppressing the ability of DCs and tumor micro-environments to attract naïve, memory and 
effector cells and induce the TEFF functions (25, 188-189, 208-211). These undesirable properties 
of PGE2 and the documented ability of PGE2-matured DCs to promote Treg expansion in cancer 
patients (54), together with the currently-described ability to instruct CD8
+
 T cells to sidestep the 
effector stage of activation, may constitute an obstacle in the utilization of PGE2 in therapeutic 
(rather than preventive) settings, highlighting the need for tools to dissociate these desirable and 
undesirable features of PGE2. Our ongoing work aims to evaluate the potential for the sequential 
application of LIDCs followed by EIDCs (to allow effector cell differentiation) in the induction of 
effective immunity.  
The existence of a distinct memory CD8
+
 T cell-inducing function of the T-bet
low
/IL-
12
low
 DCs activated for extended periods of time or activated in the presence of chronic 
inflammatory mediators, such as PGE2, suggests that the traditionally-used nomenclature of 
“exhausted DCs” does not fully reflect their nature and immune function. Their unique 
phenotype, function, and the kinetics of induction in relation to the T-bet
high
/IL-12
high
 “non-
exhausted” DCs, show strong analogy to the development of memory T cells, and indicate their 
role as a specialized “memory DC” subset, in contrast to T-bethigh/IL-12high “effector” DCs 
induced at earlier stage of response and specialized in the sequential induction of TEFF cells, 
followed by the development of TEM and TCM cells. 
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3.5 IMPLICATIONS 
Effective cancer immunotherapy is believed to rely on the induction of both effector and memory 
T cell. In contrast, prophylactic vaccines are designed to generate large number of long-lived 
memory cells. The development of large numbers of memory cells is achieved by prime-boost 
strategies, which can take weeks or months. In chapter 3 I show that DCs matured under 
conditions that mimic late/chronic inflammation, do not produce IL-12p70 and induce the direct 
differentiation of naïve CD8
+
 T cells into central-memory cells without passing through a 
cytolytic effector phase. These central-memory cells rapidly acquire cytolytic capacity upon 
restimulation with type-1 polarized DCs. The combined data from chapter 2 and 3 show that 
differentially matured DCs induce distinct differentiation pathways in naïve CD8
+
 T cells. These 
data suggests that type-1 polarized DCs would be preferred for the use as cancer vaccines, when 
cytolytic effector cells are desired for the elimination of tumor cells, while the “non-
inflammatory” DCs would be preferred for the use as prophylactic vaccines, in which the 
induction of large numbers of long-lived central-memory cells is required.  
High IL-12p70 producing type-1 polarized DCs are superior to IL-12
-
 “non-
inflammatory” DCs in the induction of anti-tumor responses. However, the generation of large 
numbers of type-1 polarized DCs requires large amounts of clinical grade cytokines, which make 
the development of DC-based cancer vaccines expensive. In chapter 4 I examine the possibility 
to generate mature type-1 polarized DCs without the need for expensive clinical grade cytokines 
by making use of the ability of autologous lymphocytes to produce DC-maturing factors (IFN  
and TNF ). 
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4.0  LYMPHOCYTE-POLARIZED DENDRITIC CELLS ARE HIGHLY EFFECTIVE 
IN INDUCING TUMOR-SPECIFIC CTLS 
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4.1 ABSTRACT 
High activity of dendritic cells (DCs) in inducing cytotoxic T cells (CTLs) led to their 
application as therapeutic cancer vaccines. The ability of DCs to produce IL-12p70 is one of the 
key requirements for effective CTL induction and a predictive marker of their therapeutic 
efficacy in vivo. We have previously reported that defined cocktails of cytokines, involving 
TNF  and IFN - induce mature type-1 polarized DCs (DC1s) which produce strongly elevated 
levels of IL-12 and CXCL10/IP10 upon CD40 ligation compared to “standard” PGE2-matured 
DCs (sDCs; matured with IL-1 , IL-6, TNF , and PGE2) and show higher CTL-inducing 
activity. Guided by our observations that DC1s can be induced by TNF  - and IFN -producing 
CD8
+
 T cells, we have tested the feasibility of using lymphocytes to generate DC1s in a 
clinically-compatible process, to limit the need for clinical-grade recombinant cytokines and the 
associated costs. CD3/CD28 activation of bulk lymphocytes expanded them and primed them for 
effective production of IFN  and TNF  following restimulation. Restimulated lymphocytes, or 
their culture supernatants, enhanced the maturation status of immature (i)DCs, elevating their 
expression of CD80, CD83 and CCR7, and the ability to produce IL-12p70 and CXCL10 upon 
subsequent CD40 ligation. The “lymphocyte-matured” DC1s showed elevated migration in 
response to the lymph-node-directing chemokine, CCL21, when compared to iDCs. When 
loaded with antigenic peptides, supernatant-matured DCs induced much high levels of CTLs 
recognizing tumor-associated antigenic epitope, than PGE2-matured DCs from the same donors. 
These results demonstrate the feasibility of generation of polarized DC1s using autologous 
lymphocytes.  
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4.2 INTRODUCTION 
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), specialized in inducing T 
cell responses (180-181).  Upon antigen encounter, DCs take up antigenic material, undergo 
maturation , and migrate from peripheral sites to draining lymph nodes where they are able to 
prime naïve antigen-specific T cells by providing them with processed antigen in the form of 
antigenic peptides complexed with MHC class I molecules (signal 1) (1, 212). In addition to this 
signal 1, mature DCs also express co-stimulatory molecules (signal 2) that regulate the 
magnitude of the T cells responses. They also to secrete different amounts of cytokines (signal 
3), which determine the type of T cell response (i.e. Th1, Th2, Th17) that is elicited (3, 26, 213-
214).   
The ability of DCs to elicit T cell responses has been the rationale for the use of DCs as 
cancer vaccines in clinical trials (215-216). Furthermore, the Food and Drug Administration 
(FDA) recently approved the use of the first DC-containing cellular immunotherapy, Sipuleucel–
T, (Provenge) for the treatment of hormone-refractory prostate cancer. While Provenge provides 
a 4 month survival benefit over placebo-treated patients, it does not affect the time to progression 
or tumor burden (60). These results indicate the feasibility of DC-based therapies for cancer, but 
also highlight the need for optimization of the methods of DC generation.  
The production of high levels of interleukin-12 (IL-12) (217) by DC vaccines has been 
shown to correlate with their enhanced induction of anti-tumor responses (39, 67-68, 218) and 
predict their therapeutic benefit in vivo (70).Various maturation protocols are being used for the 
generation of type-1 polarized monocyte-derived DCs (DC1) that have high IL-12 production 
capacity in clinically-applicable conditions. These maturation protocols are based on the use of 
inflammatory cytokines (e.g. IFN , IFN , and TNF ) and/or Toll-like receptor ligands (e.g. LPS 
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and polyI:C) (28-29, 71, 219-220). While the different maturation protocols are effective at 
polarizing DCs for high IL-12 production, for use in a clinical setting these maturation and 
polarization protocols require the use of clinical grade cytokines, which make the production of 
the DCs expensive.  
We have previously shown that activated lymphocytes produce IFN  and/or TNF . 
Naïve CD8
+
 T cells can perform a helper function, by producing IFN  and TNF , in co-
activating DCs for the secretion of high levels of IL-12 (138, 221). The ability of lymphocytes to 
produce IFN  and TNF  upon activation, and to use these factors to induce maturation and type-
1 polarization of DCs (138, 141) prompted us to analyze whether this function could be used to 
induce DC1-based cancer vaccines in a clinically-compatible process, as alternative to immature 
DCs used in the currently-approved DC-containing Provenge.  
Here we report on the ability to induce maturation and polarization of DCs using 
expanded autologous lymphocytes. The lymphocyte-matured DCs have a high expression of co-
stimulatory molecules, migrate in response to the lymph node-associated chemokine CCL21, and 
produce high levels of bioactive IL-12p70 and interferon-inducible protein 10 (IP10/CXCL10). 
When lymphocyte-matured DCs were loaded with peptides representing various tumor-
associated antigens (MART-1, gp100, PSA2 and PAP-3), they induce strong peptide-specific 
CTL responses in autologous naïve CD8
+
 T cells.  
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4.3 MATERIAL AND METHODS 
Cell lines, media and reagents 
Serum-free AIM-V medium (Invitrogen, Carlsbad, CA) was used to generate DCs and 
Iscove’s Modified Dulbecco’s Medium (IMDM; Invitrogen) with 5% human AB serum (Gemini 
Bio-products, West Sacramento, CA) was used for CTL induction experiments. The following 
factors were used to generate mature DCs: rhGM-CSF and rhIL-4 (gifts from Schering Plough, 
Kenilworth, NJ), rhTNF , rhIL-1  (both Strathmann Biotech, Germany), rhIL-6 (Genzyme, 
Cambridge, MA), Prostaglandin E2 (PGE2; Sigma, St. Louis, MO). IL-2 and rhIL-7 (Strathmann 
Biotech) were used to support the CD8
+
 T cell expansion.  
 
Generation of DCs from healthy donors and cancer patients 
Peripheral blood mononuclear cells (PMBCs) were obtained from healthy donors or from 
buffy coats (obtained from the blood bank) using lymphocyte separation medium (Cellgro, 
Mediatech, Herndon, VA). CD14
+
 monocytes were isolated from PBMCs using CD14
+
 isolation 
kit (Miltenyi Biotec, Auburn, CA, USA). Peripheral blood from melanoma patients was collected 
in accordance with the Institutional Review Board (IRB) of the University of Pittsburgh. All 
patients had given written consent. Blood was obtained by leukapheresis and cell subsets were 
separated by elutriation density gradient separation (Elutra) and stored in liquid nitrogen. In both 
cases, the resulting monocytes were cultured in serum-free AIM-V medium supplemented with 
rhGM-CSF (1000 U/ml) and rhIL-4 (1000 U/ml) in 24 well plates at 5-6 x 10
5
 cells/ml for 5 
days. On day 3, half the culture medium was replaced with fresh medium containing rhGM-CSF 
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and rhIL-4 (both at final concentration 1000 U/ml). On day 5, immature (i)DCs were matured for 
24 hours by removing half the medium and adding fresh medium containing the maturation 
factors described below.  
 
Expansion of bulk lymphocytes 
Total CD14-negative cells from healthy donors, from CD14
+
 isolation described above, 
or fraction 3 Elutra cells from cancer patients were washed and resuspended in IMDM 
supplemented with 5% human AB serum (Gemini Bio-products) at 1 x 10
6
 cells/ml. Human T-
Activator CD3/CD28 Dynabeads (Invitrogen Dynal AS, Oslo, Norway) were added to the 
lymphocytes at 5 µl/ml and cells were expanded for 6-7 days in 12 well plates with 2 ml/well. 
On day 3, fresh medium was added to the expanding cells.  
   
Cytokine production by expanded lymphocytes 
Day 6-7 expanded lymphocytes were collected in 50 ml conical tubes and CD3/CD28 
beads were removed by placing the tube in a magnet for 15 minutes. Bead-free cell suspension 
was transferred to a fresh tube and cells were washed and resuspended at 2 x 10
6
 cells/ml in 
serum-free AIM-V.  Expanded lymphocytes were restimulated in either 96 well plates (for 
analysis of cytokine production) or 6 well plates (for DC maturation) with either plate-bound 
OKT3 Ab (1µg/ml; eBioscience, San Diego, CA) or 5 µl/ml CD3/CD28 beads. At the indicated 
times, supernatant was collected and stored at -20 C until analysis by ELISA. Briefly, ELISA 
plates were coated overnight at room temperature (RT) with 2 µg/ml monoclonal anti-human 
IFN  Ab (Thermo Scientific, Rockford, IL) or 2 µg/ml monoclonal anti-human TNF  Ab 
(Endogen). After incubation, plates were blocked using PBS with 4% Bovine Serum Albumin 
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for 1 hour at RT. Plates were washed (50 mM Tris/0.2% Tween) and incubated with culture 
supernatants or appropriate cytokine standards for 1 hour. Supernatants were removed and plates 
were incubated for 1 hour with biotin-labeled monoclonal Abs against IFN  or TNF  (both at 
0.5 µg/ml). Following incubation, plates were washed and incubated with HRP-conjugated 
streptavidin (Thermo Scientific) for 30 minutes, after which the plates were washed and 
incubated with 100 µl TMB substrate solution (Pierce Biotechnology Inc, Rockford, IL). The 
color reactions were stopped by addition of 100 µl 2% H2SO4 and the absorbance was measured 
at 450nm.  
 
Maturation of DCs  
To induce the  maturation of day 5 DCs, half the medium was removed and replaced with 
500µl fresh serum-free AIM-V medium containing: (for iDC): rhGM-CSF and IL-4 (both 1000 
U/ml) only; (for PGE2-matured “standard” DC; sDC):  rhGM-CSF (1000 U/ml) rhIL-1  (25 
ng/ml) rhIL-6 (1000 U/ml) rhTNF  (50 ng/ml) and PGE2; 10
-6
 M); (for lymphocyte-CD3/CD28-
matured DCs): rhGM-CSF,  2 x 10
5
 expanded lymphocytes/ml and CD3/ CD28 beads (5 
µl/ml); (for lymphocyte-OKT3-matured DCs), rhGM-CSF,  2 x 10
5
 expanded lymphocytes/ml 
and OKT3 (1 µg/ml); or (for supernatant-matured DCs; supDC): rhGM-CSF and 500µl 
supernatant from 24 hour restimulated expanded lymphocytes. DCs were matured for 24 hours at 
37 C. The recovery of supernatant-matured DCs was less than that of PGE2-matured DCs but 
only slightly less than previously observed for other type-1 polarized DCs generated in our lab 
( DC1).  Typical cell yields were: PGE2-matured DC: 1:3-5 (1 DC recovered per 3-5 monocytes 
plated); supernatant DCs: 1:9-12; iDC: 1:6-13). For the analysis of DC maturation markers, 
matured DCs were collected, resuspended in IMDM-5% HS and kept overnight at 37 C before 
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performing flow cytometric analysis. We have previously observed that the CCL19 production 
during type-1 polarized DC maturation results in transient internalization of surface CCR7, 
which is restored after removing the cells from the CCL19-rich maturation media, resulting in 
effective migration in vitro and in vivo (208). We therefore rested the matured DCs overnight in 
fresh media before performing phenotype and migration analysis. The morphology of the DCs 
was determined using an EVOS XL Core microscope (Advanced Microscopy Group, Bothell, 
WA). 
  
Flow cytometry 
3-color flow cytometry was performed using an Accuri C6 flow cytometer. Fluorescein 
isothiocyanate (FITC)-labeled anti-human CD80, CD40, CD3, CD40L,   Phyocoerythrin (PE)-
labeled anti-human CD83, CD16,  PE-Cy5-labeled anti-human CD8, CD4, CD19, CD56 and  
Allophycocyanin (APC)-labeled anti-human CD86 were purchased from BD Biosciences (San 
Jose, CA). APC-labeled anti-human CCR7 was obtained from R&D systems.  PE-labeled 
MART-1(ELAGIGILTV) tetramer was purchased from Beckman Coulter (Immunomics, Fullerton 
CA). Cells were transferred to a V-bottom 96-well plate and washed with FACS buffer 
(PBS/0.5%BSA/0.1% Azide). Cells were incubated for 45 minutes in the dark at RT. Following 
labeling, cells were washed twice and fixed with 2% para-formaldehyde and stored at 4 C until 
analysis. Flow cytometry data was analyzed using FCS Express V3 software.   
 
 Chemotaxis 
The analysis of DC migratory function was performed using a 24-well transwell system 
with 5 µm pore size polycarbonate filter (Corning Inc, Corning, NY). 1 x 10
5
 differentially 
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matured DCs were rested overnight to allow for re-expression of CCR7, as described above, 
loaded to the top chamber of the transwell system and allowed to migrate towards rCCL21 (100 
ng/ml; Peprotech, Rocky Hill, NJ) over a 3 hour period at 37 C. Following incubation, the 
migrated cells from the bottom compartment were collected, the total volume of the cell 
suspension was measured and the cells in 100 µl of the suspension were counted using an Accuri 
C6 flow cytometer. The total number of migrated cells was calculated and is represented as 
percentage migrated cells of total cells. The number of cells that migrated in response to media 
(IMDM-5%HS) alone was subtracted from the number of chemokine-specific migrated cells to 
correct for background migration. 
 
ELISA analysis of IL-12p70 and CXCL10 production by the differentially-matured 
DCs  
Differentially matured DCs were harvested and resuspended in IMDM supplemented 
with 5% human AB serum at 2 x 10
5
 cells/ml. 100µl of DC suspension (2 x 10
4
 DCs) were 
transferred to a flat-bottom 96 well plate and stimulated for 20-24 hours with 5 x 10
4
 CD40L-
transfected J558 cells (kind gift of Dr. P. Lane, Birmingham, UK). After incubation, supernatant 
was collected and stored at -20 C until analysis.   IL-12p70 and CXCL10 analysis was 
performed as described above for IFN  and TNF , using 2µg/ml primary Ab (mouse anti-human 
IL-12(p70), Thermo Scientific Pierce) and 0.5 µg/ml biotin-labeled Ab (rat anti-human IL-
12(p70), Thermo Scientific Pierce)  for IL-12p70 and 10 µg/ml primary Ab (rabbit anti-human 
IP-10, Peprotech) and 2.5 µg/ml biotin-labeled secondary Ab (rabbit anti-human IP-10, 
Peprotech) for CXCL10. HRP-conjugated streptavidin followed by TMB substrate development 
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was used for analysis and the colorimetric reaction was stopped with 2% H2SO4 and measured at 
450nm. 
 
Isolation of naïve CD8
+
 T cells  
For the induction of CTL responses, naïve CD8
+
 T cells (CD8
+
CD45RO
-
CD45RA
+
) were 
isolated from the CD14
neg
 (lymphocyte) population by incubating the cells with anti-CD45RO-
biotin Abs (StemCell Technologies Inc, Vancouver, Canada). Following incubation, cells were 
washed and incubated with tetrameric anti-biotin complex and CD8 T cell enrichment cocktail 
(StemCell). Cells were then incubated with magnetic colloid (StemCell) after which naïve CD8
+
 
T cells were isolated using a magnetic column (StemCell).     
 
CTL induction  
For the induction of CTL responses from naïve CD8
+
 T cells, matured DCs were loaded 
with tumor-associated peptides (MART-126-35, gp100209-217, PAP-3135-143, and PSA2146-154; all 
were used at the concentration of 10 g/ml) for 2 hours at 37 C in IMDM-5% human AB serum. 
Peptide-loaded DCs were co-cultured with autologous CD8
+
 T cells at a 1:10 ratio in 48 well 
plates for 12 days. CD8
+
 T cells were supplemented with rhIL-2 (20 U/ml) on day 4 and with 
rhIL-2 and rhIL-7 (5 ng/ml) on day 7 and day 9. Day 12 CD8
+
 T cells were analyzed for the 
presence of MART-1 specific CTLs or were stimulated with individual peptides for 24 hours for 
the analysis of the frequency of tumor-peptide specific CD8
+
 T cells by IFN  enzyme-linked 
immunospot (ELISPOT).    
 
Statistical analysis 
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Data were analyzed using unpaired Student’s t test (2-tailed).  P < 0.05 was considered as 
statistically significant.  
4.4 RESULTS 
4.4.1 Expanded lymphocytes rapidly produce DC maturation- and polarization-inducing 
factors upon restimulation 
The combination of a DC maturation factor and IFN  has been shown critical for the 
induction of polarized DC1s (5) with additional need for IFN  for the complete development of 
polarized DC1s in the absence of FCS (71).  Since superantigen (SEB)-activated T cells secrete 
IFN  as well as TNF   and can use these factors to induce maturation and polarization of DCs in 
bovine-serum-supplemented cultures (138, 141), we tested whether activated bulk lymphocytes 
could be used to mature DCs in clinically-compatible protocols, involving serum-free media and 
clinically-relevant reagents.  To test this, isolated lymphocytes were expanded for 6 days with 
CD3 and CD28 beads and analyzed to determine which cells were present. As expected, the 
expanded lymphocyte cultures consisted of mostly CD4
+
 T cells (~65%) and CD8
+
 T cells 
(~20%) while there were only low percentages (~5%) of NK cells and B cells present (Fig.9A).  
The acquisition of high IL-12p70 producing ability by monocyte-derived DCs and 
counteracting DC exhaustion requires IFN  signaling during maturation (5). To test whether the 
expanded lymphocytes were able to mature DCs and prime them for high IL-12p70 production, 
we restimulated day 6 expanded lymphocytes with CD3/CD28 beads and analyzed cytokine 
secretion at various times after re-stimulation. As shown in figure 9B, the restimulated 
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lymphocytes started producing both IFN  (left panel) and TNF  (right panel) within 2 hours of 
restimulation and continued to secrete these cytokine up to at least 24 hours after restimulation.  
Since the expanded lymphocytes rapidly produced high amounts of both IFN  and TNF  
upon restimulation, we analyzed the ability of expanded lymphocytes to induce maturation and 
polarization of immature autologous DCs. For this, monocytes were isolated and cultured for 5 
days in the presence of GM-CSF and IL-4 to generate immature DCs (iDCs). The co-cultures of 
iDC with expanded lymphocytes in the absence of a TCR stimulus did not result in any IFN  or 
TNF  secretion by the lymphocytes (Fig. 9C). In contrast, when a TCR stimulus was added (i.e. 
CD3/CD28 beads or soluble OKT3), the lymphocytes secreted both these cytokines (Fig. 9C). 
 
4.4.2 Restimulated lymphocytes from healthy donors and melanoma patients induce DC 
maturation and polarization  
In order to test whether the expanded and re-activated lymphocytes were able to induce the 
maturation of autologous iDC, we analyzed the morphology and phenotype of 24 hours matured 
DCs. As seen in figure 10A, DCs matured by re-activated lymphocytes or by the supernatant of 
24 hour re-activated lymphocytes had a distinct morphology compared to iDCs or mature PGE2-
matured ”standard” DCs (sDC;  matured in the presence of recombinant cytokines and PGE2) 
(20) (Fig. 10A). To verify the maturation status of the DCs, we analyzed the expression of co-
stimulatory molecules by the DCs. DCs exposed to restimulated lymphocytes had increased 
expression of the co-stimulatory molecules and maturation-associated markers  CD83, CD80, 
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CD86 and CD40 compared to iDC and DCs co-cultured with lymphocytes in the absence of 
activation stimuli (Fig. 10B and 10C). 
Lymphocyte-matured DCs also had elevated levels of the lymphoid-homing chemokine 
receptor CCR7, which allows for the migration of mature DCs to the lymphoid organs. 
Supernatant-matured DCs showed a mixed phenotype with a population of cells having an 
immature phenotype (CD83
low
 CCR7
low
) and another population being mature (CD83
high
 
CCR7
high
)  (Fig. 10B and 10C).  
The induction of Th1 and cytolytic CD8
+
 T cell (CTL) responses requires the secretion of 
IL-12p70 by DCs during the priming of naïve CD4
+
 and CD8
+
  T cells (222). Upon interaction 
with Ag-presenting mature DCs, CD4
+
 T cells up-regulate the expression of CD40L, which 
interacts with CD40 on the DCs and induces IL-12p70 secretion. To determine the ability of the 
differentially matured DCs to produce IL-12p70, we activated them for 24 hours with CD40L-
transduced J558 cells, as a surrogate for CD40L-expressing CD4
+
 T cells (136). As shown in 
Figure 10D, while iDCs and PGE2-matured sDCs produce only low levels of IL-12p70, DCs 
matured by restimulated lymphocytes or supernatant from restimulated lymphocytes have an 
elevated ability to secrete IL-12p70.   
It has been shown that the optimal induction of Th1 responses by at least mouse DC 
vaccines relies on the secretion of CXCL10/interferon inducible protein 10 (IP-10) by mature 
DCs, which retain Th1 cells in the T cells area of the lymph nodes (76, 101). To determine if the 
lymphocyte-matured DCs were able to secrete CXCL10, we co-cultured 24 hour matured DCs 
with CD40L-expressing J558 cells and determined the levels of CXCL10 in the supernatant after 
24 hours. As shown in figure 10E, iDC and PGE2-matured sDCs lacked production of CXCL10 
while both the supernatant- and lymphocyte-matured DCs produced high levels of the CXCL10. 
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Figure 9. Ex vivo-expanded lymphocytes rapidly produce IFN  and TNF  upon restimulation.   
Isolated lymphocytes were expanded for 7 days with CD3- and CD28-coated beads. A) The phenotype of day 7 
expanded lymphocytes was determined by flow cytometry. B) Day 7 expanded lymphocytes were harvested and 
either cultured in the absence of additional stimulation (circles) or restimulated (squares). At the indicated times, 
supernatants were collected to determine the secretion of IFN  (left) and TNF  (right). C) Autologous day 5 iDCs 
were cultured in the presence of the day 7 expanded lymphocytes in the presence or absence of the indicated stimuli. 
After 24 hours of co-cultures, supernatants were collect and the production of IFN  (left) and TNF  (right) was 
determined. Data shown from one of at least 2 independent experiments that yielded similar results. 
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In order to test the feasibility of using autologous lymphocytes to induce the maturation 
of DCs obtained from cancer patients, we compared the maturation- and polarization status of 
DCs from healthy donors with that of DCs derived from melanoma patients. Restimulation of 
patients’ lymphocytes resulted in the secretion of similar levels of IFN  and TNF  with similar 
kinetics (compare Fig. 9B and Supplemental Fig. 5A). Following co-culture of autologous 
lymphocytes with iDCs in the presence of a TCR stimulus the DCs from healthy donors and 
from melanoma patients showed similar levels of up-regulation of co-stimulatory molecules and 
maturation associated markers (Fig. 10F and supplemental Fig. 5B). Furthermore, CD40L 
stimulation of matured DCs from healthy donors and melanoma patients in both cases resulted in 
the elevated secretion of IL-12p70. There was no significant difference in IL-12 production 
between DCs from healthy donors and those obtained from PBMCs from melanoma patients 
(Fig. 10G).   
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Figure 10. Restimulated expanded lymphocytes or supernatant induce the maturation of autologous DCs and 
primes them for high IL-12p70 and CXCL10 production.  
iDC were cultured for 24 hours with autologous day 7 expanded lymphocytes in the presence or absence of the 
indicated stimuli or with supernatant from 24 hours restimulated lymphocytes. A) After 24 hours, the morphology of 
the DCs was analyzed using bright field microscopy. The morphology of lymphocyte-matured DCs was compared 
with that of iDCs and with that of DCs exposed to the non-polarizing maturation-inducing cytokine cocktail (PGE2-
matured sDC: IL1 , TNF , IL-6 and PGE2). B) 24 hour matured DCs were collected, washed and rested overnight 
at 37 C in fresh media to remove any CCL19 produced during maturation and allow for re-expression of chemokine 
receptor CCR7 on the cell surface (208) (see M&M). After resting, the phenotype of the DCs was determined by 
flow cytometry. C) Average Mean Fluorescence Intensity expression of DC maturation markers of 3-5 individual 
experiments. D-E) 24 hour matured DCs were collected, washed and subsequently cultured for 24 hour with 
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CD40L-expressing J558 cells (2x10
4
 DC: 5x10
4
 J558). After co-culture, supernatant was collected and analyzed for 
the presence of (D) IL12p70 and (E) CXCL10. Data shown are representative results from at least 2 independent 
experiments. F) Comparison of average of Mean Fluorescence Intensity of DC maturation associated markers on 
lymphocyte-matured DCs from 4 healthy donors with those of 3 melanoma patients. G) Comparison of IL-12p70 
production by immature and lymphocyte-matured DCs from healthy donors (4) and melanoma patients (3) after 24 
hours of CD40L stimulation. 
 
4.4.3 Lymphocyte supernatant-matured DCs migrate in response to CCL21 
For clinical applications, the use of co-cultures of DCs and lymphocytes in the presence 
of TCR stimuli would be undesirable unless the DCs are subsequently separated from the poly-
clonally-activated lymphocytes. Therefore, the use of supernatant-matured DCs may be more 
feasible for clinical applications. For this reason, we decided to focus on these cells for the 
subsequent experiments. Also, since there was no difference between DCs from healthy donors 
and from melanoma patients, we only used DCs from healthy donors for the remaining 
experiments. 
Since the ability of mature DCs to migrate into lymph nodes is dependent on the 
expression of the lymphoid-homing chemokine receptor CCR7 (74-75),  the elevated expression 
of CCR7 on supernatant-matured DCs prompted us to determine their capacity to migrate in 
response to CCL21, the chemokine involved in attracting DCs to lymph nodes (21). Using a 
transwell system we found that, in contrast to immature DCs, PGE2-matured sDCs migrated 
efficiently towards CCL21. Supernatant-matured DCs also migrated towards CCL21 albeit to a 
lesser extent than the cytokine-matured PGE2-matured sDCs (Fig. 11), which correlates with the 
difference observed in surface expression of CCR7 (Fig. 10B). 
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Figure 11. Supernatant-matured DCs efficiently migrate in response to CCL21.  
24 hour matured DCs were collected, washed and rested overnight at 37 C. After resting, DCs were placed in the 
top chamber of a transwell system and allowed to migrate for 3 hours towards CCL21 (in the bottom chamber) in a 
chemotaxis assay. Following incubation, the migrated cells in the bottom chamber of the transwell were collected 
and counted using a flow cytometer (see M&M). Migrated cells are represented as percentage of total cells. 
Migrated cells were counted twice and data is shown as mean +/- SD. Data shown are representative results from 2 
independent experiments. 
 
4.4.4 Lymphocyte supernatant-matured DCs induce strong anti-tumor peptide CTL 
responses 
Since the DCs matured by supernatant from restimulated lymphocytes showed a 
distinctly-activated phenotype, we compared the ability of the supernatant-matured DCs to 
induce Ag-specific CTL responses with that of the PGE2-matured sDCs. DCs from a healthy 
HLA-A2
+
 donor were matured for 24 hours and loaded with a panel of 4 peptides (MART-1, 
gp100, PSA2, PAP-3) that are associated with different cancers (melanoma and prostate cancer) 
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and used to prime autologous naïve CD8
+
 T cells. As shown in Figure 12A, peptide-loaded 
supernatant-matured DCs generated a similar expansion of MART-1-specific CD8
+
 T cells as the 
PGE2-matured sDC. The CD8
+
 T cells were then tested for their ability to recognize the 
individual peptides in an IFN -ELISPOT, which has been shown to be a good correlate of CTL 
function (223).  Naïve CD8
+
 T cells primed by peptide-loaded supernatant-matured DCs induced 
strong IFN  responses against all 4 peptides, in contrast to naïve CD8
+
 primed by peptide-loaded 
PGE2-matured sDC (Fig. 12B). 
 
 
 
 
 
 
 
  
Figure 12. Tumor-peptide-loaded supernatant-matured DCs induce strong anti-tumor CTL responses from 
autologous naïve CD8+ T cells.  
24 hour-matured DCs (supernatant-matured or PGE2-matured sDC) from healthy donors were collected, washed and 
loaded for 2 hours with tumor peptides (MART-1, gp100, PAP3, and PSA2). Following peptide loading, DCs were 
cultured with autologous naïve CD8
+ 
T cells at a 1:10 ratio. A) On day 12, CD8
+
 T cells were collected and the 
percentage of MART-1-specifc CD8
+
 T cells was determined by tetramer staining. B) Day 12 CD8
+
 T cells were 
collected, washed and used in a 24 hour IFN -ELISPOT analysis against tumor-peptides. Data are shown as mean 
+/- SEM of triplicate spot counts of one of 3 independent experiments that yielded similar results. 
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4.5 DISCUSSION 
The ability of dendritic cells to induce strong adaptive immune responses has resulted in the use 
of DCs to treat malignancies in clinical trials. Since the generation of clinically-approved DCs 
requires the use of expensive cGMP cytokines, we analyzed the possibility of using activated 
lymphocytes to mature and polarize autologous iDC. We found that re-stimulation of expanded 
lymphocytes resulted in rapid secretion of inflammatory cytokines IFN  and TNF , which led to 
type-1 polarization of iDCs. These lymphocyte-matured DCs were able to migrate in response to 
the lymphoid-homing chemokine CCL21 and, when loaded with peptides, prime naïve CD8
+
 T 
cells for strong anti-tumor peptide responses.   
Animal studies and in vitro studies have shown that the ability to induce strong anti-
tumor responses is dependent on the inflammatory cytokine IL-12 (67, 224). Currently, the use 
of a mixture of IL-1 , IL-6, TNF  and PGE2 for the maturation of DCs is commonly used in the 
preparation of DCs for vaccinations. As we present here and have shown before, these cells have 
a limited IL-12 production capacity compared to type-1 polarized DCs and the use of these 
“exhausted” DCs as cancer vaccines in clinical trials might be a possible explanation for the lack 
of clinical responses in these trials. In contrast, the use of type-1 polarized DCs that have a high 
IL-12 production upon CD40L ligation (71) have been shown to be very effective in the 
treatment of malignant gliomas (70).   
 The ability of monocyte-derived DCs to produce high levels of IL-12 requires 
maturation in the presence of exogenous inflammatory factors, mimicking the conditions of 
acute (e.g. viral) infection (5, 29, 222). It is known that activated lymphocytes are able to 
produce such inflammatory signals when interacting with Ag-presenting DCs. Naïve CD8
+
 T 
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cells help CD40L-expressing CD4
+
 T cells, by producing IFN  and TNF  (138). As shown here, 
this ability of lymphocytes to produce cytokines that induce type-1 polarization of (autologous) 
iDCs could be used to circumvent the need for expensive cGMP cytokines for the generation of 
clinically applicable DCs.  
 It was recently shown in a mouse model, that the ability of DCs to produce 
CXCL10/IP-10 at a tumor site allows them to attract effector T cells (76). This ability allowed 
for enhanced anti-tumor responses and increased survival. Furthermore, the CXCL10 producing 
ability of DCs was shown to be pivotal for retaining Th1 cells in the T cell areas of the lymph 
nodes for optimal induction of Th1-mediated immune responses (101). Unlike the PGE2-matured 
sDCs, supernatant- and lymphocyte-matured DCs were able to secrete high levels of CXCL10.  
The presence of non-matured DCs in the supernatant-matured DCs may indicate that the 
soluble factors in the supernatant were less concentrated compared to the DC-lymphocyte co-
cultures due to the proximity of secretion of the factors. Since the DCs that did not mature with 
the supernatant are still immature (and not partially matured) the involvement of surface 
molecule interaction in the DC maturation is unlikely.  
 The ability of DCs to migrate in response to lymph node-homing chemokines is a 
key feature of matured DCs and required for induction of T cell responses. Although DCs 
matured in the presence of PGE2 have a high expression of the lymph node homing chemokine 
receptor CCR7, the DC1s induced by restimulated lymphocytes (or their supernatants) also 
acquire CCR7 expression (and enhance its expression upon prolonged culture)  and were able to 
migrate towards CCL21 in a transwell system. While supernatant-matured DCs contained both 
mature and non-matured cells, the expression of CCR7 is only observed on the matured (CD83
+
) 
population. The lower migration of these cells, when compared to PGE2-matured sDCs, 
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correlates with the mixed character of the supernatant-matured DC population. We anticipate 
that a subcutaneous or intradermal application of such cells in clinical settings would result in the 
CCR7
+
 subset of DCs to migrate to the lymph nodes to interact with naïve and memory T cells, 
while the CCR7
-
 iDCs are more likely to stay at the site of injection, interacting with effector- 
and effector-memory-type T cells. The presence of iDCs at the peripheral effector site could be 
beneficial since it has been shown that in the presence of tumor cells, iDCs protect tumor-
specific CTLs from tumor-mediated activation-induced cell death (AICD) (225). The iDC at the 
site of injection could also take up tumor-Ag and possibly continue to infiltrate the nodes due its 
continued process of maturation following the injection and the inflammatory milieu at the 
effector site. However, the injection of Ag-loaded iDCs has also been linked to Ag-specific 
inhibition of CTL functions (226), suggesting the need for optimization of DC maturation 
protocols. In regard of this, we have previously shown that in media without FCS the induction 
of type-1 polarized DCs could be enhanced by the addition of IFN  (71). Since IFN  (Intron A) 
is relatively inexpensive, the addition of IFN  to optimize the DC maturation by supernatant 
from restimulated lymphocytes would not greatly increase the production costs. An alternative 
approach to further enhance the maturation status of the lymphocyte-matured DCs may be the 
addition of TLR ligands, such as poly-I:C used in our earlier studies with cytokines or NK cells 
(71). 
 Whether the same protocol can be used for the large scale production of type-1 
polarized DCs in cancer patients still needs to be verified. Our preliminary comparison between 
DCs from healthy donors and melanoma patients show the elevation of the maturation status and 
priming for elevated of IL-12 production, independently on the source of the cells (Fig. 10F, 10G 
and supplemental Fig. 5). Since T cells constitute high proportion in PBMCs and can also be 
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efficiently expanded using CD3/CD28 beads (available as clinical grade reagent), the current 
method is likely to generate sufficient numbers of DCs needed for repetitive cycles of 
vaccination. Importantly for the clinical application of this method, we have shown the 
feasibility of using the cell-free supernatants from expanded T cells, eliminating the logistic 
concerns related to the presence of T cells in DC preparations,  and the risk associated with the 
contact of immature DCs  with T cells , which can lead to DC killing or suppression (141, 223, 
227).  
While the proposed approach is likely to reduce the  overall cost of generation of type-1 
polarized DCs, due to the elimination of the expensive recombinant cGMP cytokines, these 
advantages need to be balanced against the higher complexity of the whole process of DC1 
generation, which involves an additional step of T cell expansion and generation of T cell 
conditioned media, and need to decide if the  quality control process may need to include 
additional T cell-relevant variables, apart from the quality of the final DC product.  However, 
since the times of T cell expansion and generation of immature DCs can at least partially 
overlap, the overall duration of generating polarized DC1s may be comparable to the process 
involving recombinant cytokines.  
These data show that activated lymphocytes can be used to induce maturation and 
priming of autologous DCs, that these DCs produce high levels of cytokines associated with 
type-1 polarization (IL-12p70 and CXCL10) and are efficient in inducing anti-tumor responses 
by naïve CD8
+
 T cells when loaded with peptides. The use of expanded lymphocytes could 
eliminate the use of expensive clinical grade cytokines and reduce the cost for generating DCs 
for immunotherapies.       
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4.6 IMPLICATIONS 
Type-1 polarized DCs which produce high levels of IL-12p70 induce strong anti-tumor CD8
+
 T 
cell responses. However, the development of DCs for clinical use as cancer vaccines is expensive 
due to the need for clinical grade cytokines. The data presented in chapter 4 shows that type-1 
polarized DCs can be generated using restimulation of activated lymphocytes. These 
restimulated cells rapidly produce DC-maturing factors IFN  and TNF , which induce DC 
maturation and primes them for high IL-12p70 production compared to immature and “non-
inflammatory” DCs. The lymphocyte-matured DCs are able to migrate in response to CCL21, 
suggesting they would be able to migrate to lymph nodes and they induce strong anti-tumor 
CD8
+
T cells responses. These data provide an alternative method for the generation of type-1 
polarized DCs in a clinical relevant setting.  
In chapters 2, 3 and 4 I have shown that type-1 polarized DCs are strong inducers of anti-
tumor CD8
+
 T cell responses and that these T cells express the peripheral homing chemokine 
receptors CXCR3 and CCR5, which would allow them to migrate to inflamed tissues. However, 
the majority of tumors do not produce chemokines that attract cytolytic effector CD8
+
 T cells 
(e.g. CXCL10/IP10 and CCL5). Therefore, in chapter 5 I examine the ability of modulating the 
tumor chemokine environment to enhance the attraction of type-1 DC-induced CD8
+
T cells.        
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5.1 ABSTRACT 
Tumor infiltration with effector CD8
+
 T cells (Teff) predicts longer recurrence-free survival in 
many types of human cancer, illustrating the broad significance of Teff for effective 
immunosurveillance. Colorectal tumors with reduced accumulation of Teff express low levels of 
Teff-attracting chemokines such as CXCL10/IP10 and CCL5/RANTES. In this study, we 
investigated the feasibility of enhancing tumor production of Teff-attracting chemokines as a 
cancer therapeutic strategy, using a tissue explant culture system to analyze chemokine induction 
in intact tumor tissues. In different tumor explants, we observed highly heterogeneous responses 
to IFNα or poly-I:C (a TLR3 ligand) when they were applied individually. In contrast, a 
combination of IFNα and poly-I:C uniformly enhanced the production of CXCL10 and CCL5 in 
all tumor lesions. Moreover, these effects could be optimized by the further addition of COX 
inhibitors. Applying this triple combination also uniformly suppressed the production of 
CCL22/MDC, a chemokine associated with infiltration of T regulatory cells (Treg). The Teff-
enhancing effects of this treatment occurred selectively in tumor tissues, as compared to tissues 
derived from tumor margins. These effects relied on the increased propensity of tumor-
associated cells (mostly fibroblasts and infiltrating inflammatory cells) to hyper-activate NF-κB 
and produce Teff-attracting chemokines in response to treatment, resulting in an enhanced ability 
of the treated tumors to attract Teff cells and reduced ability to attract Treg cells. Together, our 
findings suggest the feasibility of exploiting NF-κB hyper-activation in the tumor 
microenvironment to selectively enhance Teff entry into colon tumors. 
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5.2 INTRODUCTION 
The ability of CD8
+ 
T cells to infiltrate cancer lesions is essential for anti-tumor immunity, as 
evidenced by studies highlighting the prognostic value of effector T (Teff) cells in multiple cancer 
types, including colorectal cancer (CRC) (77, 103, 105, 228).  In contrast, tumor infiltration with 
regulatory T cells (Tregs) predicts poor outcomes (229-232). Chemokines and their respective 
receptors are critical for T cell migration and homing (170, 233-237). High levels of 
CCL5/RANTES (CCR5 ligand) and CXCL9/MIG and CXCL10/IP10 (ligands for CXCR3) in 
tumor tissues are associated with enhanced infiltration of CD8
+
 T cells in CRC (238), melanoma 
and gastric cancer (178, 239). In contrast to the benefits of intra-tumoral expression of CCL5 and 
CXCL9-11 (240), high levels of CCL22/MDC, the CCR4 ligand preferentially attracting Tregs, 
can be associated with reduced survival, as shown in ovarian cancer patients (47).   
Several studies have indicated the propensity of colorectal tumors to over-express COX2 
and its product PGE2 (241-242), the factor shown to promote the induction of CCL22 in dendritic 
cell (DC) cultures (25). Prompted by these reports, and by our observations of the reciprocal 
impact of IFN  versus PGE2 on the production of Teff- and Treg-attracting chemokines in isolated 
DCs (25), we tested the feasibility of using these factors to manipulate tumor microenvironment 
to enhance the production of Teff-attracting chemokines in intact human tumor tissues. We used 
an ex vivo tumor/tissue explant culture system previously applied to study migration of DCs 
(243), to avoid spontaneous activation of the chemokine-producing cells in the process of tumor 
dissociation. 
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Guided by reports showing common hyper-activation of NF- B in cancer tissues (244-
247), and the requirement for this factor in the induction of both Treg- and Teff-attracting classes 
of chemokines (248-250), we tested whether the selected PGE2- and IFN -targeting strategies 
can be used to selectively enhance the production of Teff-attracting chemokines in tumor tissues, 
rather than marginal tissues, in order to selectively direct Teff cells to tumors. 
5.3 MATERIALS AND METHODS 
Patients.  
72 colorectal patients were involved in the study. Tumors and marginal tissues were 
harvested during routine surgery. The patient profile is presented in Table 1. All patients signed a 
consent approved by the Institutional Review Board of the University of Pittsburgh for collection 
of tumor samples (UPCI 02-077). 
 
Culture of macrophages, fibroblasts, HUVEC cells and colon cancer cell lines. 
 For preparation of macrophages, monocytes were cultured in AIM-V with GM-CSF for 
6 days. Fibroblasts (Cascade Biologicals, Portland, Oregon) and colon cancer cell lines CACO-2, 
HCT116, HT29, SW480 and SW620 (ATCC, Manassas, VA) were grown in IMDM+10% FBS, 
while HUVECs (AllCells, Emeryville, CA) were cultured in HUVEC complete media (Basal 
media supplemented with HUVEC stimulatory supplement; AllCells). All were washed, 
reseeded at 20,000 cells in 300µL in 96 well plates and treated with IFN  poly-I:C, and/or 
indomethacin as indicated for 48hrs, and supernatants were analyzed for chemokine production 
by ELISA. 
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Ex vivo cultures of tumor- and marginal tissue explants.  
Using a 4mm biopsy puncher, the cubes of tumor or marginal tissue were prepared and 
placed in antibiotic-containing IMDM/10% FBS (typically 3 cubes/well in 24 well plates) for 24-
48 hours, as indicated. When indicated, the tissues were treated with 10,000 units of IFN , 
20 g/mL of poly-I:C, 50 M of indomethacin  or 10 M of celecoxib. Biopsies were harvested at 
0 and 24hrs for mRNA analysis and confocal microscopy analysis. Culture supernatants were 
harvested at 24-48 hours, as indicated (all groups in a single type of experiment were harvested 
at the same time point) for ELISA and chemotaxis assays. The detailed work flow is depicted in 
Supplementary Fig. 6A. The system used, based on our previously-developed ex vivo whole 
tissue culture system (243), allowed us to avoid spontaneous induction of chemokine production 
by the process of tumor dissociation (Supplementary Fig 6B and data not shown). 
 
Taqman analysis of mRNA expression in tumors and marginal tissues.  
4mm biopsies were placed in lysing Matrix E tubes (MP Biologicals, Solon, OH) 
containing RLT buffer (RNeasy kit, Qiagen, Valencia, CA), and agitated using a FP120 
homogenizer (MP Biologicals). Debris-free supernatant from the lysis matrix tubes were 
transferred into new tubes and the total RNA was extracted using the RNeasy kit. 1 g of RNA 
extracted by the above described method was used for cDNA synthesis, and 25-50 ng of 
subsequent cDNA was used to perform mRNA expression analysis by Taqman analysis on the 
Step One Plus system (Applied Biosystems). All the primers used for the analysis were standard, 
purchased from Applied Biosystems. 
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ELISA analysis of chemokines in tumor ex vivo culture supernatants.  
Culture supernatants from tumor ex vivo cultures were analyzed by ELISAs for the 
presence of chemokine proteins CCL5, CCL22 and CXCL10, using primary and secondary 
antibodies from Peprotech, Rocky Hill, NJ. Detection was done using Streptavidin-HRP 
conjugate and TMB substrate from Pierce Biotechnology Inc, Rockford, IL.  
 
Isolation of tumor infiltrating CD8
+
 T cells.  
Tumor infiltrating lymphocytes were isolated as described by Dudley et al (251), with the 
following modifications: Tumor was cut into 4mm cubes using a biopsy punch, and each 4mm 
tumor piece cultured in 1mL of IMDM + 5% human AB serum with 1000U/mL IL-2 for 2 
weeks. Medium was changed twice a week, until lymphocytes were extruding from tumor and 
formed proliferating clusters.  
 
Chemotaxis.  
Chemotaxis assays were performed in 24 transwell plates with 5 m pore size 
polycarbonate filters (Corning Inc, Corning, NY). The lower chambers were filled with 600 L of 
tumor supernatants. As indicated, 2x10
5 
of either isolated tumor-infiltrating lymphocytes 
or DC1-activated CD8
+
 Teff cells (189), in 200 L of IMDM 10% FCS, were added to the upper 
chambers and incubated for 3hrs at 37
o
C. Migrated cells were harvested from the lower 
chambers and stained for CD8. Cell counts were performed by a 60 second limited run on a BD 
Beckman Coulter XL cytometer. For analysis of Treg cell migration, bulk CD4
+
 T cells were 
isolated by negative selection using EasySep CD4 enrichment kits (StemCell), and 1x10
6
 of the 
isolated cells in 200µL were allowed to migrate towards 600 L of tumor supernatants in the 
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bottom chambers. The migrated cells in the bottom chambers were harvested and FOXP3/GITR 
frequencies were determined by Taqman analysis or flow cytometry. 
 
In situ hybridization.  
Tissue specimens were fixed in 4% para-formaldehyde, processed and pre-treated as 
described (252), except that tissues were sectioned on a cryostat at 5µm. Gene-specific 
riboprobes were synthesized by in vitro transcription using a Maxiscript SP6/T7 kit (Ambion) 
and unincorporated nucleotides were removed using RNA Mini Quick Spin Columns (Roche). In 
situ hybridization with 
35
S-labeled riboprobes was performed as described (252-253), with 0.1M 
dithiothreitol included in the hybridization mix. Hybridizations were performed at 50
o
C 
overnight. Tissue sections were coated with NTB emulsion (Kodak) and exposed at 10
o
C for 7-
14d. Simultaneous in situ hybridization and immunohistochemistry were performed as described 
(252-253), except that the dithiothreitol concentrations were 0.01M in the hybridization mix and 
1mM in the washes. An antibody against HLA-DR (Dako) was used at a dilution of 1:25. 
 
Confocal microscopy analysis of tumor and marginal tissues.  
4mm tumor punches, either untreated or treated, were embedded in OCT medium-
containing cryomolds and immediately frozen in 2-methyl-butane. 6µm frozen sections of the 
tissues were made using the cryostat and layered on superfrost® plus slides (Thermo Scientific, 
Rockford, IL). The slides were incubated in 4% para-formaldehyde for 15 minutes, washed and 
blocked for 60 minutes at RT. The slides were then stained for 3hrs at RT with antibodies for 
P65 (ab16502) or for CD8 (ab4055), CXCL10 (ab8098) and CCL5 (ab10590; both 
AbcamCambridge, MA). The slides were washed 3 times with 1x PBS and incubated with 
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secondary antibodies anti-rabbit (Alexa 647), anti-mouse (Alexa 488; both Cell Signal, Danvers, 
MA) and anti-goat (Alexa 488; Invitrogen, Carlsbad, CA) for 30 minutes at RT. The slides were 
washed 3 times with 1x PBS and once with high salt PBS. Cover slips were mounted on the 
sections using prolong gold anti-fade solution (Invitrogen). Confocal analyses of stained slides 
were performed using a LEICA TCS SL DMRE Microsystems. To quantify the numbers of cells 
showing nuclear NF- B translocation, images were taken of 10 different fields (63x 
magnification) of the tumor and marginal tissue sections (untreated or treated). To identify the 
cells showing P65 translocation and chemokine production in response to treatment, tumor 
tissues were stained with CD45 (H130, BioLegend, San Deigo, CA),  CD326 (9C4, BioLegend), 
fibroblast marker (TE-7, EMD Millipore, Billerica, MA) and CCL5 (ab9679, Abcam) and 
CXCL10 (ab9807, Abcam), and cells were enumerated as described above. 
 
Statistical analysis.  
Pearson rank correlations between the chemokine genes and T cell markers were 
calculated on logarithmically transformed data. In situations where significant between-batch 
variation was observed, the correlation was adjusted for the batch effect by performing a 
multivariate analysis of variance (MANOVA) of each pair of variables on batch, and deriving 
the correlation from the MANOVA residual matrix. Comparisons of continuous variables 
between groups were performed by two-tailed paired t tests.  P <0.05 was considered significant.  
Analyses were performed using SAS v9.2 (SAS Institute, Cary, NC) or GraphPad Prism 5 
software. 
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5.4 RESULTS 
5.4.1 The expression of effector T cell (Teff)-recruiting chemokines in colorectal tumor 
samples correlates with effector CD8
+
 T cell markers.  
Using resected tumor material from 72 patients with advanced colorectal cancer 
(metastatic in 68 patients), we observed that local expression of two Teff cell markers (CD8 and 
Granzyme B; GZMB) is strongly correlated with the expression of two Teff-attracting 
chemokines, CCL5 and CXCL10 (Fig. 13A). In contrast, the Treg markers FOXP3 and GITR 
were correlated with CCL22 (Fig. 13B), a known Treg attractant (25, 47). Additional correlations 
were observed between CXCL9 (alternative CXCR3 ligand) and Teff markers and between 
CCL22 and the CCL22- inducing factor (22) COX2 (Supplemental Fig. 7A-B). Confocal 
microscopy analysis of the tumor sections revealed that all CXCL10-producing cells 
(Supplemental Fig. 7D; right panel) and a significant proportion of CCL5-producing cells  (left 
panel) were CD8-negative, arguing against the possibility that the above correlations result from 
the production of these chemokines by CD8
+ 
T cells themselves, instead suggesting their 
causative role in mediating CD8
+
 T cell infiltration.  
The phenotypic analysis of CD8
+
 tumor-infiltrating lymphocytes (TIL) obtained from 
colon cancer patients (see M&M) revealed that the majority of CD8
+
 TILs are CCR5
+
 CXCR3
+ 
(Supplemental Fig. 7E) and Granzyme B
+ 
(Supplemental Fig. 7F), which further indicates that 
the intra-tumoral expression of the CCR5- and CXCR3-ligands was responsible for recruiting the 
effector T cells into the tumor.   
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Figure 13. Presence of Teff- and Treg markers in tumors correlates with intra-tumoral expression of, 
respectively, Teff- or Treg-attracting chemokines.  
Tumor biopsies from colon cancer patients were lysed, RNA extracted and Taqman analysis of various markers was 
performed. (A) Correlation between Teff markers (CD8 and Granzyme B; GZMB) and Teff-attracting chemokines 
(CCL5 and CXCL10) in tumor lesions. (B) Correlation between Treg markers (FOXP3 and GITR) and the 
chemokine CCL22 in tumor lesions.  
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5.4.2 Combination of IFN  indomethacin and poly-I:C selectively enhances the 
production of Teff-recruiting chemokines in tumor tissues and suppresses Treg-recruiting 
chemokines.  
In order to test the possibility of correcting the chemokine environment in the tumors 
with low ratios of Teff- to Treg-attracting chemokines, we tested in pilot studies the feasibility of 
modulating their production using different combinations of IFN , indomethacin (COX1/2 
inhibitor) and poly-I:C in individual populations of tumor-relevant cells, such as colon cancer 
cells, macrophages, fibroblasts and HUVECs. We observed strong synergy between IFN  and 
poly-I:C in the induction of CCL5 and CXCL10, and a strong suppressive effect of IFN  on the 
production of CCL22 in macrophages and fibroblasts (Supplementary Fig. 8A-B). These 
desirable effects were further potentiated in the presence of indomethacin (Supplementary Fig. 
8B). In contrast, none of the long-term-cultured colon cancer cell lines tested (CACO-2, 
HCT116, HT29, SW480 and SW620) or HUVECs produced any detectable CCL5, CXCL10 or 
CCL22 (data not shown).  
In order to test the feasibility of using these factors to manipulate the complex 
microenvironment of whole tumor tissues, involving all the above cell types and their 
interactions, we used an ex vivo tumor/tissue explant culture system previously developed to 
study migration of DCs (243). This system allowed us to avoid nonspecific activation of the 
chemokine-producing cells during tumor dissociation (see Supplementary Figure 6B and data not 
shown). 
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Figure 14. Heterogenous response pattern of different tumor tissues to individual chemokine modulators and 
their uniform response to the combination of IFN , poly-I:C and indomethacin. 
(A) Fresh tumor samples from 11 patients with metastatic colorectal cancer were untreated or treated with IFN  and 
poly-I:C either individually or in combination for 48 hours. The release of CCL5 and CXCL10 into culture media 
was analyzed by ELISA. Numbers indicate the prevalence of tumors with each chemokine pattern (respective 
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patterns A, B or C). (B) ELISA analysis of CCL5, CCL22 and CXCL10 in tumors untreated or treated with IFN + 
poly-I:C, with or without indomethacin.  *denotes P<0.05 (the presence or absence of indomethacin). 
 
 
As shown in Figure 14, different tumor tissues treated with IFN  or poly-I:C alone showed 
variable chemokine expression, falling into three different patterns: minimal induction of CCL5 
and CXCL10; minimal induction of CCL5 but significant induction of CXCL10; or significant 
induction of both CCL5 and CXCL10 (Fig. 14A). This heterogeneity was observed between 
tumors from different patients, and even between different lesions within a single patient (Fig. 
14A and Supplemental Fig. 8C). However, combining IFN  and poly-I:C resulted in uniformly 
high expression of both CCL5 and CXCL10 in all tumors tested (Fig. 14A and Supplemental 
Fig. 8C).  
 Additional exposure to indomethacin (which blocks COX1 and COX2) further 
enhanced the production of CCL5 and CXCL10 induced by the combination IFN and poly-I:C 
and reduced CCL22 in whole tumor tissues (Fig. 14B), with similar results obtained using a 
selective COX2 blocker, celecoxib (Supplemental Fig. 8D).  
 Based on these data, we selected the triple combination of IFN , poly-I:C and 
indomethacin as the preferred treatment for all subsequent experiments. This combination 
consistently enhanced CXCL10 and CCL5 production and suppressed the production of CCL22 
in all tumor samples, as shown by individual chemokine gene expression at the single cell level 
using in-situ hybridization (ISH; Fig. 15A) and at the level of chemokine secretion, using ELISA 
(Fig. 15B). Similar observations were also made in case of CXCL9 (data not shown). 
 The dual staining for HLA-DR (immunohistochemistry) and chemokine mRNA 
(ISH) demonstrated that CCL22 was expressed predominantly by HLA-DR
+
 APCs, while 
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CXCL10 and CCL5 were expressed by both HLA-DR
+ 
and HLA-DR
-
 cells (Supplemental Fig. 
9), indicating the contribution of multiple tumor-associated cell types to the production of Teff-
recruiting chemokines within the tumor microenvironment.   
 
Figure 15. Combination of IFN , poly-I:C and indomethacin, consistently up regulates Teff-attracting 
chemokines and suppresses Treg-attracting chemokines in tumor tissues. 
(A) In-situ hybridization for respective chemokine mRNA (black grains) in tumor biopsies which were either left 
untreated or treated with the combination of indomethacin, IFN  and poly-I:C (IAP). (B) ELISA analysis of the 
chemokine contents in the supernatants of 48 hour-cultured tumor tissues (untreated or treated) from 10 different 
patients. 
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5.4.3 Enhanced activation of tumor-associated NF- B by the chemokine-modulatory 
regimen results in preferential induction of CXCL10 in tumors, rather than marginal 
healthy tissues.  
Using matched tissue samples from 10 patients with metastatic colon cancer, we 
compared the responsiveness to the chemokine-modulating regimen between liver-metastatic 
tumor tissues and marginal tissues. As shown in Fig. 16A (and Supplemental Fig. 10), while the 
baseline differences in chemokine production between the untreated liver-metastatic tumors and 
marginal liver tissues did not reach significance (P=0.12), tumor treatment with the combination 
of IFN , poly-I:C and indomethacin induced much more pronounced secretion of CXCL10 by 
tumor tissues compared to the marginal tissues (P<0.01). Similar observations at the protein and 
chemokine gene expression level were made in the case of CCL5 (Supplemental Fig. 10A, B). 
This increased responsiveness of tumors compared to marginal tissues was not due to decreased 
survival of the marginal tissues, as determined by undisturbed expression levels of glycogen 
phosphorylase (Supplemental Fig. 10C). Similarly, the differences in the responsiveness to the 
chemokine-modulatory regimen between tumors and marginal tissues could not be explained by 
potential differences between their expression of the IFN  receptor, TLR3, IRF1, IRF3, or the 
differential infiltration with APCs or NK cells, which were all similar between tumors and 
marginal tissues (data not shown).  
 Driven by the previously reported key role of NF- B in the induction of CXCL10 
and other chemokines (248-250), and the ubiquitous enhancement of the NF- B signaling in 
cancer lesions critically needed for tumor survival and growth (244-247), we tested whether 
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potential differences in NF- B activation could be responsible for the differential ability of the 
tumors versus marginal tissues to respond to the chemokine modulatory regimen.  
 In accordance with this possibility, we observed that the colorectal cancer tissues 
showed not only elevated baseline levels of NF- B activation (measured by the rate of its 
nuclear translocation; see Fig. 16B, left), but an even more pronounced ability to further activate 
NF- B after the IFN /poly-I:C/indomethacin treatment (Fig. 16B, right). The key role of NF- B 
in CXCL10 production by tumor tissues was validated by using an NF- B inhibitor, CAY10470, 
which completely abrogated CXCL10 induction (Fig. 16C).  
 CCL5 regulation showed a similar pattern (treatment-induced up-regulation in 
tumors, rather than in marginal tissues) and was also blocked by CAY10470 (Supplemental Fig. 
10B), showing the general role of the tumor-associated NF- B deregulation in the selective 
induction of Teff-attracting chemokines by the chemokine-modulating regimen. CAY10470, used 
in these experiments (at 20 M), was non-toxic, as shown by similar expression of glycogen 
phosphorylase mRNA in untreated and treated tissues (Supplemental Fig. 10C). 
 Interestingly, our confocal microscopy analysis revealed that most of the cells that 
showed nuclear translocation of NF- B and produced CCL5 and CXCL10 represented CD45
+
 
infiltrating inflammatory cells and (TE-7-binding) tumor-associated fibroblasts, with only some 
of the  CD326/EpCAM
+
 cancer cells producing CCL5 (Fig. 16D; also see Supplemental Fig. 
10D for example of single-color analyses). 
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Figure 16. NF- B-dependent selective enhancement of CXCL10 production in tumor tissues following 
exposure to the combination of IFN , poly-I:C and indomethacin. 
(A) ELISA for CXCL10 expression in matched normal liver and liver metastatic tissues from 10 different patients 
either untreated (left panel) or treated (right panel). (B) Average number of cells counted per field (confocal 
microscopy; in a total of 10 fields) showing nuclear translocation of NF- B in normal liver or liver metastatic 
tissues either untreated or treated (right panel). Representative images of each condition are shown in the left panel. 
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(C) ELISA analysis of CXCL10 production by the matched normal liver and liver-metastatic colorectal cancer 
tissues, either untreated or treated (IFN , poly-I:C and indomethacin), in the absence or presence of 20µM 
CAY10470 (NF- B inhibitor). D) Colorectal cancer tissues from three colorectal cancer patients were treated with 
indomethacin + IFN  + Poly-I:C for 30 minutes (p65 translocation) and 24 hours (chemokine production) and 
analyzed by confocal microscopy for  the translocation of  p65 and production of CCL5 and CXCL10 by infiltrating 
inflammatory cells (CD45
+
), tumor-associated fibroblasts (TE-7-binding cells) and cancer cells (CD326). 
Representative data from one of three experiments. Left panel: representative sections of the activated tumor tissue. 
Right panel: Numbers per vision field of the individual cells types showing p65 translocation and chemokine 
production. Data from 10 vision fields is expressed as average +/- SEM. 
 
5.4.4 IFN /poly-I:C/indomethacin-treated colorectal tumors preferentially attract 
effector CD8
+
 T cells.  
In order to demonstrate that the modulation of chemokine achieved by the combination of 
IFN , poly-I:C and indomethacin is indeed sufficient to affect the ability of tumors to attract 
different subsets of T cells, we used an ex-vivo chemotaxis assay involving the supernatants from 
differentially-treated tumors and either expanded tumor-infiltrating CD8
+
 T cells (TILs; see 
Supplemental Fig. 7F) or polyclonal ex-vivo-induced effector CD8
+
 T cells induced by 
superantigen-loaded DC1s (189). As shown in Fig. 17A, each type of effector CD8
+
 T cell 
showed strongly enhanced migratory responsiveness uniformly to all the IFN /poly-
I:C/indomethacin-treated tumors. In contrast, CD4
+
FOXP3
+
 T cells preferentially migrated to 
untreated tumors, as determined by Taqman analysis of the migrated blood-isolated CD4
+
 T cells 
(Fig. 17B), or flow cytometry (Supplemental Fig. 11A). As expected, Taqman analysis of 
another Treg marker, GITR, yielded similar results (Supplemental Fig. 11B). 
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Figure 17. IFN , poly-I:C and indomethacin-treated tumors show enhanced ability to attract Teff, but 
strongly-reduced ability to attract Tregs. 
(A) Ex vivo generated Teff  (left) or  isolated CD8
+
 tumor-infiltrating lymphocytes (right) (see Materials and Methods) 
were allowed to migrate towards supernatants from either untreated or treated tumors from 3 different patients in 
transwell chemotaxis assays. (B) Negatively-isolated total CD4
+
 T cells were allowed to migrate towards the treated- 
or untreated tumor supernatants. Migrating cells were lysed and analyzed for FOXP3 expression by Taqman. U.D.: 
undetectable. 
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5.5 DISCUSSION 
Our data demonstrate the feasibility of tumor-selective modulation of the chemokine 
environment, using clinically applicable combinations of pharmacologic and biologic factors to 
correct the balance between tumor-infiltrating Teff- and Treg- cells, the types of immune cells 
known to differentially affect the clinical course of cancer (77, 103, 105, 228-232). Importantly 
for the clinical application of this strategy, we observed that while the responses of the individual 
tumor lesions (even in the same patient) to the individual chemokine-modulators were highly 
variable (consistent with the limited clinical effectiveness of such factors applied individually), 
the combination of IFN , poly-I:C and cyclooxygenase inhibitors allowed for highly consistent  
and selective enhancement of Teff-attracting chemokines (CCL5 and CXCL9-10) within tumor 
lesions tested, with the concomitant uniform suppression of local CCL22, the Treg-attracting 
chemokine.  
 The IFN /poly-I:C/indomethacin-induced production of Teff-attracting 
chemokines was highly tumor-selective, suggesting that even systemic administration of these 
chemokine-modulating factors can preferentially direct effector cells to tumors. While the 
attraction of different subsets of T cells to different tumor types is known to be regulated by a 
complex network of additional chemokines not included in our current analysis (254-255) and 
can be subject to regulation at the level of chemokine receptor expression, for example by CCR5 
polymorphism (172), our current functional data (Fig 17) indicate that the proposed regimen can 
uniformly promote the influx of effector CD8
+
 T cells (both spontaneously-arising TILs and 
DC1 vaccine-induced CTLs). The known role of CXCR3 and CCR5 in the attraction of Th1 
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cells and NK cells (170, 236, 256-257) suggests that the proposed regimen may also be able to 
promote the entry of these additional types of desirable cells into tumors. 
 We observed that the tumor-selectivity of the proposed regimen depends on the 
propensity of tumor-associated fibroblasts and infiltrating inflammatory cells (with lesser 
involvement of tumor cells themselves) to not only spontaneously hyper-activate NF- B, but 
also respond to treatment with further-enhanced levels of NF- B activation. Since NF- B 
activation, critically involved in tumor survival and growth, represents an intrinsic feature of 
many tumor types (244-247), the current data suggest that the currently-described NF- B-
targeting modulation of the tumor microenvironment may be applicable to multiple types of 
cancer.  
The currently-developed chemokine-modulating regimen consists of the combination of 
IFN  (type 1 interferon), poly-I:C (TLR3 ligand), and either indomethacin (COX1 and COX2 
inhibitor) or a selective COX2 inhibitor, celecoxib. While our data demonstrate that interferons 
and prostanoids differentially regulate the NF- B-driven production of Teff-, and Treg-attracting 
chemokines, the specific mechanisms and the molecular level of interplay between these factors 
remain subjects of our current research. Our analyses performed so far did not reveal any 
differences between the expression of the IFN  receptor, TLR3, IRF1, or IRF3 between tumors 
and marginal tissues (data not shown), but our current work focuses on the differential regulation 
of each of the pathways (poly-I:C, IFN  and PGE2 responsiveness) in whole tumor tissues and 
different types of tumor-associated cells. Similarly, we are also evaluating the mechanisms 
underlying the increased sensitivity of tumor-related cells to activate NF- B and the relative 
heterogeneity of different tumors with regard to the requirement for poly-I:C activation, which 
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may help us to identify new strategies of chemokine regulation and of targeting NF- B in tumor 
therapy.  
The combination of IFN , poly-I:C and COX inhibition will be evaluated in clinical 
trials in patients with metastatic colorectal cancer, as a standalone treatment or in combination 
with DC1 vaccines (71, 189), to enhance the numbers of circulating effector-type tumor 
reactive CD8
+ 
T cells that respond to CCR5 and CXCR3 ligands (189) and enter tumor tissues. 
Our follow-up analyses will also allow us to determine whether the observed differences in the 
expression of chemokines and Teff markers in patients with metastatic colorectal cancer also 
translate into differences in clinical course of the disease and patient survival, as predicted by 
studies in primary colon cancer (77, 103, 105, 228). 
 
5.6 IMPLICATIONS 
In chapter 5 I show that the treatment of colorectal tumor tissues with IFN , indomethacin and 
poly-I:C results in the modulation of the chemokine environment to favor the production of 
effector CD8
+ 
T cell attracting chemokines CXCL10/IP10 and CCL5/RANTES. The triple 
combination treatment appears to be tumor specific, which would prevent the infiltration of 
cytolytic effector CD8
+
 T cells into healthy tissues and is mediated by NF- B translocation. 
These data, combined with the data from chapters 2, 3 and 4, which show that high IL-12p70 
producing, type-1 polarized DCs induce large numbers of  CXCR3
+
 CCR5
+
 anti-tumor CD8
+
 T 
cells, suggests that a combination of type-1 polarized DCs vaccines and the triple combination 
treatment would enhance the efficacy of DC-based cancer vaccines.     
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6.0  SUMMARY OF THE THESIS AND IMPLICATIONS 
I examined the effects of inflammatory cytokines on the maturation and polarization of DCs and 
on their ability to prime naïve CD8
+ 
T cells, and developed a novel method of polarizing DCs 
using inflammatory cytokines derived from activated lymphocytes. Furthermore, I explored the 
feasibility to enhance DC1-based cancer immunotherapies by increasing the ability of tumor-
specific CTLs to migrate into tumors by altering the tumor-chemokine-environment. 
The induction of cytolytic effector CD8
+
 T cells is essential for the clearance of virally-
infected and transformed cells, while the induction of memory T cells is necessary for long-term 
protection against reinfection or tumor recurrence. While it is well established that mature DCs 
play a key role in inducing cytolytic T cell responses, less is known about their role in inducing 
memory T cell differentiation. It has been shown that long-term matured (type-1 polarized) DCs 
become exhausted and induce non-polarized CD4
+
 T cells responses (26), but whether the same 
is true for CD8
+
 T cells and whether short-term matured DCs can be instructed to induce 
memory CD8
+
 T cells was unknown. In chapters 2 and 3 I show that in vitro generated 
monocyte-derived DCs can be matured to either induce CTL development or central-memory T 
cell development. The short-term (24-36 hour) maturation and polarization of DCs using factors 
associated with early/acute inflammation (i.e. interferons and TLR-ligands) results in the 
generation of type-1 polarized DCs (DC1s or inflammatory-DCs) that induce the differentiation 
of naïve CD8
+
T cells into cytolytic effector cells. These CTLs express the peripheral-homing 
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chemokine receptors CXCR3 and CCR5, while down-regulate the lymph node-homing 
chemokine receptor CCR7 and are thus able to leave the lymph nodes and migrate to sites of 
inflammation (infected areas or tumors). In contrast, DCs matured by prostaglandin E2 (PGE2; 
sDC or non-inflammatory-DCs) or matured for a prolonged duration (96 hours) induce CD8
+
 T 
cell expansion and activation, as observed by a switch in expression of CD45RA to CD45RO 
and CD25 expression, but do not instill cytolytic capacity in them. Instead, non-inflammatory 
DC-primed CD8
+
 T cells undergo a direct differentiation into central-memory cells. These cells 
would be retained in the lymph nodes due to expression of CCR7 and can rapidly undergo 
secondary expansion and give rise to a CTL population upon restimulation with inflammatory 
DC1s. The data described in chapters 2 and 3 prompted us to propose a model (see figure 18) in 
which the inflammatory status of Ag-presenting DCs determines whether naïve CD8
+
 T cells 
develop into CTLs, followed by differentiation into effector-memory and central-memory cells, 
or differentiate directly into central-memory cells.  
 The effect of an inflammatory environment on the development of effector and memory 
T cells has been extensively evaluated in mouse models (195-196, 258). However, in most cases, 
these models do not allow for the direct analysis of the inflammatory milieu on DC maturation 
and polarization and the role of such DCs in directing T cell differentiation. In cases where DCs 
are used, inflammation is induced by injection of a strong adjuvant and the resulting effect on T 
cell differentiation could be, in part, due to an effect of inflammatory factors directly on the T 
cells and not through the DCs. Our human in vitro model of DC maturation, using different 
maturation cocktails and a variable period of maturation and T cell priming allowed us to 
analyze the role of DCs on the induction of effector and memory T cells. One benefit of our in 
vitro model is that we can employ homogenous populations of DCs, which are matured for 
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approximately the same duration and exhibit a defined phenotype. We can thus determine T cell 
differentiation induced by the priming with one type of DC versus another, instead of trying to 
interpret the impact of heterogeneous DC population, as is the case in vivo, where different DC 
subsets, matured for different lengths of time might contribute to the overall characteristics of the 
resulting T cell response.   
 
Figure 18. The regulation of effector and memory CD8
+
 T cells by DCs: the model.  
Short-term maturation of DCs by mediators of early/acute inflammation (i.e. interferons and TLR ligands) results in 
type-1 polarized DCs that express T-bet and secrete high amounts of IL-12p70 and the CTL-attracting chemokine 
CXCL10/IP10. Naïve CD8
+
 T cells primed by these type-1polarized DCs undergo differentiation into cytolytic 
effector cells, followed by the formation of effector-memory and central-memory cells. In contrast, maturation of 
DCs by a mediator of chronic infection (PGE2; or long-term maturation of type-1 polarized DCs) results in DCs that 
do not express T-bet and do not secrete IL-12p70 (previously considered exhausted) and produce the Treg-attracting 
chemokine CCL22. Naïve CD8
+
 T cells primed by these non-inflammatory DCs undergo a direct differentiation into 
central-memory cells without passing through a cytolytic effector phase.   
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The current data help to elucidate the pathways by which memory T cells can form. 
While some mouse models suggest a linear differentiation pathway (205), in which naïve T cells 
first differentiates into CTLs and then, a portion of the effector cells, further develop into 
memory T cells, other models suggest that memory T cells arise during the initial “effector 
phase” simultaneously with the effector T cells and do not need to pass through a cytolytic 
effector phase (32). My data suggest that both pathways can occur and depend on the ability of 
DCs to provide signal 3 to responding T cells. Recently, a model of effector and memory T cell 
differentiation based on asymmetrical cell division has been proposed (118). In this model, a 
naïve T cell undergoing its first cell division during interaction with an Ag-presenting DC, gives 
rise to a daughter cell with effector properties and a daughter cell with central-memory T cell 
properties. Our observation that non-inflammatory DCs generate only central-memory T cells 
would suggest that there is no asymmetrical cell division in our model. It could be that there is 
asymmetrical cell division in our inflammatory DC1-primed CD8
+
 T cells, since there appears to 
be a population of CCR7
+
 IL-7R
+
 cells present during the effector phase, but preliminary 
experiments examining this pathway did not reveal any sign of asymmetrical cell division.         
It has been suggested that the duration of interaction of T cells with DCs affects the 
balance of effector versus memory T cell formation (45). Longer duration would allow for more 
signaling through the TCR and co-stimulatory molecules, favoring effector T cell differentiation. 
I did not detect any difference in the expression of MHC class I and class II molecules or in co-
stimulatory molecules between inflammatory DC1s and non-inflammatory-DCs which would 
suggest a difference in the interaction of DCs with the T cells that could account for the distinct 
differentiation pathway. Furthermore, the acquisition of granzyme B expression and the down-
regulation of CCR7 by DC1-primed CD8
+
 T cells could be blocked by neutralizing IL-12p70, 
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which would presumably not affect the duration of T cell interaction with the DCs. Conversely, 
preliminary experiments in which either exogenous IL-12p70 or IL-27, a IL-12 family member 
which has been shown to have Th1/CTL-inducing properties, was added to non-inflammatory 
DC-CD8
+
 T cell cultures, showed the upregulation of granzyme B by the T cells, suggesting that 
in our model, CTL differentiation depends primarily on the ability of DCs to provide signal 3 
(i.e. IL-12). However, the duration of interaction of T cells with differentially matured DCs 
could still play a role and would need to be examined. The dependence on signal 3, is in 
accordance with previous observations made in mouse models, in which the differentiation of 
CD8
+
 T cells into CTLs is regulated by IL-12p70 via the modulation of T-bet expression in T 
cells (44). High levels of IL-12p70 up-regulate T-bet expression, while in the absence of IL-
12p70 signaling, T-bet expression was diminished and memory Tcell formation was favored. 
Interestingly, IL-12p70 signaling has been shown to enhance mTOR kinase activity, which up-
regulates T-bet expression (128). Furthermore, T-bet down-regulates the expression of IL-7R , 
which is a hallmark of central-memory cells.  In our model, CD8
+
 T cells primed by IL-12-
deficient non-inflammatory DCs express reduced levels of mTOR kinase activity and T-bet and 
they retain IL-7R  expression.  
In the case of DC-based cancer immunotherapy, the use of short-term matured type-1 
polarized DCs loaded with tumor antigen would be favorable, since this would generate cytolytic 
effector T cells capable of killing tumor cells and indeed, the use of type-1 polarized DCs in 
clinical trials suggests the ability to prolong the survival of patients with malignant gliomas (70). 
The subsequent development of memory cells against the tumor would aid in the prevention of 
tumor recurrence. A combination of DC-types for use in cancer vaccination protocols could be 
envisioned, in which a patient first receives a dose of non-inflammatory DCs, which migrate to 
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the lymph nodes and induce central-memory T cell development, and they then subsequently 
receive a second vaccination with inflammatory DCs, which would induce CTL differentiation. 
The generation of central-memory T cells by the non-inflammatory-DCs would allow for the 
generation of higher numbers of CTLs by the “booster” inflammatory-DCs. However, these 
potential advantages need to be considered in the context of the undesirable attraction and 
expansion of Tregs by the PGE2-matured DCs (25, 54).      
The induction of a large pool of memory T cells is the basis for prophylactic vaccination 
therapy (as in the case of “childhood diseases” and influenza infection). In order to generate a 
large pool of memory T cells capable of rapidly responding to infection, these vaccinations must 
be given multiple times, in so-called prime-boost regiments (259). Since the number of memory 
T cells that is formed is primarily dependent on the initial clonal burst size, the prime-boosting 
strategy consists of a first dose of antigen in the presence of a strong adjuvant in order to ensure 
a robust expansion of Ag-specific T cells and specific effector T cell differentiation. Following 
the effector T cell generation and subsequent contraction phase a small population of memory T 
cells remains. The boosting dose of the vaccination regiment allows for the secondary expansion 
of the remaining memory T cells as well as new naïve T cells, allowing for a more robust 
expansion than observed during the priming phase, and the development of a larger pool of 
memory cells. Also, it has been suggested that the booster vaccines may skew the memory T cell 
population towards higher affinity clones (260). Since terminally-differentiated effector T cells 
are resistant to secondary expansion, a relatively long time interval (weeks or months) between 
the priming and subsequent booster dose is required. Furthermore, circulating CTLs have been 
shown to eliminate Ag-presenting DCs in a granzyme B- and perforin-dependent manner (139, 
141). Since, DCs present in the region of the vaccination injection would need to take up antigen 
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and transport it to the lymph node to cross-prime specific T cell responses, the ability of CTLs to 
eliminate DCs would limit the number of DCs that reach the lymph nodes, and thus, prevent the 
induction of a secondary immune response.  
 The long time interval between the priming and boosting is acceptable in certain 
situations (e.g. “childhood diseases”), but whenever rapid/sustained protection is desired (e.g. 
during epidemics or bioterrorism threats), the accelerated generation of a large pool of memory T 
cells is favorable. The observation that DCs induced in the absence of acute inflammation could 
rapidly generate central-memory T cells allows for the optimization of current vaccination 
protocols. However, the use of autologous, ex vivo matured DCs would be a costly process and is 
unlikely to be used for a large population of patients. In a recent mouse study, Pham et al., used 
cell-associated antigens or antigen-coated biodegradable microspheres to cross-prime CD8
+
 T 
cells (261). The injection of the microspheres in the absence of adjuvant, result in the rapid 
generation of CD8
+
 memory T cells responsive within days to a booster dose with secondary 
expansion and CTL development. The use of clinically-applicable microspheres for the induction 
of memory cells would strongly reduce the cost of the vaccination process compared to the 
generation of personalized DC-based vaccines.  
The induction of strong anti-tumor CTL responses by DCs is dependent on the provision 
of inflammatory signal 3 (e.g. IL-12) (67-69, 98). Type-1 polarized DCs are able to secrete high 
levels of IL-12p70 and to induce strong CTL responses. However, the generation of large 
numbers of type-1 polarized DCs in a clinical setting requires the use of expensive clinical-grade 
cytokines, making DC production costs high. While this might not be an issue for many of 
institutes in the US and Western-Europe, which have sizeable resources for conducting clinical 
trials using GMP cytokine-matured DCs, for institutes in most countries, this process would be 
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too expensive. In previous studies, we have shown that NK cells can promote the type-1 
polarization of autologous DCs and that these “NKDC1s” can generate strong anti-tumor CTL 
responses (262-263). The NK-induced type-1 polarization was dependent on NK-secretion of 
IFN  and TNF . Since activated lymphocytes can produce these same DC-polarizing factors, I 
decided to analyze the feasibility to use lymphocytes to induce DC maturation and polarization. 
During the isolation of monocytes for the generation of DCs, lymphocytes are obtained as a “by-
product”. By expanding the bulk lymphocytes, using relatively cheap expander beads, without 
further separation, I was able to obtain high numbers of lymphocytes, which mostly consisted of 
CD4
+
 and CD8
+
 T cells. These cells produce high levels of IFN  and TNF  upon reactivation 
and are able to mature autologous DCs in vitro. The lymphocyte-matured DCs produce IL-12p70 
and CXCl10/IP10 upon CD40 ligation and induce stronger anti-tumor T cell responses than non-
inflammatory DCs. While these data show the feasibility of using bulk lymphocytes for the type-
1 polarization of DCs I did not perform an extensive cost analysis. In part because this would not 
be representative for the actual cost, since different countries have different regulatory 
requirements and the costs will thus be different. Also, before the suggested protocol of DC1 
generation can be used in clinical settings, more extensive research is required. For instance, the 
amounts of inflammatory cytokines produced by the lymphocytes would be expected to 
fluctuate. It would need to be established what the minimum concentration of cytokines is for 
effective DC maturation and polarization, resulting in additional testing of the supernatant of 
restimulated lymphocytes, thus increasing the cost of DC production for clinical use. This is 
especially important in the case of using supernatants from restimulated lymphocytes for the DC 
maturation, since we observed an additional iDC population in our cultures. When used in 
clinical settings, the iDC population would be unwanted since it has been shown that Ag-
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presentation by resting/steady state (immature) DC induces the formation of Treg cells and 
immune tolerance (17, 226). Furthermore, in the analysis of matured DCs, I focused on IL-12p70 
and CXCL10, since previous studies by our group and other groups have shown that these 
factors are required for optimal CTL development. However, these DCs could also produce 
inhibitory factors, such as IL-10 or TGF , which could support Treg cell development and 
thereby inhibit immune responses. While the functional data suggest that the lymphocyte-
matured DCs induce strong anti-tumor CD8
+
 T cell responses, I did not examine its effect on 
other immune cells. However, from a practical standpoint, since the lymphocyte activation and 
restimulation can be performed simultaneously with the generation of immature monocyte-
derived DCs, the additional work involved when compared to cytokine-matured DC1 production 
would be minimal.      
My observation that DC1-primed CD8
+
 T cells acquire peripheral-homing ability (based 
on expression of CXCR3 and CCR5) is of interest since it would allow them to migrate into 
inflamed tissues (as in the case of sites of infection or cancer). The presence of tumor-infiltrating 
CD8
+
 T cells has been shown to have positive prognostic value (264). However, only a relatively 
small percentage of tumor tissues exhibit high numbers of CD8
+
 TILs. Tumors create an 
environment that favors attraction of Treg cells and exclusion of Th1 and CTLs (47) and cancer 
patients have increased percentage of Treg cells in their peripheral blood (48). The ratio of tumor 
infiltrating CD8
+
 T cells to CD4
+
 Foxp3
+
 Treg in tumor lesions has been shown to have good 
prognostic value for disease outcome (46). This suggests that one hurdle to overcome in cancer 
immunotherapy is to produce tumor-reactive CTLs that have a high cytolytic capacity and can 
infiltrate tumor tissue. The use of adoptive T cell transfer of ex vivo expanded tumor infiltrating 
lymphocytes (TILs) has shown some promise as immunotherapy. These cells are able to 
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repopulate patients after non-myeloid ablative regiments and to traffic into tumor tissue (53). 
However, since these TILs were obtained from tumors that thus already contained lymphocytes 
and thus produce factors (e.g. chemokines) that already favor T cell attraction. In the case of 
tumors that do not contain TILs, the chemokine micro environment could be such that it prevents 
CTL attraction. Indeed, genetic profiling of melanoma metastases revealed that tissues that had 
infiltrated CD8
+
 T cells, expressed the chemokines, CCL3, CCL4, CCL5 (all ligands for CCR5), 
CXCL9, and CXCL10 (ligands for CXCR3), all of which attract CXCR3
+
CCR5
+
 CTLs, while 
tumors without T cell infiltration do not express these cytokines (265). Our data show a positive 
correlation between CCL22 and Foxp3 mRNA expression message in colorectal tumor tissues, 
suggesting the attraction of Treg cells by certain (CCL22 producing) tumors (see chapter 6).  
In order to increase the tumor infiltration of (DC1-induced) CTLs and to prevent the 
unwanted attraction of Treg cells, I analyzed the feasibility to alter the tumor chemokine 
environment. Since we have previously observed the induction of CCL22 production by PGE2-
treated DCs while treatment with IFN  increased expression of CXCR3 and CCR5 ligands (25), 
I analyzed the effects of treating colorectal tumor tissue with either IFN  or with inhibitors of 
COX-2, which is the key regulator of PGE2 synthesis. I found that a combination of IFN , poly-
I:C and indomethacin (COX-1 and COX-2 inhibitor) or celecoxib (a selective COX-2 inhibitor) 
results  in reduced expression of the Treg-attracting chemokine CCL22 by tumor tissues, while 
simultaneously increasing the expression of the Teff/CTL-attracting chemokines CXCL10/IP10 
and CCL5/RANTES. The enhanced expression of CXCL10 and CCR5 was associated with 
enhanced nuclear translocation of NF- B in tumor cells, a transcription factor known to be 
involved in chemokine production (51).  Of importance is the observation that the triple 
treatment appeared to be selective for the tumor tissue, since the marginal stromal tissues didn’t 
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shown enhanced NF- B translocation. In a chemotaxis assay, the increased production of CTL-
attracting chemokines by treated tumor tissues enhanced the recruitment of ex vivo expanded 
TILs and of DC1-induced CTLs. Furthermore, the treated tissues showed a reduced recruitment 
of Foxp3
+
 T cells, when compared to untreated tissues. This ability to alter the chemokine 
environment in tumor tissue could help in optimizing the success of adoptive T cell transfer trials 
and DC-based vaccination protocols. High numbers of tumor-specific T cells, either developed 
via ex vivo expansion of TILs using current protocols or by in vitro priming of CD8
+ 
T cells with 
tumor-loaded autologous DC1s could be generated and screened for expression of CCR5 and 
CXCR3 before their adoptive transfer into patients that have previously received the triple 
combination treatment to alter the chemokine environment. This could allow for more efficient 
migration of the T cells into the tumor tissue. In the case of DC-based vaccines, one could 
envision that delivery of tumor-loaded DC1s, capable of induce tumor-specific CXCR3
+
 CCR5
+
 
CTLs (see chapter 2), followed several days later by treatment with the triple combination 
treatment, could enhance the migration of the induced anti-tumor CTLs into tumor tissues. Since 
the triple treatment appears to be specific for the tumor tissue, and not for the marginal healthy 
tissue, I assume that there would be specific migration to the desired tissue and limited “off 
target” infiltration and autoimmunity.  
The reduced attraction of Treg cells into tumors would be expected to benefit the function 
of the infiltrating anti-tumor CD8
+
 T cells making the combined treatment even more effective. 
Furthermore, the application of a COX-2 inhibitor in the triple combination treatment might have 
additional beneficial effects, other than modulating CCL22 production and Treg-attraction. 
Recent studies have shown that the presence of PGE2 in tumor tissues can drive the 
differentiation of monocytic precursors towards myeloid derived suppressor cells (MDSCs), 
 131 
which can inhibit the cytolytic function of CD8
+
T cells (52). Inhibition of COX-2 appears to 
reverse the immune-suppressive functions mediated by MDSCs in cancer patients. Also, tumor-
produced PGE2 regulates the expression of CXCR4 on MDSCs, and possibly other immune-
suppressive cells, as well as the CXCR4 ligand, CXCL12 (50). Thus, COX-2 inhibition could 
prevent the PGE2-induced CXCR4 and CXCL12 expression and reduce MDSC tumor 
infiltration. Therefore, the triple combination treatment may bias effector-over-regulatory T cell 
function in the tumor, leading to superior therapeutic. While these data are promising and might 
allow us to improve our current DC-based vaccination strategies, we have not fully analyzed 
whether the treatment actually allows CTLs to gain entry into tumor tissues and whether the 
treatment indeed reduces the presence of inhibitory cell types in the tumor tissue. Mouse studies 
with spontaneously developing tumors would be required to test these aspects. One could assume 
that the use of spontaneously developing tumors would be favorable over transplantable tumors, 
since transplanted tumors would be less vascularized, which would negatively affect  the ability 
of T cells to migrate to the tumors. Also, transplanted tumors would already have fully 
developed immune inhibitory mechanisms in place, while in early spontaneously arising tumors 
these might be less established, which could allow for clearer differences between treated and 
untreated conditions.   
In summary, our data show that the inflammatory status of DCs regulates the 
differentiation pathway of naïve CD8
+
 T cells into CXCR3
+
 CCR5
+
 cytolytic effector with 
peripheral-homing properties, and central-memory cells that retain expression of the lymph 
node-homing receptor CCR7
+
 and can rapidly undergo secondary expansion and CTL 
development upon restimulation with inflammatory DCs. Furthermore, the induction of effective 
anti-tumor responses requires the priming of naïve CD8
+
 T cells by inflammatory-DCs/DC1s, 
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which can be generated in a low cost manner by using autologous activated lymphocytes, and the 
efficacy of DC-based anti-tumor vaccinations may be enhanced by selectively modulating the 
tumor chemokine environment, using a combination treatment with IFN , poly-I:C and COX-2 
inhibitors. 
     The combined data from chapters 2, 3, 4 and 5 show that DCs can be instructed to 
preferentially induce either type-1 anti-tumor responses useful for therapeutic vaccinations when 
large numbers of cytolytic effector CD8
+
 T cells are desired, or to induce the direct 
differentiation into CD8
+
 TCM cells, useful for prophylactic vaccines where the rapid generation 
of large numbers of long-lived memory cells are desired. By manipulation of the tumor-
chemokine environment, the attraction of type-1 DC-induced CXCR3
+
CCR5
+
CD8
+
 T cells by 
tumors can be enhanced, which could lead to an improved efficacy of DC-based cancer 
vaccination strategies. Furthermore, type-1 polarized DCs can be generated by autologous 
lymphocytes which could reduce the cost of the development of DC-based cancer treatments, 
making it more accessible in countries with less funding. 
Also these data broadens our understating of the role of inflammation and of DCs in the 
induction of effector versus central-memory development, which could help in the improvement 
of the clinical effectiveness of DC-based vaccines.         
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APPENDIX A 
SUPPLEMENTAL FIGURES 
.  
Supplementary figure 1. Kinetics of induction and disappearance of killing capacity of differentially primed 
CD8
+
 T cells.  
The cytolytic activity of DC1- and standard DC-primed CD8+ T cells against SEB pulsed JY-1 cells was determined 
at specified time points after priming, using a standard 4 hour 
51
Cr release assay. 
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Supplementary figure 2. Expression of CD127 (IL-7R ) and IL-15R  on naïve CD8
+
 T cells. 
The expression of CD127 and IL-15R  (solid lines) on CD45RO
-
 CD8
+
 T cells was determined by flow cytometry. 
Dotted lines are mouse IgG1 isotype controls. 
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Supplementary figure 3. Blood isolated memory CD8
+ 
T cells require stimulation by polarized DC1s for 
secondary CTL differentiation. 
Circulating memory CD8
+
CD45RO
+
CCR7
+
 T cells were flow sorted from peripheral blood and stimulated with 
polarized DC1s or standard DCs. After 3 days, the cells were analyzed for cytolytic potential, using a standard 4 
hour 51Cr release assay. Similar data was obtained in 3 independent experiments. 
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Supplementary figure 4. Activation of bulk (previously-primed and naïve) CD8
+
 T cells by differentially 
matured DCs results in the induction of killing capacity. 
Bulk CD8
+ 
T cells, normally consisting of 60% CD45RA
+
 CD8
+
T cells and 40% CD45RO
+
 CD8
+
 T cells, were 
isolated from blood using negative selection. Cultures of dendritic cells and T cells were supplemented with 50U/ml 
IL-2. The cytolytic capacity of DC1- and standard DC-primed bulk CD8
+
 T cells against SEB-pulsed JY-1 cells was 
determined 5 days later using a standard 4 hour 
51
Cr release assay. Data from 1 of 2 experiments that yielded similar 
results. 
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Supplementary figure 5. Re-stimulated lymphocytes from melanoma patients induce DC maturation and 
polarization. 
Lymphocytes isolated from the blood of melanoma patients were expanded for 7 days with CD3 and CD28 
coated beads. A) Day 7 expanded lymphocytes were harvested and either left in complete media (circles) or were re-
stimulated (squares). At the indicated times, supernatant was collected to determine the secretion of IFN  (left) and 
TNF  (right). B) iDCs were cultured for 24 hours with autologous day 7 expanded lymphocytes in the presence or 
absence of re-stimulation stimuli. 24 hour matured DCs were collected, washed and rested overnight in fresh media 
at 37C. After resting, the phenotype of the DCs was determined by flow cytometry.  
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Supplementary figure 6. Processing of tumors and marginal tissues.  
(A) Workflow of tissue processing for ex vivo explant culture and subsequent functional analyses. Ex vivo culture 
was done for 30 min for NF- B, analysis, 24hours for RNA and 48hours for ELISA (B) CCL5, CXCL10 and 
CCL22 mRNA expression in tumors (n = 6 tumors from 6 different patients) was analyzed in freshly-harvested 
tumor tissue (fresh) or in tumor tissues cultured for 48 hrs in medium alone (untreated) or in the presence of 
indomethacin + IFN  + poly-I:C (treated). The treated and untreated tumor samples were harvested simultaneously 
at 48 hrs of culture. Note that the 48 hr-long cultures did not significantly affect the spontaneous pattern of 
chemokine production in the (untreated) tumor tissues compared to fresh tumor samples (P>0.05 for all three 
chemokines). 
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Supplementary figure 7. Presence of Treg and Teff markers in tumors correlate with intra-tumoral expression 
of Teff- and Treg-attracting chemokines. 
(A) Expression of an alternative CXCR3 ligand, CXCL9, is correlated with local expression of CXCL10 and with 
Teff markers, CD8 and GZMB. (B) Correlation between CCL22 and COX-2 (C) Example: Lack of correlation 
between CCL22 and CXCL13. (D) Confocal analysis of CD8, CCL5 and CXCL10 expression in colon tumor 
sections. Expression of CXCR3, CCR5 (E) and Granzyme B (F) in CD8+ TILs grown from tumor biopsies of 3 
different patients. The biopsies were cultured for 2-3 weeks in 1000 units of IL-2 to obtain TILs (See M&M). 
 140 
 
Supplementary figure 8. Combination of indomethacin, IFN  and poly-I:C induces the optimal pattern of 
chemokine expression in isolated cell cultures. 
(A) Dose-dependent impact of IFN  and poly-I:C on the production of Teff-, and Treg-attracting chemokines by in 
vitro generated macrophages (see M&M) and in fibroblasts (obtained from Cascade Biological). Data from one 
representative experiment of three. (B) Effects of indomethacin on Teff-, and Treg-attracting chemokines produced by 
macrophages (N=3) by ELISA analysis. The concentrations of chemokines in 48 hr cultures were analyzed by 
ELISA. Note the suppression of CCL22 production by indomethacin. (C-D): Combination of IFN  poly-I:C and 
cyclooxygenase blockade is needed for the optimal and consistent modulation of chemokine production in 
metastatic colorectal cancer lesions. (C) Heterogeneous response of different tumor lesions from the same patient 
(CCL5 and CXCL10 production) to the individual components of the chemokine-modulating cocktail. (D) 
Indomethacin and celecoxib enhance the IFN /poly-I:C-induced Teff-attracting chemokine expression, but suppress 
Treg-attracting chemokine expression in colorectal cancer lesions. All cultures were for 48hr. Combined data from 
the tumors of 3 different patients (n=3). 
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Supplementary figure 9. CCL22 is predominantly expressed by HLA-DR
+
 APC whereas CXCL10 and CCL5 
are expressed by both HLA-DR positive and negative cells. 
Immunohistochemistry analysis of HLA-DR+ protein (brown staining) and in-situ hybridization analysis of 
chemokine mRNA (black silver grains) in tumor tissues. To achieve the optimal levels of expression of each of the 
three chemokines, CXCL10 and CCL5 expression was analyzed in the treated tissues, while CCL22 expression was 
in untreated tissues. 
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Supplementary figure 10. Elevated expression of CXCL10 and CCL5 in liver metastases compared to normal 
liver tissues: role of NF- B. 
Matched samples of marginal liver tissues and liver-metastatic colorectal cancer tissues (3 biopsies in 1ml in 24 well 
plate), were cultured for 24hrs either untreated or treated with IFN + poly-I:C + indomethacin and (A) analyzed for 
CCL5 and CXCL10 expression by Taqman (see matched protein data in Fig 4). (B) Tissues were untreated or 
treated with IFN + poly-I:C + indomethacin in absence or presence of 20µM CAY10470 (NF- B inhibitor). The 
supernatants were analyzed for CCL5 production by ELISA (see matched CXCL10 data in Fig 4). (C) CAY10470 
(20µM) effects on liver glycogen phosphorylase mRNA expression in matched marginal liver tissues and liver-
metastatic colorectal cancer. (D). Example: single and composite images of p65 nuclear translocation in fibroblasts. 
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Supplementary figure 11. Tregs are preferentially attracted by untreated tumors. 
Negatively-isolated total CD4+ T cells were allowed to migrate towards the supernatants from either untreated or 
treated tumor tissues. Treg migration was analyzed either by (A) flow cytometry analysis of the percentage of 
FOXP3
+ 
cells or (B) Taqman analysis of GITR mRNA in migrated cells. 
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